

University of California San Francisco

Updated: July 1, 2023

CURRICULUM VITAE**Name** Eric J. Small, M.D., FASCO

Position: Professor in Residence, Department of Medicine
 Co-Leader, Prostate Cancer Program
 Deputy Director
 Chief Scientific Officer
 Helen Diller Family Comprehensive Cancer Center

Professor in Residence
 Department of Urology (Secondary)

Stanford W. Ascherman & Norman R. Ascherman Endowed Chair
 Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research

EDUCATION

1976-1980	Stanford University, Stanford, CA	B.S.	Biology
1980-1985	Case Western Reserve University School of Medicine Cleveland, OH	M.D.	
1982-1983	Case Western Reserve University Department of Pathology Cleveland, OH	Student Fellowship	Pathology Residency Training Program
1985-1986	Beth Israel Hospital, Boston, MA	Internship	Internal Medicine
1986-1988	Beth Israel Hospital, Boston, MA	Residency	Internal Medicine
1988-1991	University of California, San Francisco, CA	Fellowship	Hematology/ Oncology

LICENSES, CERTIFICATION

1987	State of California	License to Practice	Medicine
1988	American Board of Internal Medicine	Board Certification	Internal Medicine
1990	American Board of Internal Medicine	Board Certification	Hematology
2012	American Board of Internal Medicine	Board Certification	Oncology
2014	Alliance for Academic Internal Medicine	Executive Leadership Program	

ACADEMIC POSITIONS HELD

1991-1997	University of California, San Francisco, CA	Assistant Clinical Professor	Medicine
1996-1997	University of California, San Francisco, CA	Assistant Clinical Professor	Urology

1997-2001	University of California, San Francisco, CA	Associate Clinical Professor	Medicine, Urology
2001-2003	University of California, San Francisco, CA	Clinical Professor	Medicine, Urology
2003-present	University of California, San Francisco, CA	Professor In-Residence	Medicine, Urology

OTHER POSITIONS HELD CONCURRENTLY:

1991-2011 2018-2022	University of California, San Francisco, CA	Leader	Urologic Oncology Section, Division of Hematology and Oncology
1999-2002	University of California, San Francisco, CA	Associate Director	General Clinical Research Center
2003-2006	University of California, San Francisco, CA Division of Hematology and Oncology	Program Director	Hematology and Oncology Fellowship
2007-2014	California Institute for Quantitative Biomedical Research (QB3)	Clinical Associate	
2007-present	University of California, San Francisco, CA Helen Diller Family Comprehensive Cancer Center	Program Co-Leader	Prostate Cancer Program
2007-2009	University of California, San Francisco, CA	Interim Division Chief	Division of Hematology and Oncology
2009-2018	University of California, San Francisco, CA	Division Chief	Division of Hematology and Oncology
2009-2016	University of California, San Francisco, CA	Associate Director, Clinical Research	Helen Diller Family Comprehensive Cancer Center
2009-present	University of California, San Francisco, CA	Deputy Director	Helen Diller Family Comprehensive Cancer Center
2018-present	University of California, San Francisco, CA	Chief Scientific Officer	Hellen Diller Family Comprehensive Cancer Center

HONORS AND AWARDS

1984	Alpha Omega Alpha Honor Medical Society
1999	Janssen Research Foundation Research Award for Outstanding Clinical Research

- 2001 UCSF Division of Hematology-Oncology: Faculty Research Award
- 2011 Richard L. Schilsky CALGB/ALLIANCE Award for Clinical Research
- 2011 UCSF Academic Senate Faculty Research Lecture in Clinical Science
- 2015 Fellow of the American Society of Clinical Oncology (FASCO)
- 2022 Inductee, *OncologyLive* Giants of Cancer Care, Genitourinary Cancer

KEYWORDS/AREAS OF INTEREST

Castration Resistant Prostate Cancer, Secondary Hormone Therapy, Drug Resistance, Prostate Cancer Immunotherapeutics, Prostate Cancer Genomics, Risk Assessment, Prostate Cancer Investigational Therapeutics

PROFESSIONAL ORGANIZATIONS

American Association for Cancer Research (AACR)

- 2009 Co-Chair, Emerging Biological Observations Session, AACR Annual Meeting
- 2013-2014 Member, AACR-Millennium Fellowship in Prostate Cancer Research Scientific Review Committee
- 2019 Member, Selection Committee, AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research

American Society of Clinical Oncology (ASCO) (Member, 1991-Present)

- 1998-2000 Member, Scientific Program Committee
- 2002-2003 Vice Chair, Scientific Program Committee
- 2003-2004 Chair, Scientific Program Committee
- 2007-2010 Member, Nominating Committee
- 2009-2012 Conquer Cancer Foundation, Grants Selection Committee
- 2017-2021 Member, Board of Directors
- 2020-2021 Member, Executive Committee, Board of Directors
- 2020-2021 Member and Treasurer, Association Finance Committee
- 2021-2023 Mentor, Leadership Development Program
- 2022-2025 Member, Special Awards Committee

ASCO/ASTRO/SUO/Multidisciplinary Genitourinary Cancer Symposium

- 2005 Founding Chair, Steering Committee
- 2006 Member, Steering Committee

Cancer and Leukemia Group B (CALGB)/ALLIANCE

- 1993-2013 Member, GU Committee
- 1996-2000 Chair, GU Correlative Science Working Group
- 2000-2013 Chair, GU Committee, Member, Executive Committee

European Organisation for Research and Treatment of Cancer-National Cancer Institute (EORTC-NCI)

- 2007 Member, Scientific Program Committee
- 2008 Chair, Scientific Program Committee
- 2009 Member, Program Committee

National Comprehensive Cancer Network (NCCN)

- 1999-2009 Member, Treatment Guidelines Panel.

Prostate Cancer Foundation (PCF)

- 2022 Mentor, PCF One-on-one Networking and Engagement (PCF-ONE) Program

EDITORIAL BOARDS AND REVIEWSEditorial Board Leadership

Journal of Clinical Oncology, Associate Editor (2008-2014)

Editorial Board Memberships

American Journal of Oncology Review
 Clinical Prostate Cancer
 Journal of Clinical Oncology
 The Oncologist
 Prostate Cancer and Prostatic Diseases

Editorial Review

American Journal of Medicine
 Cancer
 Cancer Investigation
 Cancer Research U.K.
 Clinical Cancer Research
 Clinical Prostate Cancer
 Investigational Drugs
 Journal of Clinical Investigation
 Journal of the National Cancer Institute
 Journal of Urology
 New England Journal of Medicine
 The Prostate Journal
 Urologic Oncology
 Urology

STUDY SECTIONS, CANCER CENTERS ADVISORY BOARDS, GOVERNMENT AND OTHER PROFESSIONAL SERVICE

1992	NCI Consensus Conference on Late Effects of Cancer Treatment, San Francisco, CA	Discussant
1997	NCI Prostate Cancer Progress Review Group Meeting, Washington, DC	Member
1999, 2007	National Cancer Institute Consensus Panel on PSA Endpoints, Washington, DC	Discussant
2003-2007	National Cancer Institute, Initial Review Group, Subcommittee H (Cooperative Groups)	Member
2007-2011	American Board of Internal Medicine, Subspecialty Board on Medical Oncology	Member, Board of Directors
2008-2013	Genitourinary Cancer Steering Committees, National Cancer Institute	Member
2010-2012	National Cancer Institute, Initial Review Group Subcommittee A-Cancer Centers	Ad-Hoc Member
2012-2017	National Cancer Institute, Initial Review Group Subcommittee A-Cancer Centers	Member, Parent Committee
2016-present	Sidney Kimmel Cancer Center, Jefferson University Philadelphia, PA	Chair, External Advisory Board
2016-present	Fred Hutchinson Comprehensive Cancer Center, Seattle, WA	Chair, External Advisory Board
2016-present	Moore's Cancer Center, UC San Diego, San Diego, CA	Chair, External Advisory Board
2017-present	University of Kansas Cancer Center, Kansas City, KS	Chair, External Advisory Board
2017-present	Knight Cancer Institute, Oregon Health Sciences University	Chair, External Advisory Board
2022-	Yale Cancer Center, Yale University	Member, External Advisory Board

INVITED PRESENTATIONS (Selected); 2010-Present**INTERNATIONAL**

American Association for Cancer Research (AACR) Translational Cancer Medicine 2010 (Europe). Invited talk. Amsterdam, Netherlands. March 21-24, 2010.

European Society of Gene and Cellular Therapy Annual Meeting. Invited talk. Milan, Italy. October 23-25, 2010.

British Urology Group. Invited talk. York, England. September 7-12, 2011.

European Cancer Organisation (ECCO) 2011 Multidisciplinary Cancer Congress. Invited talk. Stockholm, Sweden. September 23-28, 2011.

27th Annual Congress of the European Association of Urology. Invited talk. Paris, France. February 24-26, 2012.

Venezuela Oncology Society, Congreso Caracas 2012, Invited talk. July 5, 2012, Caracas, Venezuela.

5th Conference on Translational Medicine of the Peking Union Medical College Hospital (PUMCH). Session chair, invited talk. Beijing, China. January 14-20, 2013.

Spanish Oncology Genitourinary Group (SOGUG) Annual Symposium, Invited Speaker, Madrid, Spain. November 2013.

Urological Society of Australia and New Zealand 67th Annual Scientific Meeting, International Faculty Lecturer, March, 2014. Brisbane, Australia.

Presidential Grand Round, Gustave Roussy University Hospital. Invited talk. Paris, France. March 2014.

European Society of Medical Oncology, Annual Meeting. Invited talk. Madrid, Spain. September 2014.

Advanced Prostate Cancer Consensus Conference. Invited talk. St. Gallen, Switzerland. March, 2015

Spanish Oncology Genitourinary Group (SOGUG) Annual Symposium, Invited Speaker, Madrid, Spain. December 2015.

Asia Pacific Prostate Cancer Conference, Invited Speaker, Melbourne, Australia, August 2016.

Chinese University of Hong Kong (CUHK) Urology Symposium, Hong Kong, China, November, 2016

Expert Practice in Prostate Cancer, Invited Speaker, Madrid, Spain, February, 2017.

New Challenges in UroOncology Symposium, Invited Speaker, Barcelona, Spain, May, 2017.

Xian Janssen Pharmaceutical Ltd., Invited Lectures, Chengdu, Chongqing, Xi'an and Beijing, China, March, 2018.

Argentina Society of Urology, Invited Speaker, Buenos Aires, Argentina, September, 2018

European Society of Medical Oncology (ESMO), Invited Speaker, Munich, Germany, October, 2018

IX SOGUG (Spanish Oncology Genitourinary Group) Scientific Meeting, Invited Speaker, Madrid, Spain, December, 2018

Advanced Prostate Cancer Consensus Conference (APCCC), Invited Speaker, Basel, Switzerland, August, 2019

UroUp 2020 Medical Conference, Invited Speaker, Madrid, Spain, January, 2020

United Arab Emirates and Qatar: Advances in Prostate Cancer Virtual Meeting, Invited Speaker, September, 2020

South Africa Oncology Meeting, New approaches in nmCRPC, Virtual Meeting Invited Speaker, September, 2020

Symposium on Prostate Cancer at the Italian Medical Oncology Association (AIOM), Invited Speaker, October, 2020

Prossyga 2020, Janssen Portugal Standalone Meeting, Portugal. Invited Speaker, November, 2020. "Current scientific questions influencing patient management in advanced prostate cancer - non-metastatic."

Japan Urological Association (JUA) Annual Meeting. Invited Speaker, December, 2020. "Non-metastatic Castration Resistant Prostate Cancer, A Changing Landscape."

Andrógeno 2021, Janssen Spain, Invited Speaker, February, 2021. "Non-Metastatic Castration Resistant Prostate Cancer: A Changing Landscape."

Janssen Portugal, Invited Speaker, "Meet the Expert," June, 2021. "Controversies in the treatment of nmCRPC - PSMA PET impact in nmCRPC."

Advanced Prostate Cancer Consensus Conference (APCCC) 2021, Invited Speaker, Virtual, October, 2021, April 2022.

NATIONAL

ASCO Genitourinary Cancers Symposium, Session Moderator and Invited Presenter, San Francisco, CA. February 2010.

ASCO Annual Meeting, Presenter, Invited Speaker and Poster Session and Abstract Presenter, Chicago, IL. June 2010.

Best of ASCO, Invited Faculty, San Francisco, CA. July 16-17, 2010.

Massachusetts General Hospital Cancer Center Grand Rounds, Invited Speaker, Boston, MA. November 2010.

ASCO Genitourinary Cancers Symposium, Invited Presenter, Orlando, FL. February 2010.

CALGB Richard L. Schilsky Award Lecture, Chicago, IL. September, 2011.

Beth Israel Deaconess Medical Center, Baldini Visiting Professor, Boston, MA. November 2011.

ASCO Genitourinary Cancers Symposium, Invited Presenter, San Francisco, CA. February 2012.

Planning Committee for the Designs for Contemporary Early-Phase Clinical Trials Seminar at the ASCO Annual Meeting, Invited Speaker, Chicago, IL, May 31-June 1, 2012.

ASCO Annual Meeting, Session Chair and Invited Presenter, 2012 Grant Writing Workshop Program, Chicago, IL, June 1, 2012.

16th Biennial Urologic Cancer Course, Invited Speaker. Boston, MA, October 11-13, 2012.

Ohio State University Comprehensive Cancer Center Grand Rounds, Visiting Professor. Columbus, Ohio. November, 2012.

13th Annual Meeting of the Society of Urologic Oncology, Invited Speaker, Bethesda, MD, November 28-30, 2012.

ASCO Genitourinary Cancers Symposium, Invited Presenter, Orlando, FL. February 2013.

ASCO Annual Meeting, Presenter, Invited Speaker and Poster Session and Abstract Presenter, Chicago, IL. June 2013.

AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research. Invited Speaker, San Diego, CA. January 21, 2014.

ASCO Genitourinary Cancers Symposium. Invited Speaker, Poster Session and Abstract Presenter, San Francisco, CA. January 2014.

Dana Farber Cancer Institute. Invited Speaker, Grand Rounds Lecture. Boston, MA. October 2014.

ASCO Genitourinary Cancers Symposium. Invited Speaker, Poster Session and Abstract Presenter, Orlando, FL. March 2015.

Memorial Sloan Kettering Cancer Center. Invited Speaker. New York, NY. April 2015.

AACR Annual Meeting. Invited Speaker. Washington, DC. April 2015.

ASCO Annual Meeting, Presenter, Invited Speaker and Poster Session and Abstract Presenter, Chicago, IL. June 2015.

Society of Urologic Oncology Annual Meeting. Invited Speaker. Washington, DC. December 2015.

University of California, Los Angeles, SPORE/Genitourinary Oncology. Invited Speaker. Los Angeles, CA. March, 2016.

AACR Annual Meeting. Invited Speaker. Washington, DC. April 2016.

ASCO Annual Meeting, Presenter, Invited Speaker and Poster Session and Abstract Presenter, Chicago, IL. June 2016.

MD Anderson Prostate Cancer Moonshot Symposium, Invited Presenter, Houston, TX. January 2017.

ASCO Annual Meeting, Plenary Session Discussant, Chicago, IL. June 2017.

Society of Urologic Oncology (SUO) Annual Meeting. Invited Speaker, Washington, DC. December, 2017

ASCO Genitourinary Cancers Symposium. Invited Speaker, Poster Session and Abstract Presenter, San Francisco, CA. February, 2018.

American Urological Association (AUA) Annual Meeting, Invited Speaker and Abstract Presenter, San Francisco, CA. May, 2018.

ASCO Annual Meeting. Invited Speaker, Poster Session and Abstract Presenter, San Francisco, CA. June, 2018.

ASCO Genitourinary Cancers Symposium. Invited Speaker, Poster Session and Abstract Presenter, San Francisco, CA. February, 2019.

ASCO Annual Meeting. Invited Speaker Poster Session and Abstract Presenter, Chicago, IL, June, 2019.

UCSF/California Prostate Cancer Coalition Patient Conference, Invited Speaker and Conference Director, San Francisco, CA, June, 2019.

UCSF/California Prostate Cancer Coalition Patient Conference, Invited Speaker and Conference Director, San Francisco, CA, June, 2020.

ASCO Genitourinary Cancers Symposium. Invited Speaker, Poster Session and Abstract Presenter, San Francisco, CA. February, 2020.

UCSF/California Prostate Cancer Coalition Patient Conference, Invited Speaker and Conference Director, San Francisco, CA, June, 2021.

ASCO Virtual Annual Meeting. Invited Speaker, Poster Session and Abstract Presenter, June, 2020.

ASCO Genitourinary Cancers Symposium. Invited Speaker, Poster Session and Abstract Presenter, San Francisco, CA. February, 2021.

ASCO Genitourinary Cancers Symposium. Invited Speaker, Poster Session and Abstract Presenter, San Francisco, CA. February, 2022.

UNIVERSITY/CME LECTURES

UCSF Breast Oncology Program Scientific Retreat. Invited talk. San Francisco, CA, January 2010.

UCSF Academic Senate Faculty Research Lecture in Clinical Science. Invited talk. San Francisco, CA, October 2011.

UCSF Division of Hematology and Oncology, Research Retreat, Chair, October, 2011

UCSF Prostate Cancer Research Retreat. Session Moderator. San Francisco, CA, May 2012.

UCSF Department of Medicine Grand Rounds. Lecturer. San Francisco, CA. July 2012.

UCSF Prostate Cancer Program Scientific Retreat, Chair, October 2012

UCSF Department of Bioengineering and Therapeutic Sciences Faculty Retreat. Lecturer. San Francisco, August, 2013.

UCSF Pediatric Oncology Retreat. Lecturer. San Francisco, December 2013.
 UCSF Division of Hematology and Oncology, Research Retreat, Chair, February, 2013
 UCSF Department of Medicine Grand Rounds. Lecturer. San Francisco, CA. March, 2014
 UCSF Prostate Cancer Program, Scientific Retreat, Chair, September 2014
 UCSF Division of Hematology and Oncology, Research Retreat, Chair April, 2014,
 UCSF Department of Medicine Grand Rounds. Lecturer. San Francisco, CA. October, 2015.
 UCSF Prostate Cancer Program, Scientific Retreat, Chair, September 2015
 UCSF Division of Hematology and Oncology, Research Retreat, Chair, March 2015, August, 2015
 UCSF Department of Medicine, Division of Hematology and Oncology TRIO Conference. Lecturer. August, 2016.
 UCSF Prostate Cancer Program, Scientific Retreat, Chair, October 2016
 UCSF Division of Hematology and Oncology, Research Retreat, Chair, November, 2016.
 UCSF Division of Hematology and Oncology, Research Retreat, Chair, October, 2017
 UCSF Prostate Cancer Program, Scientific Retreat, Chair, November 2017
 UCSF Prostate Cancer Program, Scientific Retreat, Chair, November 2018
 UCSF Department of Medicine Grand Rounds. Lecturer. San Francisco, CA, August, 2019
 UCSF Prostate Cancer Program, Scientific Retreat, Chair, November 2018, 2019, 2020, 2022
 UCSF Biostatistics on Cancer Immunotherapy Symposium, Invited Speaker, San Francisco, CA, April, 2020

UNIVERSITY SERVICE

SYSTEMWIDE:

2007-2016	University of California Institute for Quantitative Biomedical Research (QB3)	Clinical Associate
2017-ongoing	University of California Cancer Centers Consortium	Member and Chair, Clinical Research Working Group

UCSF CAMPUS:

1996-2010	Chair, Multidisciplinary Genitourinary Tumor Board
1996-2010	Coordinator, Multidisciplinary Case Conference and Research Symposium, GU Oncology
1997-1999	Committee on Human Research
1997-2002	General Clinical Research Center Advisory Board (Associate Director 1999-2002)
1998-2000	UCSF/Mount Zion Cancer Center Clinical Trials Program Executive Committee
1999-2000	Clinical Trials Office Planning Committee
1999-2000	Academic Senate Ad Hoc Committee to Review the Committee on Human Research
1999-2000	Cancer Therapeutics Advisory Group
1999-2005	Hellman Family Awards Committee
1999-present	UCSF Comprehensive Cancer Center Clinical Trials Office: Steering Committee
2001-2004	Comprehensive Cancer Center Clinical Investigator Research Program (CIRP) Award Committee
2004-2005	Committee on Research
2011	Steering Committee, UCSF Space Planning Committee (Backfill Project)
2011	Research Planning Subcommittee, Long Range Development Plan (LRDP) Oversight Committee
2012-present	Chair, Mission Bay Clinical Research Advisory Committee
2012-present	Member, Clinical Research Infrastructure Advisory Committee
2013	Member, Committee on Human Research (CHR) Steering Committee
2017-present	Member, Cancer Regionalization Strategy Working Group
2018-present	Member, Clinical Trials Task Force, Office of the Executive Vice President
2018-present	Chair, UCSF Cancer Research Strategic Planning (on Advance CV)
2021	Search Committee, Director of the Office of Clinical Trials Activation (OCTA)
2021-present	Clinical Trials Administration Executive Committee

SCHOOL OF MEDICINE:

2001-2002	Ad Hoc Member, Stewardship Review Committees, UCSF Departments of Urology and Medicine and Helen Diller Family Comprehensive Cancer Center
2005-present	Program Leader, Prostate Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center
2007-present	Chair, Clinical Trials Oversight Committee, UCSF Helen Diller Family Comprehensive Cancer Center

2008-2013	Chair, Search Committees for: The Robert O. and Angela Johnson Endowed Chair in Hematologic Malignancies, the Edward A. Ageno Distinguished Professorship in Hematology and Oncology, and the Krishnamurthi Endowed Chair in Hematologic Malignancies
2009-present	Deputy Director and Director of Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center
2009	Search Committee, Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology
2009	Search Committee, Director of the Osher Center for Integrative Medicine
2014	Search Committee, Chief of the Division of Obstetrics, Gynecology and Reproductive Sciences
2014	Search Committee, Chief of the Division of Head and Neck Oncology
2015	Search Committee, Chair of the Department of Radiation Oncology
2016	Search Committee, Chair of the Department of Medicine
2016	Chair, Search Committee for The Efim Guzik Distinguished Professorship in Cancer Biology
2016	Search Committee, UCSF Helen Diller Family Comprehensive Cancer Center, Cancer Services Chief Operating Officer
2017	Search Committee, UCSF Helen Diller Family Comprehensive Cancer Center, Cancer Services Chief Medical Officer
2017	Search Committee, Zuckerberg San Francisco General Hospital (SFGH) Chief of Division of Hematology and Oncology
2017	Search Committee, San Francisco Veterans Administration, Chief of Hematology and Oncology
2018	Search Committee, Chair of the Department of Urology
2020	Search Committee, Division Chief Neurologic Oncology, Department of Neurosurgery
2022	Search Committee, Chair of the Department of Urology

DEPARTMENT OF MEDICINE:

2003-2006	University of California, San Francisco	Fellowship Program Director	Division of Hematology and Oncology
2007-2009	University of California, San Francisco	Interim Division Chief	Division of Hematology and Oncology
2009-2018	University of California, San Francisco	Division Chief	Division of Hematology and Oncology
2017-present	University of California, San Francisco	Member, Promotions Sub-Committee	Department of Medicine

PUBLIC SERVICE (Selected)

East Bay Wellness Community. Invited talk. Walnut Creek, CA. June 1994.
 Marin County Prostate Cancer Support Group. Invited talk. Greenbrae, CA. August 1994.
 Santa Cruz Prostate Cancer Support Group. Invited talk. Santa Cruz, CA. December 1994.
 San Jose Prostate Cancer Support Group. Invited talk. San Jose, CA. February 1995.
 Prostate Cancer Support Group of San Jose. Invited talk. San Jose, CA. March 1996.
 Prostate Cancer Self-Help Group of the Monterey Peninsula. Invited talk. Monterey, CA. April 1996.
 Marin County Prostate Cancer Support Group. Invited talk. Greenbrae, CA. July 1996.
 Sonoma County Prostate Cancer Support Group. Invited talk. Santa Rosa, CA. January 1997.
 San Jose Prostate Cancer Support Group. Invited talk. San Jose, CA. June 1997.
 San Jose Prostate Cancer Support Group. Invited talk. San Jose, CA. June 1998.
 American Cancer Society, Santa Cruz County Unit. Invited talk. Watsonville, CA. August 1998.
 Wellness Community Center. Invited talk. Walnut Creek, CA. October 1998.
 San Jose Prostate Cancer Support Group. Invited talk. San Jose, CA. June 1999.
 American Cancer Society. Invited talk. San Francisco, CA. September 1999.
 California Prostate Cancer Coalition Advisory Board. 2000-Present.
 Prostate Cancer Support Group, Sequoia Hospital. Invited talk. Redwood City, CA. February 2002.
 UCSF Prostate Cancer Advocates Group. San Francisco, CA. June 2010.
 ASCO-ESPN Prostate Cancer Campaign Advisory Panel. October 2010-2012.

UCSF Prostate Cancer Patient Advocacy Group 2010-present.

UCSF/Calif. Prostate Cancer Coalition Annual Patient Symposium. Founding Co-Chair and Panelist. 2019-Present

CONTRIBUTIONS TO DIVERSITY

During my service as Chief of the Division of Hematology and Oncology (2009-2018), we developed a strategic plan for growth, and grew our faculty size from 28 to 65. Half of these new recruits were women. Additionally, we sought to diversify leadership within the Division. Where previously virtually all disease and modality-oriented programs in the Division were led by men, 45% of programs are now led by women. Recognizing the need to develop a strong pool of URM candidates, we developed a plan for recruitment of URM fellows, many of whom have gone on to faculty positions.

As a leader of the Prostate Cancer Program in the Helen Diller Family Comprehensive Cancer Center, an important research and service theme we have continually developed is prostate cancer disparities. African American men are disproportionately affected by prostate cancer and understanding and eliminating these disparities is a central theme that we continually address longitudinally across all research in the Program. We have worked closely with the California Prostate Cancer Coalition, a statewide patient advocacy group to develop an annual Prostate Cancer Symposium for patients and caregivers and have also worked with the CPCC and members from the community to develop patient facing materials, with a particular focus on underserved African American and Latino communities in our Catchment Area.

Within the broader context of the Cancer Center, I co-developed the Minority Enrollment and Recruitment into Trials (MERIT) initiative, and subsequently championed it across the Cancer Center. This initiative seeks to a) quantify cancer disparities with regards to access to, and participation in clinical research for each disease-specific research program, as well as across the Center, b) identify specific barriers to participation in clinical trials, and c) design and test interventions to address these barriers and issues.

TEACHING AND MENTORING

My teaching and education activities at UCSF largely take place in the clinic. In addition to providing didactic sessions for trainees several times a year, I generally see patients with a hematology/oncology fellow. I work in 6 to 12 month blocks with fellows who have decided to train in GU medical oncology, and also teach rotating earlier phase fellows, typically in 1 month blocks.

My mentoring activities range from less structured periodic ad hoc mentoring, to formal ongoing mentoring relationships. The less structured mentoring generally takes the form of periodic meetings with trainees or early career stage faculty members from across a number of different departments, to discuss a specific issue or decision point. It has been wonderful to see these relationships evolve from mentoring individuals about individual projects, to mentorship about building teams and programs, and to helping these individuals become mentors themselves. In helping mentees develop their own mentorship and leadership skills, I have applied for and obtained NCI Cancer Clinical Investigator Team Leadership Awards for several early career stage faculty. Many of my mentees have gone on to highly successful careers in academia. It is gratifying that many of them, now full professors scattered around the country, and the world, periodically will check in to discuss ideas or career issues. I serve in a more official capacity as mentor to trainees and junior faculty. Each year, I directly mentor one to two fellows and three to four early career stage faculty members and trainees at UCSF, who range in rank from senior fellow to associate professor. I meet individually with each mentee every 2 to 4 weeks in a meeting with agenda and action items, to work on career development, project development and design, and leadership mentorship. I also serve as co-mentor to 3 other trainees, meeting regularly either alone, or with their other mentors, to provide input into their academic and career mentoring plans. Outside of UCSF, I was honored to serve as a mentor for two years (2021-2023) in the ASCO Leadership Development Program (LDP). I also serve as mentor to an early career prostate cancer investigator from another institution under the auspices of the Prostate Cancer Foundation.

POSTDOCTORAL FELLOWS DIRECTLY SUPERVISED OR MENTORED

Dates	Name	Project	Current Position
1987-1991	John Timmerman	Germ Cell Tumors/HIV Infection	Faculty, UCLA
1990-2000	Uzair Chaudhary	Intermittent Androgen Deprivation in PCA	Faculty, UCSF-Fresno

1999-2001	Katherine Harris	Adrenal Androgens in Prostate Cancer Progression	Private Practice
1999-2001	Mark Frohlich	Micrometastases in Prostate Cancer	Biotechnology
1992-1994	Sandhiya Srinivas	Chemotherapy for Hormone Refractory Prostate Cancer	Faculty, Stanford University
1994-1996	Ari Baron	Advanced Prostate Cancer	Private Practice
1999-2002	Robert Bok	Growth Factors in Prostate Cancer	Faculty, UCSF
2000-2002	Robert Ross	Osteoporosis due to Androgen Deprivation	Biotechnology
2001-2002	Christopher Haqq	Gene Expression in Prostate Cancer	Biotechnology
2002-2004	Jorge Garcia	Intermediate Markers in Prostate Cancer	Faculty, Cleveland Clinic
2002-2003	Jonathan Rosenberg	Advanced Bladder Cancer	Faculty, MSKCC
2003-2006	Amy M. Lin	Imaging in Prostate Cancer	Faculty, UCSF
2004-2007	Amir Goldkorn	Telomerase in TCC	Faculty, University of Southern California
2005-2008	Andrea Harzstark	Immunotherapeutics/Kidney Cancer	Private Practice
2008-2011	Terence Friedlander	PCA Pharmacogenomics	Faculty, UCSF
2008-2011	Shreya Shah	Novel Cytotoxic Therapy in Prostate Cancer	Private Practice
2009-Present	Andrew Hsieh	Pharmacogenomic dissection of the mTOR pathway in human prostate cancer	Faculty, University of Washington, Fred Hutchinson Comprehensive Cancer Center
2010-2014	Rahul Aggarwal	The role of highly selective androgen receptor blockade in biochemically relapsed prostate cancer	Faculty, UCSF
2011-2014	Won Kim	Identification of adaptive pathways activated by PI3K inhibition in human prostate cancer	Private Practice
2015-Present	Malika Dhawan	BRCA2 in Prostate Cancer	Biotechnology
2016-Present	Jonathan Chou	Mechanisms of Resistance in mCRPC	Faculty, UCSF
2016-Present	Hala Borno	Prostate Cancer Disparities and Accrual Enhancement	Faculty, UCSF
2016-Present	David Oh	Molecular Determinants of toxicity in Immunologic Oncology	Faculty, UCSF
2017-2021	Yao Yao Pollock	Prostate Cancer in Geriatric Patients	Private Practice
2019-present	Daniel Kwon	Cognitive Changes in Prostate Cancer Patients undergoing Androgen Deprivation Therapy	Faculty, UCSF
2020-present	Ivan de Kouchovsky	Functional Imaging in Prostate Cancer	Faculty, UCSF

2021-2023	Alberto Carretero	Biology of Prostate Cancer Bone Metastases	Visiting Fellow, Madrid, Spain
2021-present	Ana Velasquez Manana	Equity and Workforce Development	Faculty, UCSF
2022-present	Edward Maldonado	Hereditary Prostate Cancer	Hematology and Oncology Fellow

FACULTY MENTORED:

Dates	Name	Department	Current Position
1992-2003	Gary Grossfeld	Urology	Private Practice
1997-2001	Mark Frohlich	Medicine	Biotechnology
1998-2000	Robert Bok	Medicine	UCSF Faculty
2000-present	Jocelyn Speight	Radiation Oncology	Private Practice
2001-2005	Christopher Haqq	Medicine	Biotechnology
2001-2005	Brian Rini	Medicine	Cleveland Clinic
2001-2006	June Chan	Epidemiology	UCSF Faculty
2003-present	Jonathan Rosenberg	Medicine	Harvard Faculty
2003-present	Charles Ryan	Medicine	U of Minnesota Faculty, CEO Prostate Cancer Fnd
2003-present	Michelle Melisko	UCSF Faculty	UCSF Faculty
2008-present	Andrea Harzstark	Medicine	Private Practice
2008-present	Amy M. Lin	Medicine	UCSF Faculty
2008-present	Larry Fong	Medicine	UCSF Faculty
2009-present	John Chan	Ob/Gyn	Private Practice
2009-present	Jennifer Schutzman	Medicine	Biotechnology
2009-present	James Rubenstein	UCSF Faculty	UCSF Faculty
2009-present	Amy Jo Chien	Medicine	UCSF Faculty
2010-present	Rahul Aggarwal	Medicine	UCSF Faculty
2010-Present	Eric Collisson	Medicine	UCSF Faculty
2010-present	Phillip Febbo	Medicine	Biotechnology
2010-present	Jeffrey Venstrom	UCSF Faculty	Biotechnology
2010-present	Katie Kelley	UCSF Faculty	UCSF Faculty
2011-present	Matthew Gubens	UCSF Faculty	UCSF Faculty
2011-present	Max Meng	Urology	UCSF Faculty
2011 present	Alain Algazi	Medicine	UCSF Faculty
2011-present	Terence Friedlancer	Medicine	UCSF Faculty

2011-present	Andrew Hsieh	Medicine	UW/Hutch
2011-present	Benjamin Kim	UCSF Faculty	Biotechnology
2013-present	Albert Chang	Radiation Oncology	UCLA Faculty
2014-present	Won Kim	Medicine	Private Practice
2016-present	John Gordan	Medicine	UCSF Faculty
2016-present	Pelin Cinar	Medicine	UCSF Faculty
2016-present	Melanie Majure	Medicine	UCSF Faculty
2016-present	Katy Tsai	Medicine	UCSF Faculty
2016-present	Melisa Wong	Medicine	UCSF Faculty
2016-present	Collin Blakely	Medicine	UCSF Faculty
2016-present	Felix Feng	Radiation Oncology	UCSF Faculty
2018-present	Hala Borno	Medicine	UCSF Faculty
2018-present	Vadim Koshkin	Medicine	UCSF Faculty
2018-present	Arpita Desai	Medicine	UCSF Faculty
2018-present	Ross Okimoto	Medicine	UCSF Faculty
2018-present	Franklin Huang	Medicine	UCSF Faculty
2018-present	Rohit Bose	Anatomy	UCSF Faculty
2016-Present	Jonathan Chou	Medicine	Faculty, UCSF
2016-Present	David Oh	Medicine	Faculty, UCSF
2020-present	Daniel Kwon	Medicine	Faculty, UCSF
2020-present	Ivan de Kouchovsky	Medicine	Faculty, UCSF
2021-present	Ana Velasquez Manana	Medicine	Faculty, UCSF

RESEARCH AND CREATIVE ACTIVITIES

Our primary research focuses on the mechanisms by which advanced prostate cancer develops resistance to systemic therapy. The discovery of androgen receptor amplification in “hormone resistant” prostate cancer led to our development of adrenal androgen ablation as a therapeutic approach. Subsequently, we conducted the first in human, phase 2, and phase 3 trials that led to the FDA approval of Abiraterone, an androgen signaling inhibitor (ASI). More recently, I have served as global PI of a study of apalutamide, a novel ASI, which led to NEJM and Lancet Oncology publications as senior author (Smith et al, NEJM 378, 2018; Saad et al, Lancet Oncol 9, 2018), and subsequent FDA approval of this agent.

In order to study mechanisms of resistance to these agents, we developed a unique prostate cancer metastasis biopsy program with a team of clinical investigators, nurses, clinical research coordinators, interventional radiologists, tissue processing technicians, pathologists, laboratory-based investigators, and computational biologists. We developed a consortium involving six institutions in Canada, Washington, Oregon, and California supported by a \$10 million peer-reviewed grant from AACR and SU2C (Stand Up to Cancer; PI: Small). Over 450 patients have undergone a metastasis biopsy and subsequent molecular analysis, including whole exome, transcriptional, whole genome and methylation sequencing capabilities. This work has resulted in a series of high impact publications including important genomic landscape resources, and the description of a new clinical subtype of prostate cancer. (Quigley et al, Cancer Discov. 2017; Wyatt et al, JNCI 2017; Aggarwal et al, J Clin Oncol 2018; Quigley et al, Cell, 2018; Aggarwal et al, Mol Cancer Res 2019; Chen et al, Eur. Urol. 2019; Zhang et al, Nature Gen 2020. Moving forward, the program is leveraging the comprehensive data from these molecular studies to undertake mechanistic studies as the first step to developing targeted

therapeutics for newly identified cancer subtypes. Clinically, we will continue to use this biopsy infrastructure to identify mechanisms of resistance to novel therapeutic agents being tested in our clinical trials.

RESEARCH AWARDS AND GRANTS

CURRENT/Awarded

1. NIH/NCI Cancer Center Support Grant P30 (Co-Investigator) CA82103	08/01/18-05/31/23 \$3,572,268 /yr 1 \$24,857,440/yr 18-23
2. Prostate Cancer Foundation-Special Challenge Award (Principal Investigator) Advancing the Drug Development Process in Metastatic Prostate Cancer Through Machine Learning	09/06/2022-09/05/2024 \$1,000,000

UNDER REVIEW

1. P50 National Institutes of Health (NIH) (Co- Principal Investigator) UCSF Specialized Programs of Research Excellence (SPOREs) in Prostate Cancer (Priority Score = 15)	07/01/2024-06/30/2029 \$11,506,875
2. R01 National Institutes of Health (Principal Investigator) Investigating Biological Drivers and Clinical Consequences of a Novel Hypermethylated Subtype of Metastatic Castration Resistant Prostate Cancer (mCRPC)	07/01/2022-06/30/2027 \$4,030,615

PAST (Since 2006)

1. DOD US Army Med. Res. Acq. Activity (Co-Investigator) Clinical Consortium UCSF FY 2017 W81XWH-18-2-0039 Principal Investigator: Aggarwal	09/30/2018 – 09/29/2021 \$822,000
2. Oregon Health & Science University (Principal Investigator) Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment ENZA-13J16	06/01/15 – 05/31/2021 \$100,382
3. Prostate Cancer Foundation (Principal Investigator) Targeting CD46 as a Novel Therapeutic Strategy in Metastatic Castration Resistant Prostate Cancer 17CHAL20	12/31/2017 – 12/31/2020 \$1,000,000
4. The Washington University. Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence WU-19-267 Principal Investigator: Chau	12/14/2018 – 11/30/2020 \$500,476
5. Prostate Cancer Foundation (PCF) (PI) 2017 PCF Challenge Award CD46 as a Novel Means to Target Immune Defense Mechanisms and Androgen Pathway Inhibitor Resistance in Metastatic Lethal Prostate Cancer	12/31/17-12/31/19 \$500,000 direct/yr 1 \$1,000,000 total
6. Department of Defense – Department of the Army (PI) Medical Research Acquisition Activity (Challenge Award) Targeting Adaptive Pathways in Abiraterone and Enzalutamide Refractory	10/01/16-09/30/19 \$250,000 direct/yr 1 \$937,909 total

Intermediate Atypical Carcinoma

7. Department of Defense Prostate Cancer Research Program (Co-Investigator) Idea Award Annotating MYC Status in Treatment-Resistant Metastatic Castration-Resistant Prostate Cancer with Gallium-68 Citrate PET (PI: Aggarwal)	10/01/16-09/30/19 \$125,059/yr 1 \$375,178 total
8. Prostate Cancer Foundation (PCF) (PI) PCF Special Challenge Award Precision Oncology and Molecular Targeting in Advanced Prostate Cancer	10/05/15-10-05-18 \$500,000 direct/yr 1 \$1,500,000 total
9. American Association for Cancer Research (AACR) (PI) P0047584 AACR/Prostate Cancer Foundation-Stand Up to Cancer Targeting Adaptive Pathways in Castration Resistant Prostate Cancer	01/01/13-12/31/16 \$3,348,818 direct/yr 1 \$10,000,000 total
10. Prostate Cancer Foundation (PCF) (PI) PCF Special Challenge Award Accelerating Precision Oncology at the University of California, San Francisco	09/01/13-09/01/16 \$500,000 total
11. NIH/NCI R01 (Co-Investigator) CA155296-01A1 Duke University (Halabi) Developing and Validating Prognostic Models of Progression-Free Survival and Overall Survival In Men With Castration Resistant Prostate Cancer Treated With One Prior Cycle Of Cytotoxic Chemotherapy	07/01/11-06/30/16 \$151,132/yr 1 \$755,660 total
12. Department of Defense Prostate Cancer Clinical Consortium Award (PI) W81XWH-08-PCR-CCA	02/15/09-08/14/14 \$188,613/yr 1 \$1,000,000/yrs 1-5
13. NIH R01 (Co-investigator) CA129034 Predictive Markers in Metastatic Renal Cancer	07/22/08-05/31/14 \$662,324/yr 1 \$1,936,612 yrs 1-6
14. Prostate Cancer Foundation Therapy Consortium (PI)	01/1/99-7/1/14 \$400,000/yr 1 \$5,600,000/yrs 1-14
15. CALGB Genitourinary Committee Chair (PI)	01/01/99-7/1/13 \$27,273 annual direct
16. NIH/NCI Cancer Center Support Grant P30 CA82103 (Co-Investigator)	08/05/99-05/31/12 \$850,000/yr 1 \$48,379,252/yrs 1-13
17. Merck & Co., Inc., OncoNet Member Agreement (PI)	07/14/09-06/30/12 \$716,923/yr 1 \$3,969,045/yrs 1-5
18. Cell Genesys, Inc. Protocol # G-0034 (PI) "A Phase 3 Randomized Open-Label Study of Docetaxel in Combination	03/01/06-03/02/10 \$96,355/yr 1

with CG1940 and CG8711 versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain”.	\$96,355/yr 1-4
19. UCSF Prostate Cancer SPORE P50 CA089520 (Co-Principal Investigator)	09/25/00-06/30/09 \$612,504/yr 1 \$4,315,016/yr 1-9
20. Department of Defense Prostate Cancer Clinical Trials Group PC051380 (PI)	01/15/06-01/14/09 \$230,769/yr 1 \$692,308/yr 1-3
21. CALGB Genitourinary Committee Chair (PI)	01/01/99-12/31/08 \$22,727/yr 1 \$222,727/yr 1-9
22. Dendreon Corporation Protocol # D9902B (PI) “A Randomized, Double Blind, Placebo Controlled Phase III Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA 2024 (Provenge, APC8015) in Men with Metastatic Androgen Independent Prostatic Adenocarcinomas”	06/01/06-12/31/08 \$119,320/yr 1 \$119,320/yr 1-2
23. Department of Defense DAMD 17-03-1-0112 (Co-Investigator) “Racial Differences in Outcomes in Men with Advanced Prostate Cancer.”	02/01/03-02/28/07 \$9,940/yr 1 \$30,121/yr 1-13
24. AstraZeneca A103686 (PI) A prospective study of the effects of high dose bicalutamide monotherapy on bone density in patients w/ recurrent or non-localized prostate cancer	08/01/02-07/31/04 \$77,000
25. AstraZeneca 2171L/0003 (PI) A Phase I, Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects with Advanced Prostate Adenocarcinoma.	11/01/03-10/31/04 \$244,501
26. Cell Genesys, Inc. L-0017 (PI) Long-Term Follow-up of Patients Treated w/ Adeno-Associated Viral-Based Gene Therapy.	04/01/02-04/01/05 \$45,945
27. Cell Genesys, Inc. G-0034 (PI) A Phase 3 Randomized Open-Label Study of Docetaxel in Combination with CG1940&CG8711 vs. Decetaxel & Prednisone in Taxane-Naive Patients w/ Metastatic Hormone-Refractory Prostate Cancer with Pain.	03/03/06-03/02/10 \$117,553
28. Dendreon Corporation D9902B (PI) A Phase III Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (Provenge, APC8015) in Subjects with Androgen Independent Prostatic Carcinomas.	09/01/03-12/31/08 \$145,570
29. Dendreon Corporation D9901 (PI) Trial of Immunotherapy with Autologous Antigen-Loaded Dendritic Cells (APC8015) for Asymptomatic Metastatic Hormone-Refractory Prostate Cancer.	03/01/00-02/28/05 \$388,453
30. Dendreon Corporation D9903 (PI)	03/01/00-02/28/05

Phase II Trial with Cryopreserved Autologous Antigen-Loaded Dendritic Cells (APC 8015F) for Hormone-Refractory Prostate with Objective Disease Progression.	\$96,577
31. Genetics Institute, Inc. 3066K1-201-US (PI) A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Intravenous CCI-779 Administered Weekly to Patients with Androgen-Independent Prostate Cancer.	12/01/00-11/30/05 \$115,513
32. Novartis Pharma AG CPTK787AUS11 (PI) A Phase I/II Study of Docetaxel/Prednisone and PTK 787/ZK 222584 in Previously Untreated Metastatic Hormone Refractory Prostate Cancer.	09/16/04-09/15/07 \$503,905
33. Novartis Pharma AG ST1571BUS60 (PI) A Phase I/II Study of Estramustine, Docetaxel & ST15171 (Gleevec) in Men w/ Hormone Refractory Prostate Cancer	12/01/02-07/01/05 \$275,569
34. Novartis Pharma AG CZOL446-0704 (PI) Phase III trial evaluating Zoledronate + standard therapy vs. placebo + standard therapy in patients w/ recurrent carcinoma of the prostate	08/01/99-11/30/05 \$273,703
35. DOD Army Med. Res. Acq. Activity W81XWH-06-1-0256 (PI) Prostate Cancer Clinical Trials Group - UCSF Site	01/15/06-01/14/09 \$900,000

PEER REVIEWED PUBLICATIONS (Includes Reviews):

1. **Small EJ**, Katzman JA, Russell TP, Ratnoff OD. A monoclonal antibody that inhibits activation of human Hageman factor (Factor XII). *Blood* 65: 202, 1985.
2. **Small EJ**, Gordon JG, Dahms BB. Malignant rhabdoid tumor of the heart. *Cancer* 55:2850, 1985.
3. **Small EJ**, Sivakoff MC. Dual origin of the left coronary artery in an infant. *Pediatr Pathol* 5: 373, 1986.
4. Roessmann U, **Small EJ**, Velasco ME. Neuropathology of septo-optic dysplasia (DeMorsier syndrome) *J Neuropathol Exp Neurol* 46:5, 597, 1987.
5. **Small EJ**, Venook AP, Damon LE. Gallium-avid thymic hyperplasia in an adult after chemotherapy for Hodgkin's disease. *Cancer* 72: 905-908, 1993.
6. Wilkinson MJ, Frye JW, **Small EJ**, Venook AP, Carroll PR, Ernest ML, Stagg RJ. A Phase II study of constant infusion floxuridine for the treatment of metastatic renal cell carcinoma. *Cancer* 71: 3601-3604, 1993.
7. **Small EJ**. Prostate Cancer: Who to screen, and what the results mean. *Geriatrics* 48: 28, 1993.
8. Wolf JS, Aronson FR, **Small EJ**, Carroll PR. Nephrectomy for metastatic renal cell carcinoma: A component of systemic treatment regimens. *J Surg Oncol* 55: 7-13, 1994.
9. **Small EJ**, Carroll PR. Prostate specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. *Urology* 43: 408-410, 1994.
10. **Small EJ**, Frye JW, Carroll PR. A phase I/II study of alternating constant infusion floxuridine with constant

- infusion vinblastine for the treatment of metastatic renal cell carcinoma. *Cancer* 73: 2803-07, 1994.
11. **Small EJ.** Treatment of advanced prostate cancer. *Western Journal of Medicine* 160: 253, 1994.
 12. Timmerman JM, Northfelt DW, **Small, EJ.** Malignant germ cell tumors in men infected with the human immunodeficiency virus: Natural history & results of therapy. *J Clin Oncol* 13:1391, 1995.
 13. **Small EJ, Srinivas S.** The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients. *Cancer* 76: 1428-1434, 1995.
 14. **Small, EJ.** Update on renal cell carcinoma. *Cancer Response System.* Am Cancer Soc. January 1995.
 15. **Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP.** Doxorubicin and dose-escalated cyclophosphamide with GM-CSF for the treatment of hormone resistant prostate cancer. *J Clin Oncol* 14: 1617-25, 1996.
 16. **Small EJ.** Treatment options for hormone refractory prostate cancer. *New Developments in Prostate Cancer and Treatment* 1: 1-6, 1996.
 17. Cher ML, Bova S, Moore DH, **Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH.** Genetic alterations in untreated metastases and androgen independent prostate cancer detected by comparative genomic hybridization and allelotyping. *Ca Res* 56:3091-3102, 1996.
 18. **Small EJ, Kantoff P, Vogelzang N.** CALGB trials for advanced prostate cancer. *Sem Oncol* 23:28, 1996.
 19. **Small EJ, Srinivas S.** Antiandrogen withdrawal in patients with advanced prostate cancer. *Urology Digest (Milan)* 3: 8-11, 1996.
 20. **Small EJ, Fippin L, Ernest ML, Carroll PR.** A carboplatin-based regimen for the treatment of advanced transitional cell carcinoma of the urothelium. *Cancer* 78: 1775-1780, 1996.
 21. Roach M, Meehan S, Weil M, Ryu J, **Small EJ, Margolis LW, Presti J, Carroll PC, Phillips TL.** Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. *J Urol* 156:5, 1719-1723, 1996.
 22. **Small EJ, Baron A, Fippin L, Apodaca D.** Ketoconazole retains activity in advanced prostate cancer patients who have progressed despite flutamide withdrawal. *J Urol* 157:4, 1204, 1997.
 23. **Small EJ, Vogelzang NJ.** Second line hormonal therapy for advanced prostate cancer: A shifting paradigm. *J Clin Oncol* 15: 382,1997.
 24. Schellhammer PF, Venner P, Haas GP, **Small EJ, Niet PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJ.** Prostate-specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. *J Urol* 157:5, 1731-35, 1997.
 25. Carroll PR, Presti JC, **Small EJ, Roach M.** Focal therapy for prostate cancer 1996: Maximizing outcome. *Urology* 49:84, 1997.
 26. **Small EJ, Baron A, Bok R.** Simultaneous anti-androgen withdrawal and treatment with ketoconazole in patients with advanced prostate cancer. *Cancer* 80:9, 1755-1759, 1997.
 27. **Small EJ.** Prostate Cancer. *Current Opinion in Oncology* 9: 277-286, 1997.
 28. Roach M, **Small EJ.** Using the serum prostate specific antigen (PSA) to screen for and manage prostate cancer. *PPO Updates* 11:9, 1-14, 1997.

29. **Small EJ**, Fippin LJ, Whisenant SP. Pyrazoloacridine for the treatment of hormone refractory prostate cancer. *Cancer Investigation* 16:17, 456–461, 1998.
30. Grossfeld GD, **Small EJ**. Long term side effects of treatment for testis cancer. *Uro Clin of N.Am* 25:23, 1998.
31. **Small EJ**, Weiss GR, Walther PJ, Johnson DJ, Wilding G, Paton V. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. *Ca J Scientific Am* 4:3, 162–67, 1998.
32. Frohlich MW, **Small EJ**. Stage II nonseminomatous testis cancer: The roles of primary and adjuvant chemotherapy. *Urologic Clinics of North America* 25:3, 451, 1998.
33. Grossfeld G, **Small EJ**, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: Initial experience. *Urology* 51:1, 137–144, 1998.
34. **Small EJ**. Prostate cancer: Incidence, management and outcomes. *Drugs & Aging. Adis Int'l* 13:71, 1998.
35. **Small EJ**. Update on diagnosis and treatment of prostate cancer. *Current Opinion in Oncology* 10:244, 1998.
36. Savarese D, Halabi S, Hars V, Akerley W, Godley P, Hussain A, **Small EJ**, Vogelzang NJ. A phase II study of docetaxel, estramustine and low dose hydrocortisone in men with hormone refractory prostate cancer: Preliminary results of CALGB 9780. *Semin Oncol* 26 (suppl. 17):39, 1999.
37. Reese DM, **Small EJ**. Secondary hormonal manipulations in hormone-refractory prostate cancer. *Urologic Clinics of North America* 26: 311, 1999.
38. Coakley F, Presti Jr J, **Small EJ**. Diffuse retroperitoneal amyloidosis due to renal cell carcinoma. *Br J Radiol* 72: 412-413, 1999.
39. Bok R, **Small EJ**. The treatment of advanced prostate cancer with ketoconazole: Safety issues. *Drug Safety.* 20:5, 451, 1999.
40. Taplin ME, Bubley GJ, **Small EJ**, Upton M, Yoo-Joung K, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. *Cancer Res* 59: 2511-2515, 1999.
41. **Small EJ**. Advances in prostate cancer. *Current Opinion in Oncology* 11: 226, 1999.
42. Kashani-Sabet M, Sagebiel RW, Glassberg AB, Allen RE, **Small EJ**. Outpatient combination chemoimmunotherapy for metastatic melanoma: Results of a phase I/II trial. *Cancer* 86: 2160-65, 1999.
43. Reese DM, **Small EJ**. The treatment of hormone refractory prostate cancer. *Acta Gerontol* 49:11, 1999.
44. **Small EJ**, Reese DM, Whisenant S, Um B, Dixon SC, Figg WD. Therapy of advanced prostate cancer with Granulocyte Macrophage Colony-stimulating Factor. *Clin Cancer Res* 5:1738, 1999.
45. **Small EJ**, Reese DM. Hormone refractory prostate cancer: An evolving standard of care. *Semin. Oncol* 26: 61-7, 1999.
46. Bubley G, Carducci M, Dawson N, Eisenberger M, Figg W, Halabi S, Oh W, Scher H, **Small EJ**, Smith MR, Trump DL, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: Recommendations from the PSA Working Group. *J Clin Oncol* 17: 3461-3467, 1999.
47. Reese DM, Corry M, **Small EJ**. Infusional floxuridine-based therapy for metastatic renal cell carcinoma. *Cancer* 88: 1310-1316, 2000.
48. **Small EJ**, Meyer M, Marshall ME, Reyno LM, Myers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ,

- Eisenberger M. Suramin therapy for patients with symptomatic hormone refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. *J Clin Oncol* 18: 1440-1450, 2000.
49. **Small EJ**, Reese DM. New Treatment Strategies in Advanced Prostate Cancer in: *Radiologic Clinics of North America* 38: 203-211, 2000.
 50. Dawson NA, Conway MR, Halabi S, **Small EJ**, Vogelzang NJ. A randomized study comparing standard vs. moderately high-dose megestrol acetate in advanced prostate cancer: CALGB 9181. *Cancer* 88:825-34, 2000.
 51. **Small EJ**, Reese DM. Update on prostate cancer research. *Curr Opinion in Oncol* 12: 265-272, 2000.
 52. Hussain M, Petrylak D, **Small EJ**, Eisenberger MA, Crawford ED. Androgen deprivation plus 4-courses fixed schedule suramin in patients with newly diagnosed metastatic prostate cancer: A SWOG Study. *J Clin Oncol* 18:1043-49, 2000.
 53. Reese DM, **Small EJ**. Therapy of advanced prostate cancer, Part I: Antiandrogen withdrawal, androgen receptor mutations, and secondary hormonal manipulations. *The Prostate Journal* 2:3, July 2000.
 54. **Small EJ**, Figlin R, Petrylak D, Vaughn DJ, Sartor O, Horak I, Pincus R, Kremer A, Bowden C. A phase I/II pilot study of KW-2189 in patients with advanced renal cell carcinoma. *Investigational New Drugs* 18: 193-197, 2000.
 55. Reese DM, **Small EJ**. Therapy of advanced prostate cancer, Part II: Response endpoints and the use of chemotherapy. *The Prostate Journal* 2:4, 173-178, 2000.
 56. Tigrani VS, Reese DM, **Small EJ**, Presti Jr. JC, Carroll PR. The potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: A retrospective analysis. *Urology* 55: 36, 2000.
 57. **Small EJ**, Lew D, Petrylak D, Eastham J, Crawford E. SWOG study of paclitaxel and carboplatin for advanced transitional cell carcinoma: Importance of survival as a clinical trial endpoint. *J Clin Oncol* 18:2537-44, 2000.
 58. Grossfeld GD, Tigrani VS, Roach M III, Weinberg VK, Presti JP Jr., **Small EJ**, Carroll PR. Management of a positive surgical margin after radical prostatectomy: Decision analysis. *J Urol* 164: 93-100, 2000.
 59. **Small EJ**, Reese DM, Frohlich M, Bok R, Shinohara K, Grossfeld G, Kelly WK. A prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. *J Clin Oncol* 18: 3595-3603, 2000.
 60. **Small EJ**, Fratesi P, Reese DM, Strang G, Laus R, Peshwa M, Valone FH. Immunotherapy of hormone refractory prostate cancer with antigen-loaded dendritic cells. *J Clin Oncol* 18:3894, 2000.
 61. Halabi S, Conway MR, **Small EJ**, Vogelzang NJ, Dawson NA. Serum prostate specific antigen as an outcome variable: Analysis of a randomized phase III trial in hormone refractory prostate cancer, treated with second-line hormonal therapy. *The Prostate Journal* 3: 18-25, January 2001.
 62. Laus R, Yang DM, Ruegg CL, Shaper MH, **Small EJ**, et al. Dendritic cell immunotherapy of prostate cancer: Preclinical models and early clinical experience. *Ca Res Ther & Control* 00:1-10, 2000.
 63. Harris KA, **Small EJ**. Hormonal treatment for prostate cancer. *Exp. Opin. Invest. Drugs* 10:493, 2001.
 64. Kelly WK, Curley T, Slovin S, Bajorin D, Kantoff P, Oh W, **Small EJ**, Schwartz L, Larson S, Tong W, Scher H. Paclitaxel, estramustine phosphate and carboplatin (TEC) in patients with advanced prostate cancer. *J Clin Oncol* 19: 44-53, 2001.
 65. **Small EJ**. Docetaxel in prostate cancer: Current status of studies. *AntiCancer Drugs* 12:S17-S20, 2001.

66. **Small EJ**, McMillan A, Meyer M, Chen L, Slichenmyer W, Lenehan P, Eisenberger M. Serum PSA decline as a marker of clinical outcome in hormone refractory prostate cancer patients: Association with progression-free survival, pain endpoints and survival. *J Clin Oncol* 19: 1304-1310, 2001.
67. Rini BI, **Small EJ**. Anti-tumor effects of granulocyte-macrophage colony-stimulating factor in prostate cancer. *Immune-Enhancing Cytokines* 3: 5-7, 2001.
68. Mehta R, Kyshtoobayea A, Kurosaki T, **Small EJ**, Kim H, Stroup R, McLaren CE, Li KT, Fruehauf JP. Independent association of angiogenesis index with outcome in prostate cancer. *Clin Cancer Res* 7: 81-88, 2001.
69. Rini BI, **Small EJ**. Immunotherapy for Prostate Cancer. *Current Oncol Reports* 3: 418-423, 2001.
70. Ko Y-J, **Small EJ**, Kabbinavar F, Reese D, DePaoli A, Bublely GJ. A multi-institutional phase II study of SU101, a platelet-derived growth factor inhibitor, for patients with HRPc. *Clin Cancer Res* 7:800-05, 2001.
71. Rini BI, **Small EJ**. An update on prostate cancer. *Current Opinion in Oncology* 13: 204-211, 2001.
72. Savarese D, Halabi S, Hussain A, **Small EJ**, Vogelzang NJ. A phase II study of docetaxel, estramustine and low dose hydrocortisone in men with HRPc: CALGB 9780. *J Clin Oncol* 19: 2509-16, 2001.
73. **Small EJ**, Harris KA, Frohlich MW, Bok, RA. The UCSF advanced prostate cancer program. *Urologic Oncology* 6: 197-201, 2001.
74. Reese DM, **Small EJ**, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. *Am J Clin Path* 116: 234-239, 2001.
75. Valone FH, **Small EJ**, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R. Dendritic cell-based treatment of cancer: Closing in on a cellular therapy for prostate cancer. *Cancer Journal* 7:S53-S61, 2001.
76. Kantoff PW, Halabi S, Hayes DF, Vogelzang NJ, **Small EJ**. Prognostic significance of reverse transcriptase polymerase chain reaction (rt-PCR) for prostate specific antigen in men with hormone refractory prostate cancer. *J Clin Oncol* 19: 3025-3028, 2001.
77. Bok RA, Halabi S, Vogelzang NJ, Shuman M, **Small EJ**. VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: A CALGB study. *Cancer Res* 61: 2533-36, 2001.
78. Grossfeld G, Chaudhary U, Carroll P, **Small EJ**. Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. *Urol* 58:240-245, 2001.
79. Grossfeld G, **Small EJ**, Carroll P. Androgen deprivation therapy for patients with clinically localized prostate cancer and in patients with biochemical recurrence following radical prostatectomy. *Urology* 58 [suppl 2A]: 56-64, 2001.
80. **Small EJ**, Bok RA, Reese DM, Sudilovsky D, Frohlich M. Docetaxel, estramustine plus trastuzumab in patients with metastatic androgen-independent prostate cancer. *Semin Oncol* 28:71,2001.
81. **Small EJ**, Reese DM, Frohlich MW, Bok RA, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. *Classic Papers and Current Comments* 6: 301-310, 2001.
82. Reese DM, Fratesi P, Corry M, Novotny W, **Small EJ**. A phase II trial of humanized anti-VEGF antibody for the treatment of androgen-independent prostate cancer. *The Prostate Journal* 3:2, 2001.
83. George DJ, Halabi S, Vogelzang NJ, Hayes DF, **Small EJ**, Kantoff PW. Prognostic significance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone refractory prostate cancer: A CALGB study. *Clin*

Cancer Res 7: 1932-36, 2001.

84. Lipton A, **Small EJ**, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J. The new bisphosphonate Zometa (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: A comparison to pamidronate. *Cancer Invest* 20: 45-47, 2002.
85. **Small EJ**, Roach III M. PSA in prostate cancer: A case study in the development of a tumor marker to monitor recurrence and assess response. *Semin Oncol* 29: 264-273, 2002.
86. Harris KA, Harney E, **Small EJ**. Liposomal doxorubicin for the treatment of hormone refractory prostate cancer. *Clinical Prostate Cancer* 1: 37-41, 2002.
87. Ross RW, **Small EJ**. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. *J Urol* 167: 1952-1956, 2002.
88. Harris KA, **Small EJ**. Low-dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen-independent prostate cancer. *J Urol* 168: 542-545, 2002.
89. Rini BI, **Small EJ**. Prostate cancer update. *Current Opinion in Oncology* 14:286-291, 2002.
90. **Small EJ**, Halabi S, Ratain M, Rosner G, Ansari R, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. A phase III study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of CALGB 9480. *J Clin Oncol* 20, 3369-3375, 2002.
91. Oh WK, **Small EJ**. PC-SPES and prostate cancer. *Urol Clinics of N. America* 29, 59-66, 2002.
92. Rini BI, **Small EJ**. Treatment of hormone refractory prostate cancer. *Current Treatment Options in Oncology* 3, 437-446, 2002.
93. Smaletz O, Scher HI, **Small EJ**, McMillan A, Regan K, Kelly WK. A nomogram for overall survival of patients with progressive metastatic prostate cancer following castration. *J Clin Oncol* 20:3972-82, 2002.
94. Harris KA, **Small EJ**. Secondary hormonal manipulation of prostate cancer. *Semin Urol Oncol* 20:24-30, 2002.
95. Herbst RS, Maddox AM, Rothenberg MD, **Small EJ**, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. The selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors: Results of a phase I trial. *J Clin Oncol* 20: 3815-3825, 2002.
96. Bok RA, **Small EJ**. Bloodborne biomolecular markers in prostate cancer development and progression. *Nature Reviews Cancer* 2: 918-926, 2002.
97. Rini B, Weinberg V, Bok R, **Small EJ**. PSA kinetics as a measure of the biologic effect of GM-CSF in patients with serologic progression of prostate cancer. *J Clin Oncol* 21: 99-105, 2003.
98. Meng MV, Grossfeld GD, Carroll PC, **Small EJ**. Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. *Semin Urol Onc* 20:10-18, 2002.
99. Oh W, **Small EJ**. Complementary & alternative therapies in prostate cancer. *Semin Oncol.* 29:575, 2002.
100. Halabi S, **Small EJ**, Hayes DF, Vogelzang NJ, Kantoff PW. The prognostic significance of reverse transcriptase polymerase chain reaction (rt-PCR) for prostate specific antigen in prostate cancer patients with one prior hormonal

- therapy: A nested study within CALGB 9583. *J Clin Oncol* 21: 490-495, 2003.
101. **Small EJ**, Halabi S, Bajorin D. Overview of Bladder Cancer Trials in the Cancer and Leukemia Group B (CALGB). *Cancer* (supplement 97/8), 2090-2098, 2003.
 102. Halabi S, **Small EJ**, Kantoff P, Dawson N, Levine E, Vogelzang NJ. A prognostic model for predicting overall survival in men with hormone refractory metastatic prostate cancer. *J Clin Oncol* 21:1232-37, 2003.
 103. Rosenberg J, **Small EJ**. Prostate cancer update. *Current Opinion in Oncology* 15: 217-221, 2003.
 104. Taplin ME, Halabi S, Wods B, Picus J, Hayes DF, Kantoff P, Vogelzang NJ, **Small EJ**. Androgen receptor mutations in androgen independent prostate cancer: CALGB 9663. *J Clin Oncol* 21: 2673-2678, 2003.
 105. Rini BI, **Small EJ**. The potential for prostate cancer immunotherapy. *Critical Reviews in Oncology/Hematology* 46: S117-125, 2003.
 106. **Small EJ**, Smith MR, Seaman JJ, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. *J Clin Oncol* 21: 4277-4284, 2003.
 107. Fong L, **Small EJ**. Immunotherapy for prostate cancer. *Semin Oncol* 30: 649-658, 2003.
 108. LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, **Small EJ**, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) in non-small cell lung cancer and other solid tumors. *Clin Ca Res* 9: 2040-48, 2003.
 109. Ryan CJ, **Small EJ**. Role of secondary hormonal therapy in the management of recurrent prostate cancer. *Urology* 62 (suppl 6B): 87-94, 2003.
 110. Oh W, Halabi S, Kelly W, Werner C, Godley P, Vogelzang N, **Small EJ**. A phase II study of estramustine, docetaxel and carboplatin with G-CSF support in patients with hormone refractory prostate cancer: Cancer and Leukemia Group B 99813. *Cancer* 98: 2592-2598, 2003.
 111. Eastham JA, Kelly WK, Grossfeld GD, **Small EJ**. CALGB 90203: A randomized phase III study of radical prostatectomy alone versus estramustine and docetaxel prior to radical prostatectomy for patients with high-risk localized disease. *Urology* 62 (suppl 6B): 55-62, 2004.
 112. Garcia JA, **Small EJ**. State-of-the-art strategies for managing hormone refractory prostate cancer. *Contemporary Urology* 26-37, April 2004.
 113. Scher HI, Eisenberger M, D'Amico AV, Halabi S, **Small EJ**, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA: Recommendations from the PSA Working Group. *J Clin Oncol* 22: 537-556, 2004.
 114. Ryan CJ, **Small EJ**. Androgen-independent prostate cancer: Target evolution and disease dynamics. *Drug Discovery Today* 1: 223-228, 2004.
 115. **Small EJ**, Halabi S, Dawson NA, Stadler WM, Rini BI, Pincus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. A phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: Results of CALGB 9583. *J.Clin Oncol* 22: 1025-1033, 2004.

116. Ryan CJ, **Small EJ**. Prostate cancer update. *Current Opinion in Oncology* 16: 242-246, 2004.
117. Higano C, Vogelzang NJ, **Small EJ**. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in bone scan negative hormone refractory prostate cancer. *Clin Ca Res* 10:1219-25, 2004.
118. Rini BI, Weinberg V, **Small EJ**. Practice and progress in kidney cancer: Methodology for novel drug development. *J Urol* 171: 2115-2121, 2004.
119. Rini BI, Halabi S, Taylor J, **Small ES**, Schilsky RL. CALGB 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-VEGF antibody (bevacizumab, Avastin®) in metastatic renal cell carcinoma. *Clinical Cancer Research* 10: 2584-2586, 2004.
120. Rini BI, **Small EJ**. Biology and clinical efficacy of VEGF targeted therapy in renal cell carcinoma. *J Clin Oncol* 23: 1028-43, 2004.
121. Rini BI, Weinberg V, Shaw V, Bok RA, Park JW, **Small EJ**. Time to disease progression to evaluate a novel protein kinase C inhibitor (UCN-01) in renal cell carcinoma. *Cancer* 101: 90-95, 2004.
122. Rosenberg JE, **Small EJ**. Second-line chemotherapy for hormone refractory prostate cancer: Has the time come? *Clin Prostate Cancer* 3:2, 122-124, 2004.
123. Oh WK, Kantoff PW, Weinberg V, Rini BI, Bok RA, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, **Small EJ**. A prospective, multicenter, randomized phase II trial of the herbal supplement PC-SPES and diethylstilbestrol in patients with androgen-independent prostate cancer. *J Clin Oncol* 22:3705-12, 2004.
124. Ryan CJ, **Small EJ**. The selection of hormonal therapy in prostate cancer: Who, when and for how long? *J Nat'l Comp Ca Network* 2:3, 2004.
125. Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang NJ, **Small EJ**. 9-nitrocamptothecin as second-line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of CALGB 99901. *Urologic Oncology* 22: 398-403, 2004.
126. Petrylak DP, Tangen CM, Hussain M, Lara PN, Jr., Jones JA, **Small EJ**, Raghavan D, Crawford ED. Docetaxel and estramustine versus mitoxantrone and prednisone: Results of SWOG 99-16. *New Engl J Med* 351: 1513-1520, 2004.
127. Ahles TA, Herndon JE, **Small EJ**, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. Quality of life impact of three different doses of suramin (bevacizumab) in metastatic renal cell carcinoma. *Clin Cancer Res* 10: 2584-2586, 2004.
128. Halabi S, **Small EJ**, Vogelzang NJ, Barrier RC, George SL, Gilligan TD. Impact of race on survival in men with hormone refractory prostate cancer. *Urology* 64: 212-217, 2004.
129. Ryan CJ, **Small EJ**. Long-term response to ketoconazole as secondary hormonal therapy in prostate cancer. *Am J Oncology Rev* 3: 471-474, 2004.
130. Smith MR, Manola J, Kaufman D, Oh W, **Small EJ**, Kantoff PW. Rosiglitazone vs. placebo for men with prostate cancer and a rising serum prostate specific antigen after radical prostatectomy and/or radiation therapy. *Cancer* 101: 1569-74, 2004.
131. Galsky M, **Small EJ**, Oh W, Chen I, Smith D, Colevas A, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone with or without estramustine phosphatase in patients with progressive castrate metastatic prostate cancer. *J Clin Oncol* 23: 1439-1446, 2005.
132. Ryan CJ, **Small EJ**. Secondary hormonal manipulations in prostate cancer. *Current Oncology Reports* 7: 228-233, 2005.

133. Rini BI, Weinberg VW, **Small EJ**. A Phase I Trial of Fixed Dose Rate Gemcitabine and Capecitabine in Metastatic Renal Cell Carcinoma. *Cancer* 103: 553-558, 2005.
134. Rosenberg JE, Carroll PR, **Small EJ**. Update on chemotherapy for advanced bladder cancer. *J Urol* 174: 14-20, 2005. 2005.
135. George D, Kantoff P, Halabi S, Vogelzang N, Sanford B, Shepard T, **Small EJ**. The prognostic significance of plasma interleukin-6 levels in patients with metastatic, hormone refractory prostate cancer: Results from CALGB 9480, version 2. *Clin Cancer Res* 11: 1815-20, 2005.
136. Ryan CJ, **Small EJ**. Progress in detection and treatment of prostate cancer. *Current Opinion in Oncology* 17: 257-260, 2005.
137. Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, **Small EJ**. High-dose etoposide, thiotepa and dose-adjusted carboplatin with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. *Am J Clin Oncol* 28: 130-37, 2005.
138. Webster WS, **Small EJ**, Rini BI, Kwon E. Prostate Cancer Immunology: Biology, Therapeutics and Challenges. *J Clin Oncol* 23(32): 8262-69, 2005.
139. Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, **Small EJ**. A phase II trial of R1157, an oral farnesyltransferase inhibitor in patients with advanced urothelial tract transitional cell carcinoma. *Cancer* 103: 2035-2041, 2005.
140. Ryan CJ, **Small EJ**. Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate. *J Clin Oncol* 23(32): 8225-31, 2005.
141. Rini BI, Wadhwa M, Bird C, **Small EJ**, Gaines-Das R, Thorpe R. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte-macrophage colony-stimulating factor. *Cytokine* 29: 56-66, 2005.
142. Sheriff S, Dumican S, **Small EJ**, Carroll P. Lifestyle correlates of health perception and treatment satisfaction in a clinical cohort of men with prostate cancer. *Clin Prostate Ca* 3: 239-45, 2005.
143. Smith MR, Kabbavar F, Saad F, Hussain A, Gittleman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnarz R, Zheng, M, Goessl C, Hei YJ, **Small EJ**, Cook R, Higano CS. Natural history of rising serum prostate specific antigen in men with castrate non-metastatic prostate cancer. *J Clin Oncol* 23: 2918-25, 2005.
144. Stadler WM, Rosner G, **Small EJ**, Hollis D, Rini BI, Zaentz SD, Mahoney J, Ratain MJ. Successful implementation of the randomized discontinuation trial design: An application to the study of putative antiangiogenic agent carbxyaminoimidazole (CAI) in renal cell carcinoma: CALGB 69901. *J Clin Oncol* 23:3726-32, 2005.
145. Rini BI, Beinart G, Weinberg V, **Small EJ**. APC8015 (Provenge) in patients with androgen-independent, biochemically relapsed prostate cancer. *Clin Prostate Cancer* 4: 55-60, 2005.
146. Taplin ME, George DJ, Halabi S, Sanford BL, Febbo PG, Hennessey KT, Kanotff P, **Small EJ**. The prognostic significance of plasma chromogranin A levels in hormone refractory prostate cancer patients treated on CALGB 9480. *Urology* 66: 386-91, 2005.
147. Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, **Small EJ**, Taplin ME, Kantoff PW. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer: A CALGB Study. *Clin Ca Res* 11:5195-5198, 2005.
148. Vaishampayan U, Faulkner J, **Small EJ**, Petrylak D, Crawford ED. Phase II trial of carboplatin and paclitaxel in

- cisplatin refractory advanced transitional cell carcinoma: A SWOG study. *Cancer* 104: 1627-1632, 2005.
149. Garcia JA, Weinberg V, **Small EJ**. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in androgen-independent prostate cancer patients. *Clin Prostate Cancer* 4:113-117, 2005.
 150. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok RA, Simko J, **Small EJ**. Maximal Cox-2 immunostaining predicts clinical response to celecoxib and interferon-alpha therapy in metastatic renal cell carcinoma. *Cancer* 106: 566-75, 2006.
 151. **Small EJ**, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. *J Urol* 176:S66, 2006
 152. Rosenberg JE, Galsky MD, Weinberg VK, Oh WK, Kelly WK, **Small EJ**. A retrospective evaluation of second-line chemotherapy response in hormone refractory prostate cancer. *Cancer* 106: 58-62, 2006.
 153. So-Rosillo R, **Small EJ**. Sipuleucel-T (APC8015) for prostate cancer. *Exp Rev Anticancer Ther* 6:1163, 2006.
 154. Petrylak DP, Ankerst D, Taplin ME, **Small EJ**, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. *J Natl Ca Inst* 98: 516-21, 2006.
 155. **Small EJ**, Halabi S, Kantoff P, D'Amico A, Stadler W. Activities and accomplishments of the Cancer and Leukemia Group B Genitourinary Committee. *Clin Cancer Res* 12: 3596s-600s, 2006.
 156. **Small EJ**, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Anda D, Work P, Kim D, Wilding G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-target oncolytic adenovirus for the treatment of hormone refractory prostate cancer. *Mol Ther* 14: 107-17, 2006.
 157. Ryan CJ, **Small EJ**. Androgen deprivation therapy in locally advanced and metastatic prostate cancer. *Minerva Urol Nefrol* 58: 119-26, 2006.
 158. Rini BI, Fong L, Weinberg V, Kavanaugh B, **Small EJ**. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. *J Urol* 175: 2087-91, 2006.
 159. Montie JE, Abrahams NA, Eisenberger MA, Lange PH, Pollack A, Sexton WJ, Shipley WU, **Small EJ**, Trump DL, Walther PJ, Wilson TG. Bladder cancer. *J Natl Compr Ca Netw* 4:984-1014, 2006.
 160. Wilding G, Soulie P, Trump D, Das-Gupta A, **Small EJ**. Results from a pilot trial of Gefitinib (Iressa ZD19839) in combination with docetaxel and estramustine in patients with hormone refractory prostate cancer. *Cancer* 106: 1917-24, 2006.
 161. Ryan CJ, **Small EJ**. High-risk biochemical relapse and the timing of androgen deprivation therapy. *J Urol* 176: S61-65, 2006.
 162. Humphrey P, Halabi S, **Small EJ**, Kantoff P. Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480. *Clin GU Cancer* 4: 269-74, 2006.
 163. Fong L, **Small EJ**. Immunotherapy for prostate cancer. *Curr Urol Rep* 7: 239-46, 2006.
 164. Halabi S, Vogelzang NJ, Ou SS, **Small EJ**. Survival of octagenarians with hormone refractory prostate cancer: A pooled analysis of 8 Cancer & Leukemia Group B (CALGB) studies. *J Urol* 176: 81-86, 2006.
 165. Lin AM, Rini BI, **Small EJ**. Clinical trials in patients with biochemically relapsed prostate cancer. *BJU International* 97: 905-10, 2006.
 166. Rini B, Fong L, Weinberg V, Conry S, **Small EJ**. Combination immunotherapy with prostatic acid phosphatase-

pulsed antigen presenting cells plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. *Cancer* 107: 67-74, 2006.

167. Ryan CJ, Lin AM, **Small EJ**. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. *Urol Oncol* 24: 250-53, 2006.
168. **Small EJ**, Schellhammer PF, Higano C, Redfern CH, Nemunaitis J, Valone FH, Verjee S, Jones LA, Hershberg RM. Results of a placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol* 24: 3089-94, 2006.
169. So-Rosillo R, **Small EJ**. New immunotherapy for prostate cancer. *Am J Cancer* 5:1175, 2006.
170. Rini BI, Halabi S, Barrier R, Margolin KA, Linker CA, **Small EJ**. CALGB 90003: Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: An intergroup phase II study. *Blood & Bone Marrow Transplant* 12:778-85, 2006.
171. Lin AM, Hershberg RM, **Small EJ**. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen-presenting cells. *Urol Oncol* 24: 434-41, 2006.
172. Ryan CJ, **Small EJ**. Prostate cancer update. *Current Opinion in Oncology* 18: 284-288, 2006.
173. Kornblith AB, Dowell JM, Herndon JE, Engelman BJ, Bauer-Wu S, **Small EJ**, Morrison VA, Atkins J, Cohen HJ, Holland JC. Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: A Cancer and Leukemia Group B study. *Cancer* 107: 2706-14, 2006.
174. Lin AM, Rini BI, Weinberg V, Ryan CJ, Rosenberg JE, Fong L, **Small EJ**. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. *BJU Int.* 98:763-69, 2006.
175. Hussain M, Tangen C, Higano CS, Schellhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, **Small EJ**, Donnelly B, MacVicar G, Raghavan D. Absolute PSA value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from SWOG 9346 (INT-0162). *J Clin Oncol* 24: 3894-90, 2006.
176. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, **Small EJ**, Waldman F. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Impact of patient characteristics and Von Hippel-Lindau gene status. *BJU Int.* 98: 756-62, 2006.
177. Stadler W, Halabi S, Rini B, Ernstoff M, Davila E, **Small EJ**. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: A report of Cancer and Leukemia Group B protocol 90008 *Cancer* 107: 1273-79, 2006.
178. Ryan CJ, Elkin EP, **Small EJ**, DuChane J, Carroll P. Reduced incidence of bony metastasis at the time of initial prostate cancer diagnosis: Data from CaP SURE. *Urol Oncol* 24: 396-402, 2006.
179. Halabi S, Vogelzang NJ, Ou S-S, **Small EJ**. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: A pooled analysis of 9 Cancer and Leukemia Group B trials. *J Urol* 177: 531-34, 2007.
180. Hsieh AC, **Small EJ**, Ryan CJ. Androgen-response elements in hormone refractory prostate cancer: Implications for treatment development. *Lancet Oncol* 8: 933-39, 2007.
181. **Small EJ**, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 (Ipilimumab, MDX-010) in patients with hormone refractory prostate cancer. *Clin Cancer Res* 13; 1810-15, 2007.

182. Lin AM, Ryan CJ, **Small EJ**. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. *Crit Rev Oncol-Hematol*, 61: 243-54, 2007.
183. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, **Small EJ**, Goldfine ID. Expression of insulin-growth factor-1 receptor in local and metastatic prostate cancer. *Urol Oncol* 25: 134-40, 2007.
184. Fong L, **Small EJ**. Immunotherapy for prostate cancer. *Curr Oncol Rep* 9: 226-33, 2007.
185. Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, **Small EJ**. Evaluation and significance of circulating epithelial cells in patients with hormone refractory prostate cancer. *BJU Int* 99:519-24, 2007.
186. Rosenberg JE, **Small EJ**. Biology and clinical development of VEGF-directed therapy in kidney cancer. *Grand Rounds in Urology* 14-18, May 2007.
187. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, **Small EJ**. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a Cancer and Leukemia Group B study. *Clin Cancer Res* 13: 2030-37, 2007.
188. Lin AM, **Small EJ**. Prostate cancer update: 2006. *Curr Opinion in Oncology* 19: 229-33, 2007.
189. Lin AM, Rini B, Derynck M, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, **Small EJ**. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone refractory prostate cancer. *Clin Genitourin Cancer* 5: 323-28, 2007.
190. Harzstark AL, **Small EJ**. Immunotherapy for prostate cancer using antigen-loaded antigen presenting cells: APC8015 (Provenge). *Expert Opin Biol Ther* 7: 1275-80, 2007.
191. Ryan CJ, Stadler W, Roth B, **Small EJ**. Phase I dose escalation and pharmacokinetic study of AZD2171, a highly potent VEGFR tyrosine kinase inhibitor, in patients with hormone refractory prostate cancer. *Invest New Drugs* 25: 445-51, 2007.
192. Halabi S, Ou SS, Vogelzang NJ, **Small EJ**. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. *Cancer* 110: 1478-84, 2007.
193. Rosenberg JE, Weinberg VK, Kelly WK, Hussain MH, Wilding G, Gross M, Hutcheon D, **Small EJ**. Activity of second-line chemotherapy in docetaxel-refractory hormone refractory prostate cancer patients: a randomized phase II study of ixabepilone or mitoxantrone and prednisone. *Cancer* 110: 556-63, 2007.
194. **Small EJ**, Fontana J, Tannir N, DiPaola R, Wilding G, Rubin M, Iacona RB, Kabbinavar F. A phase II trial of Gefitinib in patients with non-metastatic hormone refractory prostate cancer. *BJU Int* 100:765-9, 2007.
195. **Small EJ**, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. *Clinical Cancer Research* 12(13):3883-91, 2007.
196. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, **Small EJ**. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. *J. Urol.*, 178(6):2372-6, 2007.
197. Ryan CJ, Hazstark AH, Rosenberg JE, Lin A, Goldfine ID, Kerner JF, **Small EJ**. A pilot dose escalation study of the effects of nordihydroguareacetic acid (NDGA) on hormone levels and prostate specific antigen in patients with relapsed prostate cancer. *BJU Int*. 101(4):436-9, 2008.

198. Fong L, **Small EJ**. Anti-CTLA-4 Antibody: The first in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment. *J Clin Oncol*, 2008.
199. D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, **Small EJ**, Kantoff PW. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II cancer and leukemia b study (CALGB 9682). *Urology*, 71(5):933-7, 2008.
200. Harzstark AL, **Small EJ**. Sipuleucel-T for the treatment of prostate cancer. *Drugs Today* 44(4):271-8, 2008.
201. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, **Small EJ**. Pain predicts overall survival in men with metastatic castration-resistant prostate cancer. *J Clin. Oncol.*, 26(15):2544-9, 2008.
202. Lin AM, **Small EJ**. Prostate Cancer Update: 2007. *Curr Opin Oncol* 20(3):294-9, 2008.
203. D'Amico AV, Halabi S, Tempany C, Titlebaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, **Small EJ**. Tumor volume changes on 1.5 tesla endorectal mri drug neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. *Int J Radiat Oncol Biol Phys.*, 71(1):9-15, 2008.
204. Scher, HI, Halabi S, Tannock I, Moris M, Sternberg CN, Carducci MA, Higano C, Bubley GJ, Driecer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, **Small EJ**, Beer TM, Wilding G, Martin A, Hussain M. Design and Endpoints of Clinical Trials for Patients with Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2). *J Clin. Oncol.*, 26(7):1148-59, 2008.
205. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CZP, Gittleman M, Simons JW, Sacks N, Aimi J, **Small EJ**. Phase 1/2 dose-escalation study of GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. *Cancer*, 113(5):975-84, 2008.
206. Dawson NA, Halabi S., Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, **Small EJ**, For Cancer and Leukemia Group B. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone-refractory prostate cancer: results of Cancer and Leukemia Group B Trial 90004. *Clinical Genitourinary Cancer*, 6(2): 60-150, 2008.
207. Kavanaugh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, **Small EJ**, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependant fashion. *Blood*, 112(4):1175-83, 2008.
208. Urba WJ, Nemunaitis J, Marshall F, Smith DC, Nguyen M, Ma J, Hege KM, **Small EJ**. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor (GM-CSF) secreting, allogeneic, cellular immunotherapy. *Journal of Urology*, 180(5):2011-7, 2008.
209. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S-S, Archer L, Atkins JN, Pincus J, Tanguay S, Dutcher J, **Small EJ**. Bevacizumab plus interferon-alpha compared with interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of CALGB 90206. *J Clin. Oncol.*, 26(33):5422-8, 2008.
210. Philips GK, Halabi S, Sanford BL, Bajorin D, **Small EJ**, Cancer and Leukemia Group B. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukemia Group B 90102. *BJU Int.*, 101(1):20-5, 2008.
211. Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, **Small EJ**, Cancer and Leukemia B. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before

- radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. *Cancer*, 113(11):3137-45, 2008.
212. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, **Small EJ**, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. *J Urol.*, 180(3):860-5, 2008.
213. Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, **Small EJ**. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. *Int. J. Radiat. Oncol. Biol. Phys.*, 72(3):814-9, 2008.
214. Fong L, Kwek SS, O'Brien S, Kavanagh, B, McNeel DG, Wenberg V, Lin AM, Rosenberg J, Ryan C, Rini BI, **Small EJ**. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. *Cancer Research*, 69(2): 609-615, 2009.
215. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, **Small EJ**, Trump DL, Walther PJ, Wilson TG. National Comprehensive Cancer Network. Bladder cancer. *J Natl. Compr. Canc. Netw.*, 7(1):8-39, 2009.
216. Philips GK, Halabi S, Sanford BL, Bajorin D, **Small, EJ** for the Cancer and Leukemia Group B (CALGB). A phase II trial of Cisplatin (C), Gemcitabine (G) and Gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. *Ann Oncol.*, 20(6):1074-9, 2009.
217. Harzstark AL, **Small EJ**. Immunotherapeutics in development of prostate cancer. *Oncologist*, 14(4):391-8, 2009.
218. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, **Small EJ**, Donnelly BJ, Sundram SK, Burch PA, DiPaola RS, Crawford ED. Prostate-specific antigen progression (PSA-P) predicts overall (OS) in patients with metastatic prostate cancer (PC): data from Southwest Oncology Group (SWOG) Trials 9346 (INT 0162) and 9916. *J Clin. Oncol.*, 27(15):2450-6, 2009.
219. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, **Small EJ**, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Research. *Clin Genitourin Cancer*, 7(1):51-7, 2009.
220. Higano CS, Schellhammer PF, **Small EJ**, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. *Cancer*, 115(16):3670-9, 2009.
221. Chien AJ, Ja I, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, **Small EJ**, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day Ipatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. *Clin Cancer Res*, 15(17):5569-75, 2009.
222. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, **Small EJ**. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of devense prostate cancer clinical trials consortium. *J Clin Oncol.*, 27(17):2772-8, 2009.
223. Bajorin DF, Halabi S, **Small EJ**. Arsenic Trioxide in Recurrent Urothelial Cancer: A Cancer and Leukemia Group B Phase II Trial. *Clinical Genitourinar Cancer*, 7(33):E66-70, 2009.

224. Halabi S, Vogelzang N, Ou S, Owzar K, Archer L, **Small EJ**. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. *J Clin Oncol.*, 27(17):266-71, 2009.
225. Aggarwal R, Weinberg V, **Small EJ**, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. *Clin Genitourin Cancer*, 7(3):E71-6, 2009.
226. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff, PW, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, **Small EJ**. Phase I Clinical Trial of the CPY 17 Inhibitor Abiraterone Acetate (CB7630), Demonstrating Clinical Activity in Castration-Resistant Prostate Cancer Patients with Prior Ketoconazole Therapy. *J Clin Oncol.*, 28(9):1481-8, 2010.
227. Harzstark AL, **Small EJ**. Castrate-resistant prostate cancer: therapeutic strategies. *Expert Opin Pharmacother*, 11(6):137-45, 2010.
228. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, **Small E**, Scher HI, de Bono JS. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with CYP17 inhibitor abiraterone acetate. *J Clin Oncol.*, 28(9):1489-95, 2010.
229. **Small EJ**, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. *J Clin Oncol*, 28(7):1085-7, 2010.
230. Rini B, Halabi S, Rosenberg J, Stadler W, Vaena D, Archer A, Atkins J, Picus J, Czaykowski P, Dutcher J, **Small, EJ**. A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma—final results of CALGB 90206. *J Clin. Oncol.*, 28(13):2137-43, 2010.
231. Higano CS, **Small EJ**, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. Sipuleucel-T. *Nat Rev Drug Discov.*, 9(7):513-4, 2010.
232. Kantoff PW, Higano CS, Shore ND, Berger ER, **Small EJ**, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med.*, 363(5): 411-22, 2010.
233. Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, **Small EJ**. Ixabepilone, Mitoxantrone, and Prednisone for Metastatic Castration Resistant Prostate Cancer (CRPC) after Docetaxel-based therapy—a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. *Cancer*, 2010, [Epub ahead of print].
234. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, **Small EJ**; for Cancer and Leukemia Group B. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. *Cancer*, 117(3):526-33, 2011.
235. **Small EJ**, de Bono JS. Prostate cancer: evolution or revolution? *J Clin Oncol.*, 29(27):3595-8, 2011.
236. Harzstark A, **Small EJ**, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase I study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. *Cancer*, 117(18):4194-200, 2011.
237. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bublely GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, **Small EJ**. Phase II study of abiraterone acetate in chemotherapy-naïve metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. *Clin Cancer Res.*, 17(14):4854-61, 2011.
238. Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, Dibiase SJ, **Small EJ**. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: Long-term results of CALGB 99809. *Cancer*, 117(24):5570-88, 2011.

239. Friedlander TW, Weinberg VK, **Small EJ**, Sharibb SJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: Results of a phase II study. *Urol Oncol.*, 30(4):408-14, 2012.
240. Kantoff PW, Higano CS, **Small EJ**, Whitmore JB, Frohlich MW, Schellhammer PF. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. *J Natl Cancer Inst.*, 104(14):1107-9, 2012.
241. Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, **Small EJ** for the Cancer and Leukemia Group B. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782. *Cancer*, 118(17):4138-47, 2012.
242. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, **Small EJ**, Harzstark AL, Lin AM, Fong L, Ryan CJ. A Phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. *Oncol Rep.*, 27(1):3-9, 2012.
243. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, **Small EJ**, Fong L. Diversity of antigen-specific responses included in vivo with ctla-4 blockade in prostate cancer patients. *J Immunol.*, 189(7):3759-66, 2012.
244. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, **Small EJ**, Wilding G, Gonnely BJ, Schellhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM Jr. Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346). *J Urol.*, 188(4):1164-9, 2012.
245. Kelley WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, **Small EJ**. Randomized, double-blind placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in metastatic castration-resistant prostate cancer: CALGB 90401. *J Clin Oncol.*, 30(13):1534-40, 2012.
246. Bluestone JA, **Small EJ**. The future of cancer treatment: will it include immunotherapy? *Cancer Cell*, 22(1):7-8, 2012.
247. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, **Small EJ**, Harzstark AL, Gordon MS, Viashampayan UN, Haas NB, Spira AI, Lara PN Jr., Lin CC, Srinivas S, Sella A, Schoffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients with Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. *J Clin. Oncol.*, 31(4):412-9, 2013.
248. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, NG S, Charles J, Mulders PF, Basch E, **Small EJ**, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttman H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl. J Med.*, 368(2):138-48, 2013.
249. Goodwin PJ, Ballman KV, **Small EJ**, Cannistra SA. Evaluation of Treatment Benefit in Journal of Clinical Oncology. *J. Clin. Oncol.*, 31(9):1123-4, 2013.
250. Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, **Small EJ**, Milowsky MI, Bajorin DF. Prognostic Model for Predicting Survival of Patients with Metastatic Urothelial Cancer Treated with Cisplatin-Based Chemotherapy. *J Natl. Cancer Inst.*, 105(7):499-503, 2013.
251. Hussain M, Tangen CB, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga SS, **Small EJ**, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B,

- Moinpour CM, Vogelzang NJ, Thompson IM Jr. Intermittent versus continuous androgen deprivation in prostate cancer. *N Engl J Med*, 368(14):1314-25, 2013.
252. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimak ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, **Small EJ**, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. *J Natl Compr Canc Netw*. 11(4):446-75, 2013.
253. Ryan CJ, Molina A, Li J, Kheoh T, **Small EJ**, Haqq CM, Grant RP, deBono J, Scher HI. Serum Androgens as Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results from an Analysis of a Randomized Phase III Trial. *J. Clin. Oncol.*, 31(22):279-8, 2013.
254. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, **Small EJ**, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA. Metabolic Imaging of Patients with Prostate Cancer Using Hypoerpolized [1-13C] Pyruvate. *Sci Transl Med*, 5(198):198ra108, 2013.
255. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, **Small EJ**, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.*, 11(5):594-615, 2013.
256. Cha E. **Small EJ**. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? *Cancer Med.*, 2(2):243-52, 2013.
257. Halabi S, Lin CY, **Small EJ**, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. *J Natl. Cancer Inst.*, 105(22):1729-37, 2013.
258. Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, **Small EJ**. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. *J Natl. Cancer Inst.*, 31(31):3944-50, 2013.
259. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, **Small EJ**; for the Alliance for Clinical Trials in Oncology. The effects of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). *Cancer*, 119(20):3636-43, 2013.
260. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Pilmack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, **Small EJ**, Srinivas S, Stein C, Strobe SA, Tward J, Walsh PC, Shead DA, Ho M. Prostate cancer, version 1.2014. *J Natl. Comp. Canc Netw.*, 11(12):1471-9, 2013.
261. Halabi S, Rini B, Escudier B, Stadler WM, **Small EJ**. Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients with Metastatic Renal Cell Carcinoma. *Cancer*, 120(1):52-60, 2014.
262. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris M, **Small EJ**. Updated prognostic model for predicting overall survival in chemotherapy naïve metastatic castrate-resistant prostate cancer patients. *J Clin Oncol*, 32(7):671-7, 2014.
263. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efsthathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, **Small EJ**, Scher HI, Molina A, Ryan CJ, Saad F.

- Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). *Eur Urol.*, S0302-2838(14)00185-7, 2014.
264. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, **Small EJ**. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and more metastases: Results of CALGB 90202 (Alliance). *J Clin Oncol.*, 32(11):143-50, 2014.
265. Aggarwal R, Harris A, Formaker C, **Small EJ**, Molina A, Griffin TW, Ryan CJ. Response to subsequent docetaxel in patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate. *Clin Genitourin Cancer*, 12(5):e167-72, 2014.
266. **Small EJ**, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. *Prostate Cancer Prostatic Dis.*, 17(3):259-64, 2014.
267. Kim W, Jones JO, Diamond M Haqq C, Molina A, **Small EJ**, Ryan CJ. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. *Prostate Cancer Prostatic Dis.*, 17(3):292-9, 2014.
268. Aggarwal RR, **Small EJ**. Small-cell/neuroendocrine prostate cancer: a growing threat? *Oncology*, 28(10), 2014.
269. **Small EJ**. Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die? *J Clin Oncol*, 32(33):3689-91, 2014.
270. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, **Small EJ**. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. *J Natl Cancer Inst.*, 106(11), 2014.
271. McNeel DG, Gardner TA, Higano CS, Kantoff PW, **Small EJ**, Wener MH, Sims RB, DeVries T, Sheikh NA, Driecer R. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive Sipuleucel-T. *Cancer Immunol Res.*, 2(10):988-99, 2014.
272. Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, **Small EJ**, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelley WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). *Cancer*, 121(7):1025-31, 2015.
273. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RA, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, **Small EJ**, Ryan CJ. Sequential use of the androgen synthesis inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. *Clin Cancer Res*, 20(24):6269-76, 2014.
274. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, **Small EJ**. Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: a Department of Defense Prostate Cancer Clinical Trials Consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF. *Clin Genitourin Cancer*, 13(3):e191-8, 2015.
275. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, **Small EJ**, Charles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Khoeh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall

- survival analysis of a randomized, double-blind placebo-controlled phase 3 study. *Lancet Oncol.*, 16(2):152-60, 2015.
276. Morris JM, Molina A, **Small EJ**, de Bono JS, Logothetis CJ, Higano K, Li J, Kheoh T, Larson SM, Matheny S, Niani V, Burzyk T, Ryan CJ. Radiographic progression-free survival as a response biomarker in metastatic castration results. *J Clin Oncol.*, 33(12):1356-63, 2015.
277. Azaad AA, Volik SV, Wyatt AW, Haegert A, LeBihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, **Small EJ**, Wang Y, Gleave ME, Collins CC, Chi KN. Androgen receptor gene aberrations in circulating cell-free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. *Clin Cancer Res.*, 21(10): 2315-24, 2015.
278. **Small EJ**, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. A Randomized Phase II Trial of Sipuleucel-T Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res.*, 21(17):3862-9, 2015.
279. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, **Small EJ**, Fong L. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. *Cancer Immunol Res.*, 3(9):1008-16, 2015.
280. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fiazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, **Small EJ**, Scher HI, Molina A, Ryan CJ. Impact of Bone-targeted Therapies in Chemotherapy naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. *Eur Urol*, 68(4): 570-7, 2015.
281. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Azaka H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenrich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, **Small EJ**, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St. Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol*, 26(8):1589-604, 2015.
282. Halabi S, Rini BI, Escudier B, Stadler WM, **Small EJ**. Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint? *Cancer*, 121(11):1906, 2015.
283. Guha Thakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher T, Hall SJ, Kantoff P, Higano CS, **Small EJ**, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG. Humoral immune response against non-targeted tumor antigens after treatment with sipuleucel-t and its association with improved clinical outcome. *Clin Cancer Res.*, 21(16):3619-30, 2015.
284. Kaplan CP, Napoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, Leykin Y, **Small EJ**. Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. *Contemp Clin Trials*. 45(Pt B): 445-8, 2015.
285. Wei XX, Fong L, **Small EJ**. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. *Expert Rev Vaccines*, 14(12):1529-41, 2015.
286. Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, **Small EJ**, Shore ND, Ferrari A. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. *Can J Urol.*, 22(6), 2015.
287. Bellmunt J, Kheoh T, Yu MK, Smith MR, **Small EJ**, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. Prior

- Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. *Eur Urol.*, S0302-2838(15)01002-7, 2015.
288. Kim HL, Halabi S, Li P, Mayhew G, Simko J, Nixon AB, **Small EJ**, Rini B, Morris MJ, Taplin ME, George D; Alliance for Clinical Trials in Oncology. *EBiomMedicine* 2(11)1814-20, 2015.
289. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, **Small EJ**, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol.*, 26(8):1589-604, 2015.
290. Wei XX, Fong L, **Small EJ**. Prospects for the use of ipilimumab in treating advanced prostate cancer. *Expert Opin Biol Ther.*, 16(3):421-32, 2016.
291. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, **Small EJ**, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 1.2016. *J Natl Compr Canc Netw.*, 14(1): 19-30, 2016.
292. Halabi S, Kelly W, Ma H, Zhou H, Solomon N, Fizazi K, Tangen C, Rosenthal M, Petrylak D, Hussain M, Vogelzang N, Thompson I, Chi K, de Bono J, Armstrong A, Eisenberger M, Fandi A, Li S, Araujo J, Logothetis C, Quinn D, Morris M, Higano C, Tannock I, **Small EJ**. Meta-analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men with Castration-Resistant Prostate Cancer. *J. Clin. Oncol.*, 34(14):1652-9, 2016.
293. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, **Small EJ**, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations from the Prostate Cancer Clinical Trials Working Group 3. *J Clin Oncol.*, 34(12):1402-18, 2016.
294. de Bono, JS, Smith MR, Saad F, Rathkopf DE, Mulders PF, **Small EJ**, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. *Eur Urol*, S0302-2838(16)30385-2, 2016.
295. Premasakharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, **Small EJ**, Bivona TG, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for paring with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. *Cancer Lett.*, 380(1) 144-52, 2016.
296. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, **Small EJ**, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacologic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. *Clin Cancer Res.*, 22(19):4890-4900, 2016.
297. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, **Small EJ**, Evans MJ. A feasibility study showing [⁶⁸Ga]Citrate PET Detects Prostate Cancer. *Mol Imaging Biol.*, 18(6):946-951, 2016.

298. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, **Small EJ**, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. *Cancer Immunol Res.* 4(11):948-958, 2016.
299. Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, **Small EJ**. Targeting adaptive pathways in metastatic treatment-resistance prostate cancer: update on the Stand Up to Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. *Eur Urol*, 2(5):469-471, 2016.
300. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, **Small EJ**, Evans MJ. ⁶⁸Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. *J Nucl Med.*, 58(1):81-84, 2017.
301. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, **Small EJ**, Dakhil S, George DL, Morris MJ. Cabozantinib versus sunitinib as initial target therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial. *J Clin Oncol*, 35(6):591-597, 2017.
302. Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppala IL, So A, Lo G, Aggarwal R, **Small EJ**, Nykter M, Gleave ME, Chi KN, Wyatt AW. Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer. *Eur Urol.*, 72(1):34-42, 2017.
303. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, **Small EJ**. A multicenter phase 1 study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. *Urol Oncol.*, 35(4):147.e7-149.e13, 2017.
304. Aggarwal RR, Feng FY, **Small EJ**. Emerging categories of disease in advanced prostate cancer and their therapeutic implications. *Oncology*, 31(6):467-74, 2017.
305. Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bonon JS, **Small EJ**, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. *Eur Urol*, 72(1):10-13, 2017.
306. Anantharaman, A, **Small EJ**. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. *Expert Rev Anticancer*, 17(7):625-633, 2017.
307. **Small EJ**. Redefining hormonal therapy for advanced prostate cancer: results from the LATITUDE and STAMPEDE studies. *Cancer Cell*, 32(1):6-8, 2017.
308. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, **Small EJ**, Evans MJ. Real-time transferrin-based PET detects MYC-positive prostate cancer. *Mol Cancer Res.*, 15(9):1221-1229, 2017.
309. Homes MG, Foss E, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, **Small EJ**, Link TM. *J Vasc Interv Radiol*, 28(8):1073-1081, 2017.
310. Podolak J, Eilers K, Newby T, Slotke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, **Small EJ**, Graff JN, Alumkal JJ, Beer TM, Thomas GV. Androgen receptor amplification is concordant between circulating tumor cells and biopsies for men undergoing treatment for metastatic castration resistant prostate cancer. *Oncotarget*, 8(42):71447-71455, 2017

311. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A*, **Small EJ***, Feng FY*. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. *Cancer Discov*, (9):999-1005, 2017.
312. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg M, Feng F, Chang A, Ryan CJ, **Small EJ**, Carroll PR. Impact of Ga-68 PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. *J Nucl Med.*, 58(12):1956-1961, 2017.
313. Friedlander TW, Graff JN, Zejnullahu K, Anantheraman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Al Yamani M, Dittamore R, **Small EJ**, Paris PL, Ryan CJ. High-dose abiraterone acetate in men with castration resistant prostate cancer. *Clin Genitourin Cancer*, 15(6):733-741, 2017.
314. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, **Small EJ**, Evans MJ. Real-time transferrin-based PET detects MYC-positive prostate cancer. *Mol Cancer Res*. 15(9):1221-1229, 2017.
315. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, **Small EJ***, Gleave ME*. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. *Journal of the National Cancer Institute*, 110(1):118, 2017.
316. Parsons JK, Pierce JP, Mohler J, Paskett E, Jung S-H, Morris MJ, **Small EJ**, Hahn O, Humphrey P, Taylor J, Marshall J. Men's eating and living (MEAL) study (CALGB 70807) [Alliance]: recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. *BJU Intl.*, 121(4):534-539, 2018.
317. Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, **Small EJ**, Carroll PR, Hope TA. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. *EJNMMI Res.*, 19(1):77, 2017.
318. Pezaro CJ, Omlin A, Mastris K; ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, deBono JS, Efsthathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, **Small EJ**, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillesen S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. *Ann Oncol.*, 28(8):1692-1694, 2017.
319. Atkins KM, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, **Small EJ**, D'Amico AV. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. *Cancer*, 124(7):1383-1390, 2018.
320. Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, **Small EJ**. Clinical variables associated with overall survival in metastatic castration-resistant prostate cancer patients treated with sipuleucel-T immunotherapy. *Clin Genitourin Cancer*, 16(3):184-190, 2018.
321. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff NJ, Olmos D, Mainwaring PN, Lee JY, Eumura H, Lopez-Gitliz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, **Small EJ**; SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med.*, 378(15):1408-1418, 2018.

322. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, **Small EJ**, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomized trial): Progression-free survival by independent review and overall survival update. *Eur J Cancer*, 94:115-125, 2018.
323. Antonarakis ES, **Small EJ**, Petrylak D, Quinn DI, Kibel AS, Chang N, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. *Clin Cancer Res.*, 24(19):462-4671, 2018.
324. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichellis F, Rubin MA, Stuart JM, **Small EJ**. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-Institutional Prospective Study. *J Clin Oncol*, 36(24):2492-2503, 2018.
325. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MG, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr., Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM*, Ashworth A*, Chinnaiyan AM*, Maher CA*, **Small EJ***, Feng FY*. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell*, 174(3):758-769, 2018.
326. Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, **Small EJ***, Alumkal JJ*. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients with Metastatic Castration-Resistant Prostate Cancer. *J Natl Compr Canc Netw*, 16(8):933-937, 2018.
327. Saad F, Celia D, Basch E, Hadaschik B, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, **Small EJ**. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomized, placebo-controlled phase 3 trial. *Lancet Oncol.*, 9(10):1404-1416, 2018.
328. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, **Small EJ**, Kelly WK. Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with Docetaxel. *J Clin Oncol.*, 37(5):403-410, 2019.
329. Koshkin VS, **Small EJ**. Apalutamide in the treatment of castration-resistant prostate cancer: evidence from clinical trials. *Ther Adv Urol.*, 10(12):445-454, 2018.
330. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnards TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Dguyen PL, Maher CA, **Small EJ**, Feng FY. Clinical and genomic implications of luminal and basal subtypes across carcinomas. *Clin Cancer Res.*, 25(8):2450-2457, 2019.
331. Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, **Small EJ**, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, GreeneKL, Langton-Webster B, Berckman CE, Seo Y. First-in-Human Phase I study of CTT1057, a Novel ¹⁸F labeled imaging agent with phosphoramidate core targeting prostate specific membrane antigen in prostate cancer. *J Nuc Med.*, 60(7):910-916, 2019.

332. Borno HT, **Small EJ**. Apalutamide and its use in the treatment of prostate cancer. *Future Oncol.*, 15(6):591-599, 2019.
333. Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, **Small EJ**. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. *Prostate Cancer Prostatic Dis.*, 22(2):309-316, 2019.
334. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack N?A, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou L, Li H, Das R, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr., Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A*, Chinnaiyan AM*, Maher CA*, **Small EJ***, Feng FY*. Genomic hallmarks and structural variation in metastatic prostate cancer. *Cell*, 175(3)15, 2018.
335. Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, **Small EJ**. A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. *Contemp Clin Trials Commun.*, 12:60-67, 2018
336. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, **Small EJ**, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate and poor risk (Alliance A031203 CABOSUN randomized trial): Progression-free survival by independent review and overall survival update.' *Eur J Cancer*, 94:115-125, 2018.
337. Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NJ, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, **Small EJ**, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. *JCI Insight* 3(17), 2018.
338. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, **Small EJ**, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. Itraconazole as a noncastrating treatment for biochemically recurrent prostate cancer: a phase 2 study. *Clin Genitourin Cancer.*, 17(1):e92-e-96, 2019.
339. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Shozo O, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, **Small EJ**, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of ⁶⁸Ga-PSMA-PET Accuracy in Localizing Recurrent Prostate Cancer. *JAMA Oncol.*, 5(6):856-863, 2019.
340. Perez PM, Hope TA, Behr SC, van Zante A, **Small EJ**, Flavell RR. Intermural Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases. *Clin Nucl Med.*, 44(1):e28-e-32, 2019.
341. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, **Small EJ**, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. *Prostate Cancer Prostatic Dis.*, 22(4):531-583, 2019.
342. Raghavan K, Wen KW, **Small EJ**, Ha P, Flavell RR. Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT. *Clin Nucl Med.*, 44(5):e367-e369, 2019.

343. Aggarwal R, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, **Small EJ**. Whole Genome and Transcriptional Analysis of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Demonstrates Intra-Class Heterogeneity. *Mol Cancer Res.*, 17(6):1235-1240, 2019.
344. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas V, Beer Tm, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY*, **Small EJ***, Alumkal JJ*, on behalf of the West Coast Prostate Cancer Dream Team. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. *European Urology*, 76(5):562-571, 2019.
345. Ryan C, Dutta S, Kelly W, Russell C, **Small EJ**, Morris M, Taplin M-E, Halabi S. Androgen Decline and Survival During Docetaxel Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC). *Prostate Cancer and Prostatic Diseases*, May 3, 2019, Epub ahead of print.
346. Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, **Small EJ**, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. The role of lineage plasticity in prostate cancer therapy resistance. *Clin Cancer Res.*, 25(23):6916-6924, 2019.
347. Desai A, **Small EJ**. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. *Future Oncol.*, 15(20):2237-2348, 2019.
348. Aggarwal R, Wei X, Kim W, **Small EJ**, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. *Eur Urol Oncol.*, 1(1):78-82, 2018.
349. Fendler WP, Weber M, Irvani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, **Small EJ**, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res.*, Sep 11, 2019, Epub ahead of print.
350. George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, **Small EJ**, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. *Oncologist*, 24(11):1497-1501, 2019.
351. Cheng HH, Sokolova AO, Schaeffer EM, **Small EJ**, Higano CS. Germline and Somatic Mutations in Prostate Cancer for the Clinician. *J Natl Compr Canc Netw.*, 17(5):515-521, 2019.
352. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, **Small EJ**, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.*, 17(5):475-505, 2019.
353. Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, **Small EJ**, Nguyen PL, Feng FY. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. *Clin Cancer Res.*, 25(14):4290-4299, 2019.
354. **Small EJ**, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Mainwaring PN, Lee JY, Uemura H, DePorre P, Smith AA, Zhan GK, Lopez-Gitlitz A, Smith MR. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. *Annals of Oncology*, 30(11):1813-1820, 2019.

355. Kwon DH, Borno HT, Cheng HH, Zhou AY, **Small EJ**. Ethnic disparities among men with prostate cancer undergoing germline testing. *Urol Oncol.*, 38(3):80.e1-80.e7. 2019.
356. Borno H, **Small EJ**, Zhang L, DeRouen M, Griffin A, McGuire J, Ryan CJ, Hiatt RA, Kaplan CP. How current reporting practices mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. *Contemporary Clinical Trials Communications*, 16(100476), 2019.
357. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, **Small EJ**, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol.*, 30(12):e3, 2019.

2020

358. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, **Small EJ**, Sharifi N, Zhao SG. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. *Prostate Cancer Prostatic Dis.*, 23(2):316-323, 2020.
359. Chen HY, Aggarwal R, Bok RA, Olinger MA, Zhu Z, Lee P, Gordon JW, van Criekinge M, Caraval J, Slater JB, Larson PEZ, **Small EJ**, Kurhanewicz J, Vigneron DB. Hypoerpolarized ¹³C-puravate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. *Prostate Cancer Prostatic Dis.*, 23(2):269-276, 2020.
360. Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, **Small EJ**, Chinnaiyan AM, Alva AS, Feng FY, Chou J. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. *Eur Urol.*, 77(3):333-341, 2020.
361. Smith MR, Mehra M, Nair S, Lawson J, **Small EJ**. Relationship Between Metastasis-Free Survival and Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. *Clinical Genitourinary Cancer*, 18(2):e180-e189, 2020.
362. Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK, Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L, **Small EJ**, Morris MJ, Pierce JP, Marshall J. Effect of Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. *JAMA*, 323(2):140-148, 2020.
363. Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. *Prostate Cancer Prostatic Dis.*, 23(3):517-526, 2020.
364. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, **Small EJ**, Kelly WK. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. *JNCI Cancer Spectr.*, 4(2):pkaa003, 2020.
365. Borno HD, **Small EJ**. Does COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research? *Contemp Clin Trials.*, 92:105997, 2020.

366. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, **Small EJ**, Kelly WK. Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. *Ann Oncol.*, 31(7):930-941, 2020.
367. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, **Small EJ**, Witte ON, Xia Z. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. *Proc Natl Acad Sci*, 117(22):12315-12323, 2020.
368. Perez-Ruixo C, Ackaert O, Ouellet D, Chien C, Uemura H, Olmos D, Mainwaring P, Lee JY, Yu MK, Perez-Ruixo JJ, Smith MR, **Small EJ**. Efficacy and Safety Explore-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res.*, 26(17):4460-4467, 2020.
369. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, **Small EJ***, Quigley DA*, Feng FY*. The DNA methylation landscape of advanced prostate cancer. *Nat Genet.*, 52(8): 778-789, 2020.
370. Eastham J, Heller G, Halabi S, Monk JP, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL*, **Small EJ***, Morris MJ*. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Adjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. *J Clin Oncol.*, 38(26):3042-3050, 2020.
371. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P Jr, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, **Small EJ**, Xia Z, Alumkal JJ. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res.*, 26(17): 4616-4624, 2020.
372. Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhota S, Feng FY, **Small EJ**, Abida W, Alumkal JJ. A Phase Ib/IIa Study of Pan-BET Inhibitor Zen-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. *Clin Cancer Res.*, 26(20):5338-5347, 2020.
373. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN Jr, Thomas GV, Li P, Lui A, **Small EJ**, Aggarwal RR. Down-regulation of ADBR2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. *Urol Oncol.*, 38(12):231.e9-931.e16, 2020.
374. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig MB, Gleave ME, Evans CP, Lara PN, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, **Small EJ**, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. Autoantibody landscape in patients with advanced prostate cancer. *Clin Cancer Res.*, 26(23):6204-6214, 2020.

375. Uemura H, Satoh T, Tsumura H, Arai G, Imanaka K, Shibayama K, Fujii K, Rooney B, Lopez-Gitlitz A, Espina B, Perez-Ruixo C, **Small EJ**, Smith M. Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study. *Prostate Int.*, 8(4):190-197, 2020.

2021

376. Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, **Small EJ**. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. *Prostate Cancer Prostatic Dis.*, 24(1)81-87, 2021.

377. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, **Small EJ**. Apalutamide and Overall Survival in Prostate Cancer. *Eur Urol.*, 79(1):150-158, 2021.

378. Kwon DH, Vashisht R, Borno HT, Aggarwal RR, **Small EJ**, Butte AJ, Huang FW. Androgen deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. *Ann Oncol.*, 32(5)678-679, 2021.

379. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, **Small EJ**, Alva AS, Chi KN, Feng FY, Koshkin VS. Differential Treatment Outcomes in BRCA1/2-, CDK12-, and ATM-Mutated Metastatic Castration-Resistant Prostate Cancer. *Cancer*, 127(12):1965-1973, 2021.

380. Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, **Small EJ**, Sharma P, Fong L. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. *J Immunother Cancer*, 9(5):e002254, 2021.

381. de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, **Small EJ**, Friedlander TW, Koshkin V. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. *J Immunother Cancer*, 9(5):e002127, 2021.

382. Bitterman DS, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, **Small EJ**, D'Amico AV. Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. *Cancer*, 127(15)2623-2630, 2021.

383. Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, **Small EJ**. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. *JAMA Oncol.*, 7(7):1005-1014, 2021.

384. Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, **Small EJ**, Ashworth A, Feng FY, Gilbert LA. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. *Nat Commun.*, 12(1):4601, 2021.

385. Rabow M, Wang C, Zhang S, Tahir PM, **Small EJ**, Borno HT. Examining reporting and representation of patients with cancer in COVID-19 clinical trials. *Cancer Rep (Hoboken)*, 4(4):e1355, 2021.

386. Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, ***Small EJ**, ***Morris MJ**. Randomized Phase III Trial of Gemcitabine and Cisplatin with Bevacizumab or Placebo in

- Patients with Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). *J Clin Oncol*, 39(22):2486-2496, 2021.
387. Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW, Li M, Attard G, **Small EJ**. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. *Clin Cancer Res*, 47(16):4359-4548, 2021.
388. Kim DH, Sun D, Storck WK, Welker Leng KR, Jenkins C, Coleman DJ, Sampson DA, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman J, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman I, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, **Small EJ**, Spratt DE, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhota S, Campeau E, Yates JA, Xia Z, Alumkal JJ. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. *Clin Cancer Res*, 27(17):4923-4936, 2021.
389. Rydzewski NR, Peterson E, Lang JM, Yu M, Laura Chang S, Sjöström M, Bakhtiar H, Song G, Helzer KT, Bootsma ML, Chen WS, Shrestha RM, Zhang M, Quigley DA, Aggarwal R, **Small EJ**, Wahl DR, Feng FY, Zhao SG. Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. *Genom Med*, 6(1):76, 2021.
390. Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, **Small EJ**, Feng FY, Zhao SG. Prognosis Associated with Luminal and Basal Subtypes of Metastatic Prostate Cancer. *JAMA Oncol.*, 7(11):1644-1652, 2021.
391. Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, **Small EJ**, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. *Nat Commun*, 12(1):7349, 2021.
392. Kentfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen Y-H, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, **Small EJ**, Chan JM. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. *Cancer Med*, 10(22):8058-8070, 2021.
393. Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, **Small EJ**, Spratt DE, Bankhead A 3rd, Rao A, Gesner EM, Attwell S, Lakhota S, Campeau E, Yates JA, Xia Z, Alumkal JJ. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. *Clin Cancer Res.*, 27(17), 2021.
394. Oudard S, Hadaschik B, Saad F, Cella D, Basch E, Graff JN, Uemura H, Dibaj S, Li S, Brookman-May SD, De Porre P, Bevans KB, Trudeau JJ, **Small EJ**, Smith MR. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy. *Eur Urol Focus*, Epub ahead of print, August 31, 2021.
395. Borno HT, Lin TK, Zhang S, Skafel A, Lalanne A, Dornsife D, Johnson R, Spicer D, **Small EJ**, Rhoads KF. Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. *J Cancer Policy*, 30:100305, 2021.

2022

396. Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, **Small EJ**, Aggarwal RR, Belkora J. Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. *JCO Oncol Pract*, 18(5):e648-e658, 2022.
397. *Saad F, ***Small EJ**, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. *Eur Oncol*, 81(2):184-192, 2022.
398. Nixon AB, Halabi S, Liu Y, Starr MD, Brady JC, Shterev I, Luo B, Hurwitz HI, Febbo PG, Rini BI, Beltran H, **Small EJ**, Morris MJ, George DJ. Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN α \pm Bevacizumab: Results from CALGB 90206 (Alliance). *Clin Cancer Res.*, 28(13):2771-2778, 2022.
399. Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, **Small EJ**. COVID-19 Outcomes Among Patients with Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. *Oncologist*, 27(5):398-406, 2022.
400. Borno HT, Zhang L, Zhang S, Kaplan C, Palmer NR, Bell A, Bakke B, Lin A, Aggarwal R, **Small EJ**. Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. *JCO Clin Cancer Inform*, 6:e21000182, 2022.
401. de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, **Small EJ**, Friedlander T, Fong L, Paris PL, Ryan CJ, Szmulewitz RZ, Aggarwal R. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. *Clinical Cancer Res.*, 28(8):1531-1539, 2022.
402. Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JW, Lack NA, Nykter M, Aggarwal R, **Small EJ**, Gleave ME; SU2C/PCF West Coast Prostate Cancer Dream Team, Quigley DA, Feng FY, Chi KN, Wyatt AW. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. *Nature*, 608(7921):199-208, 2022.
403. Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, **Small EJ**, Yates JA, Xia Z, Alumkal JJ. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. *Nat Commun.*, 13(1):5345, 2022.
404. Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, **Small EJ**, Chou J, Wells JA, Aggarwal R, Evans MJ. CUB domain containing protein 1 (CDCP1) is a target for radioligand therapy in castration resistant prostate cancer including PSMA null disease. *Clin Cancer Res.*, 28(14):3066-3075, 2022.
405. Kwon DH, Paciorek A, Zhang L, Borno HT, Bucknor M, **Small EJ**, Aggarwal RR. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. *Urol Oncol.*, 40(8):379.e17-379.e24, 2022.
406. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L,

- Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, **Small EJ**, He HH, Wyatt AW, Quigley DA, Feng FY. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. *Cancer Res.*, 82(21):3888-3902, 2022.
407. Feng E, Rydzewski NR, Zhang M, Lundberg A, Bootsma M, Helzer KT, Lang JM, Aggarwal R, **Small EJ**, Quigley DA, Sjöström M, Zhao SG. Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res.*, 28(24):5396-5404, 2022.
408. Ragavan MV, Legaspi N, LaLanne A, Hong JC, **Small EJ**, Borno HT. Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic. *JAMA Oncol.*, 8(12):1849-1851, 2022.
409. Gupta N, Song H, Wu W, Ponce RK, Lin YK, Kim JW, **Small EJ**, Feng FY, Huang FW, Okimoto RA. The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression. *Elife*, Nov 16, 2022, epub ahead of print.
410. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, **Small EJ**, Sweet-Cordero A, Koshkin VS. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients with Advanced Urothelial Cancer. *Front Oncol.*, Mar 7, 2022, eCollection.
411. Kellogg Parsons J, Zahrieh D, Patel D, Mohler JL, Chen RC, Paskett ED, Liu H, Peil ES, Rock CL, Hahn O, Taylor J, Van Veldhuizen PJ Jr, **Small EJ**, Morris MJ, Naughton MJ, Pierce JP, Marshall J. Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). *Eur Urol Focus*, April 30, 2022, online ahead of print.
412. Tamukong PK, Kuhlmann P, You S, Su S, Wang Y, Yoon S, Gong J, Figlin RA, Janes JL, Freedland SJ, Halabi S, **Small EJ**, Rini BI, Kim HL. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. *Urol Oncol.*, Aug 13, 2022, epub ahead of print.
413. Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, **Small EJ**. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. *Prostate Cancer*, Sep 28, 2022, epub ahead of print.
- 2023**
414. Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, **Small EJ**. Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study. *J Immigr Minor Health*, 25(3):624-633, 2023.
415. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, **Small EJ**, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. *Cancer Res.*, 83(2):301-315, 2023.
416. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, **Small EJ**. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. *Urol Oncol.*, 41(3):145.37-145.315, 2023.
417. Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS,

- Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, Harzstark AL, **Small EJ**, Kenfield SA. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. *Urol Oncol*, 41(3):146.e1-146.311, 2023.
418. Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, **Small EJ**, Dhawan M. Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. *JCO Oncol Pract.*, 19(5):e773-e783, 2023.
419. Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, **Small EJ**. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. *Prostate Cancer Prostatic Dis.*, 26(1):156-161, 2023.
420. Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, **Small EJ**, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. *J Clin Oncol*. 2023 Jun 20;41(18):3339-3351.
421. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, **Small E**, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khaulil RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. *Eur Urol*. 2023 Mar;83(3):267-293.
422. Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, **Small EJ**. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). *J Clin Oncol.*, Mar 30, 2023, epub ahead of print.
423. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, **Small EJ**, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. *Front Oncol.*, Apr 5, 2023, epub ahead of print.
424. Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, **Small EJ**, Kelly WK. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. *J Clin Oncol.*, May 20, 2023, epub ahead of print.
425. Lundberg A, Zhang M, Aggarwal RA, Li H, Zhang L, Foye A, Sjostrom M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein A, Younger N, Alumkal J, Beer T, Chi K, Evans C, Gleave M, Lara P, Reiter R, Rettig M, Witte O, Wyatt A, Feng F, **Small EJ**, Quigley DA. The genomic and epigenomic landscape of double-negative metastatic prostate cancer. *Cancer Res.*, Jun 8.

NON-PEER REVIEWED PUBLICATIONS**Books and Chapters**

1. Carroll PR, **Small EJ**. Neoadjuvant Androgen Deprivation Before Radical Prostatectomy: Current Status and Trial Design in: Prostate Cancer. Dawson and Vogelzang, eds. Wiley-Liss, New York, 1994.
2. **Small EJ**. Chemotherapy of Urologic Tumors in: Smith's General Urology (14th edition). Tanagho and McAnich, eds. Appleton and Lange, 1994.
3. **Small EJ**, Damon LE. Geriatric Hematology in: Clinical Manual of Geriatrics. ET Lonergan, ed. Appleton and Lange, 1995.
4. **Small EJ**, Prins GS. Physiology and Endocrinology of the Prostate in: Comprehensive Textbook of Genitourinary Oncology. Vogelzang, Scardino, Shipley and Coffey, eds. Williams & Wilkins, 1995.
5. **Small EJ**, Torti FM. Testicular Carcinoma in: Clinical Oncology. Abeloff, Armitage, Lichter, and Niederhuber, eds. Churchill Livingstone, New York, 1996.
6. Roach M, **Small EJ**. Using serum PSA to screen for & manage prostate cancer. PPO Updates 11:1-14, 1997.
7. **Small EJ**, Kashani-Sabet M, Bouffard DY, Scanlon K. The Molecular Basis of Bladder Cancer and Prospects for Gene Therapy Using Hammerhead Ribozymes in: Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. Eric Wickstrom, ed. Marcel Dekker, 1998.
8. **Small EJ**, Torti FM, Yagoda A. Bladder, Kidney, Testis in: Everyone's Guide to Cancer Therapy (revised 3rd edition). Dollinger, Rosenbaum and Cable, eds. Andrews and McMeel, 1998.
9. **Small EJ**, Torti FM. Germ Cell Tumors in: Clinical Oncology. Abeloff, Armitage, Lichter, and Niederhuber, eds. W. B. Saunders, Philadelphia, 1998.
10. **Small EJ**, Prins GS, Taplin ME. The Androgen Receptor and Physiology and Endocrinology of the Prostate in: Comprehensive Textbook of Genitourinary Oncology. Vogelzang, Scardino, Shipley and Coffey, eds. Williams and Wilkins, 1999.
11. **Small EJ**. Chemotherapy of Urologic Tumors in: Smith's General Urology (15th edition). Tanagho and McAnich, eds. Appleton and Lange, 2000.
12. **Small EJ**. Immunology and Immunotherapy of Urologic Tumors in: Smith's General Urology (15th edition). Tanagho and McAnich, eds. Appleton and Lange, 2000.
13. Roach MR, **Small EJ**, Reese DM, Carroll PR. Urologic and Male Genital Cancers in: Clinical Oncology. W. B. Saunders, Philadelphia, 2001.
14. Rini BI, Torti FM, **Small EJ**. Kidney Cancer in Everyone's Guide to Cancer Therapy, Dollinger, Rosenbaum and Cable, eds. Andrews and McMeel, 2002.
15. **Small EJ**, Harris KA, Grossfeld GD. Bladder Cancer in: Everyone's Guide to Cancer Therapy, Dollinger, Rosenbaum and Cable, eds. Andrews and McMeel 2002.
16. Reese DM, **Small EJ**. Alternative Hormone Approaches: Intermittent, Peripheral, Triple in: Prostate Cancer. P. Kantoff, PR Carroll, AV D'Amico, eds. 2002.

17. Harris KA, **Small EJ**. Androgen Deprivation Therapy: Timing and Type in: Atlas of Clinical Oncology. Prostate Cancer: A Spectrum of Disease. B. C. Decker, Inc., Ontario, Canada. 2002.
18. **Small EJ**, Motzer RJ. Interferon for Renal Cell Carcinoma in: Renal and Adrenal Tumors: Biology and Management. Beldegrun A, Ritchie AW, and Figlin RA. Oxford University Press, UK, 2003.
19. Fong L, **Small EJ**. Novel Systemic Therapy for Prostate Cancer in: Atlas of Clinical Oncology. Prostate Cancer: A Spectrum of Disease. B. C. Decker, Inc., Ontario, Canada, 2003.
20. **Small EJ**. Chemotherapy of Urologic Tumors in: Smith's General Urology (16th edition), 316. Tanagho and McAnich, eds. Appleton and Lange, 2003, 2018, 2019.
21. **Small EJ**. Immunology and Immunotherapy of Urologic Tumors in: Smith's General Urology (16th edition), 311. Tanagho and McAnich, eds. Appleton and Lange, 2003, 2018, 2019.
22. **Small EJ**. Prostate Cancer in Cecil Textbook of Medicine (22nd edition). Goldman and Ausiello, eds. W. B. Saunders, 2004.
23. Gleave ME, **Small EJ**. Androgen Deprivation Therapy for Prostate Cancer in Report to the Nation on Prostate Cancer. Prostate Cancer Foundation. Medscape, 2004.
24. Zelefsky M, Kollmeier M, **Small EJ**, Rosenberg JE. Cancer of the Bladder in Leibel and Phillips Textbook of Radiation Oncology, 3rd Edition. Elsevier, 2010.
25. Harzstark AH, **Small EJ**. Where Do We Need to Go with Clinical Trials in Oncology? in: Oncology Clinical Trials. Kelly and Halabi, eds. Demos Medical Publishing, New York, 2010.
26. Figg WD, Chau CH, **Small EJ** (eds). Drug Management of Prostate Cancer. Springer, 2010.

ABSTRACTS

1. **Small EJ**, Erle DJ, Pytela R, Shuman MA. The b2 integrin subunit mRNA and protein is expressed in non-leukocyte tumor cells. Clin Res 39:2, 357A, 1991.
2. **Small EJ**, Frye J, Carroll P, Wilkinson M. A Phase I, II study of constant rate floxuridine infusion alternating with constant rate vinblastine infusion in pts with metastatic RCC. Proc Am Soc Clin Oncol 11:217, 1992.
3. Rearden TP, **Small EJ**, Valone F, Carroll P, Ernest ML, Wilkinson M. Phase II study of mitoxantrone for hormone-refractory metastatic prostate cancer. Proc Am Soc Clin Oncol 11: 218, 1992.
4. **Small EJ**, Ernest ML, Carroll P, Wilkinson M. A Phase II study of carboplatinum, methotrexate and vinblastine for advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 12: 240, 1993.
5. **Small EJ**, Srinivas S, Ernest ML, Carroll P, Wilkinson M. Treatment of advanced transitional cell carcinoma in elderly patients: the use of carboplatin instead of cisplatin. Proc ASCO 13, 1994.
6. **Small EJ**, Srinivas S, Rearden TP. The effect of prior radiotherapy on response and survival in HRPC. Proc Am Soc Clin Oncol 13, 1994.
7. Timmerman JM, Northfelt DW, **Small EJ**. Malignant germ cell tumors in men infected with the human immunodeficiency virus: Natural history and results of therapy. Proc ASCO 13, 1994.
8. **Small EJ**, Madhavan S, Fruehauf JP. C-erbB-2, epidermal growth factor receptor and androgen receptor expression in advanced hormone sensitive and hormone refractory prostate cancer. Proc Am Soc Clin Oncol 14: 82, 1995.

9. Dawson NA, Conaway M, **Small EJ**, et al. A randomized study comparing standard versus moderately high dose megestrol acetate in advanced prostate cancer: a CALGB study, Proc Am Soc Clin Oncol 14: 236, 1995.
10. **Small EJ**, Srinivas S, Rearden TP. Use of doxorubicin and dose-escalated cyclophosphamide with granulocyte colony stimulating factor in the treatment of HRPc. Proc Am Soc Clin Oncol 14: 243, 1995.
11. **Small EJ**, Damon L, Frye J, Wolf J, Rugo H, Ries C, Linker C. Thiotepa, VP-16 and dose-adjusted carboplatin with autologous bone marrow or peripheral blood stem cell rescue for treatment of refractory germ cell tumors: efficacy & pharmacokinetic data. Proc Am Soc Clin Oncol 14: 466,1995.
12. Srinivas S, **Small EJ**. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected advanced prostate cancer patients. Proc Am Uro Assn, 153, 1995.
13. Cher ML, **Small EJ**, Carroll PR, Jensen RH, Bova S, Isaacs WB. Genetic alterations in advanced prostate cancer. Proc Am Uro Assn 153, 1995.
14. **Small EJ**, Srinivas S, Rearden TP. Treatment of hormone refractory prostate cancer with doxorubicin and dose-escalated cyclophosphamide with granulocyte colony stimulating factor. Proc Am Uro Assn 153, 1995.
15. Schelhammer P, Venner P, Haas G, **Small EJ**, Nieh P et al. Casodex in combination therapy: A double-blind assessment of antiandrogen withdrawal from Casodex or Eulexin therapy while continuing luteinizing hormone releasing hormone analogue therapy for patients with stage D2 prostate cancer. Proc Eu Assn Uro, 1996.
16. Roach M, Meehan S, Weil M, Ryu J, **Small EJ**, et al. Radiotherapy (XRT) for high-grade clinically localized adenocarcinoma of the prostate. Proc Am Soc Clin Oncol 15, 1996.
17. **Small EJ**, Schellhammer P, Venner P, Haas G et al. A double-blind assessment of antiandrogen withdrawal from casodex or eulexin therapy while continuing luteinizing hormone releasing hormone analogue therapy for patients with stage D2 prostate cancer. Proc Am Soc Clin Oncol 15, 1996.
18. **Small EJ**, Weiss G, Dutcher J, Walther P et al. Preliminary results from a multi-center open-label trial of actimmune® interferon gamma-1b injection (rIFN-g) for the treatment of metastatic renal cell carcinoma: Favorable safety profile. Proc Am Soc Clin Oncol 15, 1996.
19. Dawson NA, **Small EJ**, Conaway M, Lake D, et al. Megestrol acetate (MA) in men with hormone-refractory prostate cancer: prostate specific antigen (PSA) response and anti-androgen withdrawal data: Cancer and Leukemia Group B (CALGB) 9181. Proc Am Soc Clin Oncol 15, 1996.
20. Marshall ME, **Small EJ**, Eisenberger M. Suramin has a highly favorable safety profile in Phase III trial of suramin + hydrocortisone vs. placebo + hydrocortisone for HRPc. Proc Am Assn for Can Res 37:173, 1996.
21. **Small EJ**, Marshall E, Meyers F et al. A multicenter phase III trial of suramin + hydrocortisone vs. placebo + hydrocortisone in metastatic HRPc: Favorable safety profile. Proc Am Soc Clin Oncol 15, 1996.
22. **Small EJ**, Egan B, Apodaca D, Fippin LJ. Ketoconazole retains significant activity in patients with advanced prostate cancer who have progressed despite flutamide withdrawal. Proc ASCO 15, 1996.
23. **Small EJ**, Egan B, Fippin LJ, Srinivas S, Ernest ML, Carroll PR. Methotrexate, vinblastine, mitoxantrone, and carboplatin (MVNcA) for the treatment of advanced transitional cell carcinoma. Proc ASCO15, 1996.
24. **Small EJ**, Grossfeld GD, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer. Proc Am Soc Clin Oncol 16, 1997.

25. **Small EJ**, Apodaca D, Baron A. Second-line chemotherapy with doxorubicin/cyclophosphamide for hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 16, 1997.
26. **Small EJ**, Baron A, Apodaca D. Simultaneous anti-androgen withdrawal and treatment with ketoconazole/hydrocortisone in patients with advanced hormone refractory prostate cancer. Proc ASCO 16, 1997.
27. **Small EJ**, Weiss G, Dutcher P, Walther D, Johnson G, Wilding T, Kuzel G, Kralik G, Paton V. A multicenter open-label trial of Actimmune® interferon gamma-1b injection (rIFN-g) for the treatment of metastatic renal cell carcinoma (mRCCC). Proc Am Soc Clin Oncol 16, 1997.
28. Hussain M, **Small EJ**, Eisenberger M, Crawford ED. Androgen deprivation + 4-courses of fixed-schedule suramin in D2 prostate cancer patients: A SWOG phase II study. Proc Am Soc Clin Oncol 17: 314, 1998.
29. Whisenant S, **Small EJ**, Guild C, Figg WD. Immunologic therapy of prostate cancer with granulocyte- macrophage colony stimulating factor (GM-CSF). Proc Am Soc Clin Oncol 17: 348, 1998.
30. **Small EJ**, Harney E, Chang S. Infusional floxuridine (FUDR)-based therapy for metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 17: 263, 1998.
31. Vogelzang NJ, **Small EJ**, Halabi S, Ansari R, Palchak D, Rago R, Cooper M, Hudson J, Schultz P, Hars V. A phase III trial of 3 different doses of suramin (SUR) in metastatic hormone refractory prostate cancer: Safety profile of CALGB 9480. Proc Am Soc Clin Oncol 17: 347, 1998.
32. Valone FH, **Small EJ**, Whisenant S, Peshwa MV, Strang G. Immunotherapy of hormone refractory prostate cancer with antigen-pulsed dendritic cells: A phase I/II trial. Proc Am Soc Clin Oncol 17: 346, 1998.
33. **Small EJ**, Marshall ME, Reyno L, Meyers F, Natale R, Meyer M, Lenehan P, Chen L, Eisenberger M. Superiority of suramin + hydrocortisone over placebo + hydrocortisone: Results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 17: 308, 1998.
34. Ko Y-J, **Small EJ**, Chachoua A, Kabbinavar F, Reese D, Balk S, DePaoli A, Hannah A, Bublely G. A phase II study of SU101 in patients with PSA-positive prostate cancer. Proc Am Assn Ca Res, 1998.
35. **Small EJ**, Weiden P, Knox S, Horak I. A phase II trial of Yttrium-90-Dota-Biotin pretargeted by murine NRLU-10/streptavidin in patients with metastatic hormone-resistant prostate cancer. Cancer Invest 17 (suppl 1), 1999.
36. Reyno LM, Eisenberger M, Cella D, **Small EJ**, Meyer M, Lenehan P, Slichenmeyer W. Relationship between pain response and indices of quality of life in symptomatic men with hormone refractory prostate cancer treated with hydrocortisone plus suramin plus placebo. Proc ASCO 18, 1999.
37. Eisenberger M, Meyer M, Lenehan P, Chen L, Klohs W, Slichenmeyer W, **Small EJ**. Suramin induced decrease in PSA is associated with prolonged objective progression-free and overall survival in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 18, 1999.
38. Wilding G, **Small EJ**, Collier M, Dixon M, Pithavala Y. A phase I pharmacokinetic evaluation of the matrix metalloproteinase (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients having advanced prostate cancer. Proc Am Soc Clin Oncol 18, 1999.
39. Dawson NA, Halabi S, Hars V, **Small EJ**, Vogelzang NJ. Prostate specific antigen decline as a predictor of survival: Cancer and Leukemia Group B (CALGB) 9181. Proc Am Soc Clin Oncol 18, 1999.
40. Lenehan PF, Chen L, Lam R, Morrell L, Meyer M, Slichenmyer W, **Small EJ**, Eisenberger M. Modulation of plasma insulin-like growth factor I (IGF-I) levels in patients with hormone refractory prostate cancer during treatment with suramin + hydrocortisone (H) versus placebo + H. Proc ASCO 18, 1999.

41. Valone FH, **Small EJ**, Strang G, Laus R, van Schooten W. Immunotherapy of hormone refractory prostate cancer with prostatic acid phosphatase (PAP)-loaded dendritic cells. Proc Am Soc Clin Oncol 18, 1999.
42. Weiden P, **Small EJ**, Hudes GR, Knox SJ, Hawkins R, Breitz H, Adams G, French J, Gaffigan S, Bryan K, Horak ID, Gentner L. A phase II trial of pretargeted radioimmunotherapy (PRIT®) in patients with metastatic hormone resistant prostate cancer. Proc Am Soc Clin Oncol 18, 1999.
43. Kelly K, Slovin S, Curley T, McCaffrey J, Dalbagni G, Scardino P, Scher H, Kantoff P, Smith M, Oh W, **Small E**. Paclitaxel, estramustine and carboplatin in patients with advanced prostate cancer. Proc Am Urol Assn, 1999.
44. Ko YJ, Chachoua A, **Small EJ**, Reese DM, Kabbinavar F, Taneja S, DePaoli A, Hannah A, Balk S, Bubley G. Phase II study of SU-101 in patients with PSA-positive prostate cancer. Proc Am Soc Clin Oncol 18, 1999.
45. Kameda H, **Small EJ**, Reese DM, Correy M, Frohlich MA, Bok RA, Kelly WK. A phase II study of PC-SPES, an herbal compound, for the treatment of advanced prostate cancer. Proc Am Soc Clin Oncol 18, 1999.
46. Reese D, Frohlich M, Bok R, Corry M, **Small E**. A phase II trial of humanized rhuMAb VEGF in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 18, 1999.
47. **Small EJ**, Lew D, Petrylak DP, Crawford ED. Carboplatin and paclitaxel (Carbo/Tax) for advanced transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol 18, 1999.
48. Lenehan PF, Bycott P, Meyer M, Slichenmyer W, **Small EJ**, Eisenberger M. Effect of suramin + hydrocortisone versus placebo + hydrocortisone on plasma concentrations of insulin-like growth factor-I, IGF binding protein-3, and vascular endothelial growth factor during the treatment of patients with hormone refractory prostate cancer. Fifth International Symposium on Insulin-Like Growth Factors. Brighton, UK, November 1999.
49. Chaudhary UB, Grossfeld GD, Reese DM, **Small EJ**, Carroll PR. Intermittent androgen deprivation as treatment for localized and recurrent prostate cancer. Proc Am Urological Assn, 2000.
50. **Small EJ**, Reese DM, Valone FH, Figg WD. Immunotherapy of hormone-refractory prostate cancer: GM-CSF or antigen-loaded dendritic cells. Cancer Investigation 18: 77-78, 2000.
51. Taplin ME, Rajeskumar B, Woda B, Halabi S, Prins G, Picus J, Hayes D, Vogelzang N, **Small EJ**. Androgen receptor analyses in hormone androgen independent prostate cancer: Cancer and Leukemia Group B (CALGB) 9663. Proc Am Soc Clin Oncol 19: 330, 2000.
52. Halabi S, **Small EJ**, Ansari R, Wilding G, Petrylak D, Palchak D, Marshall E, Rago R, Hars V, Vogelzang NJ. Results of CALGB 9480: A phase III trial of 3 different doses of suramin for the treatment of hormone refractory prostate cancer. Proc Am Soc Clin Oncol 19: 328, 2000.
53. Chaudhary U, Grossfeld GD, Reese DM, Carroll PR, **Small EJ**. Intermittent androgen deprivation: Patterns of failure in clinically localized prostate cancer. Proc Am Soc Clin Oncol 19: 333, 2000.
54. Higano CS, **Small EJ**, Vogelzang NJ, Caron D. Safety and biologic activity of multiple cycles of FLT-3 ligand in patients with bone scan negative hormone refractory prostate cancer. Proc Am Soc Clin Oncol 19: 458, 2000.
55. Bok R, Halabi S, Schaal M, Fei D, Rodriguez C, Hayes D, Vogelzang NJ, **Small EJ**. VEGF and bFGF urine levels as predictors of response to therapy with suramin in CALGB 9480: A phase III study of hormone refractory prostate cancer patients. Proc Am Soc Clin Oncol 19: 347, 2000.
56. Reese DM, **Small EJ**, Waldman FM, Chew K, Sudilovsky D. HER-2 expression in androgen-independent prostate cancer. Proc Am Soc Clin Oncol 19: 347, 2000.

57. Kantoff PW, Halabi S, Farmer D, Hayes D, Vogelzang N, **Small EJ**. RT-PCR for prostate specific antigen in peripheral blood predicts survival duration in patients with hormone refractory prostate cancer: A CALGB study. *Proc Am Soc Clin Oncol* 19: 336, 2000.
58. **Small EJ**, Corry M, Frohlich MA, Bok RA, Kelly WK, Reese DM. Effects of PC-SPES, an herbal compound, in patients with androgen-dependent prostate cancer. *Proc Am Soc Clin Oncol* 19: 335, 2000.
59. Simons J, **Small EJ**, Nelson W, Nemunaitis J, Urba W, Smith D, Marshall F, Borellini F, Sy J, Marshall M. Vaccination with a GM-CSF gene-transduced, irradiated prostate cancer vaccine (GVAX) induces a tumoricidal immune response. *Proc Am Soc Clin Oncol* 20: 269a, 2001.
60. Hsei V, Novotny WF, Margolin K, Gordon M, **Small EJ**, Griffing S, Siguenza P, Gaudreault J. Population pharmacokinetic analysis of bevacizumab in cancer subjects. *Proc Am Soc Clin Oncol* 20: 69a, 2001.
61. **Small EJ**, Kivitz S, Harris KA, Frohlich MW, Bok RA, Corry M, Um B. A phase I/II trial of docetaxel, estramustine and herceptin for the treatment of hormone resistant prostate cancer. *Proc ECCO*, 2001.
62. Um B, **Small EJ**, Harris KA, Frohlich MW, Bok RA, Corry M, Hall M. A phase I/II trial of docetaxel, estramustine and Herceptin for the treatment of hormone resistant prostate cancer. *Proc Am Soc Clin Oncol* 20: 172b, 2001.
63. LeBlanc G, **Small EJ**, Bok RA, Frohlich MW, Kakefuda M, Corry M, Hall M, Reese DM. Granulocyte macrophage colony-stimulating factor therapy for prostate cancer patients with serologic progression after definitive local therapy. *Proc Am Soc Clin Oncol* 20: 182a, 2001.
64. Bok R, **Small E**, Curnow R, Roach, M Carroll P, Frohlich M. CD₄ and CD₈ counts are suppressed in patients with advanced prostate cancer treated with chemotherapy or radiation therapy. *Proc Am Soc Clin Oncol* 20:151,2001.
65. Frohlich MW, **Small EJ**, Bok RA, Gulla S, Valone FH, Harris KA, Reese DM. Immunotherapy with prostatic acid phosphatase-loaded dendritic cells (Provenge) in prostate cancer patients with serologic progression after definitive local therapy. *Proc Am Soc Clin Oncol* 20:188a, 2001.
66. Ross R, Kussmaul S, **Small EJ**. The effect of the herbal supplement PC-SPES on bone mineral density in men with prostate cancer. *Proc Am Soc Clin Oncol* 20: 151b, 2001.
67. Harris KA, **Small EJ**, Frohlich MW, Bok RA, Randall M. Prospective trial of low-dose ketoconazole therapy in patients with androgen-independent prostate cancer. *Proc Am Soc Clin Oncol* 20: 167b, 2001.
68. Vogelzang NJ, Halabi S, Picus J, Gable P, Hayes DF, Kantoff P, **Small EJ**. Prospective assessment of adrenal androgen levels as predictors of survival in androgen independent prostate cancer patients treated with ketoconazole: A correlative study to CALGB protocol 9583. *Proc Am Soc Clin Oncol* 20:188a, 2001.
69. **Small EJ**, Carducci M, Wilding G. A phase I/II dose finding trial of the intravenous injection of CV787, a PSA-dependent cytolytic adenovirus in pts with advanced hormone refractory prostate cancer. *Proc ECCO*, 2001.
70. Halabi S, **Small EJ**, Farmer D, Cen Y, Paradis A, Hayes DF, Vogelzang NJ, Kantoff P. Reverse transcriptase polymerase chain reaction for prostate specific antigen as a prognostic factor for survival among androgen independent prostate cancer patients: A companion study to CALGB 9583. *Proc Am Soc Clin Oncol* 20: 176a, 2001.
71. Taplin ME, Halabi S, Rajeskumar B, McQuain C, Woda BA, Picus J, Hayes DF, Vogelzang NJ, **Small EJ**. Androgen receptor mutations in androgen independent prostate cancer do not correlate with antiandrogen withdrawal response: CALGB 9663. *Proc Am Soc Clin Oncol* 20: 435a, 2001.

72. **Small EJ**, Halabi S, Picus J, Cheng Y, Vogelzang NJ. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: Results of CALGB 9583. *Proc Am Soc Clin Oncol* 20:174a, 2001.
73. Stadler WM, Rosner G, **Small EJ**, Ratain MJ. Feasibility of the randomized discontinuation clinical trial design for assessing cytostatic drug activity. *Mol Targets and Ca Therapeutics Mtg. AACR-NCI-EORTC*, 2001.
74. Lipton A, **Small EJ**, Saad F, Gleason D, Gordon D, Smith M, Rosen L. Broad clinical utility of zoledronic acid in the treatment of lytic to blastic bone metastases. *Proc 3rd Int PC Meeting*, abstract #2, 2002.
75. Wilding G, **Small EJ**, Soulie P, Trump D, Das-Gupta A. A pilot trial of ZD1839 (Iressa), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with docetaxel and estramustine in patients with hormone refractory prostate cancer. *Proc AUA*, 2002.
76. Valone FH, **Small EJ**. Assessment of the tissue specific antigen prostatic acid phosphatase as a target for immunotherapy trials in prostate cancer. *Proc AACR*, 2002.
77. **Small EJ**, Kantoff P, Weinberg V, Nguyen S, Smith M, Bublely G, Rini BI, Bok RA, Haqq C, George D, Oh WK. A prospective multicenter randomized trial of the herbal supplement PC-SPES vs. Diethylstilbestrol in patients with advanced, androgen-independent prostate cancer. *Proc Am Soc Clin Oncol* 21:178a, 2002.
78. Valone FJ, Higano C, Peshwa M, Jones L, Pickering G, Glossa K, Rathbun J, **Small EJ**. A phase III randomized, double-blind, placebo-controlled trial of autologous dendritic cells pulsed with prostatic acid phosphatase in men with asymptomatic, metastatic, hormone refractory prostate cancer. *Proc Am Urol Assn* 167: 305, 2002.
79. Picus J, Halabi S, Hussain A, Philips G, Kaplan E, **Small E**, Vogelzang NJ. Efficacy of peripheral androgen blockade on prostate cancer: Initial results of CALGB 9782. *Proc Am Soc Clin Oncol* 21:182a, 2002.
80. Haqq C, Bernstein H, Downs T, Shinohara K, **Small EJ**. Expression array analysis of microdissected core needle biopsies in prostate cancer reveals a defect in apoptosis. *Proc Am Soc Clin Oncol* 21:182a, 2002.
81. Halabi S, **Small EJ**, Kantoff P, Dawson N, Levine E, Vogelzang NJ. A model for predicting survival in men with hormone refractory prostate cancer: An analysis of CALGB studies. *Proc Am Soc Clin Oncol* 21:425a, 2002.
82. Simons J, Nelson W, Neumunaitis J, Centeno A, Dula E, Urba W, Smith D, Marshall F, Howard C, Ando D, **Small E**. Phase II trials of GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. *Proc Am Soc Clin Oncol* 21:183a, 2002.
83. Davis TA, Tchekmedyian S, Korman A, Keler T, Deo Y, **Small EJ**. MDX-010 (human anti-CTLA4): A phase I trial in hormone refractory prostate carcinoma. *Proc Am Soc Clin Oncol* 21:19a, 2002.
84. Gilligan TD, Halabi S, Kantoff PW, Dawson NA, Kaplan EB, **Small EJ**, Vogelzang NJ. African-American race is associated with longer survival in patients with metastatic hormone refractory prostate cancer in four randomized phase III Cancer and Leukemia Group B (CALGB) trials. *Proc Am Soc Clin Oncol* 21:182a, 2002.
85. Oh WK, Halabi S, Kelly WK, Godley PA, Werner C, Kantoff PW, Vogelzang NJ, **Small EJ**. A phase II study of estramustine, docetaxel, and carboplatin with G-CSF support in men with hormone refractory prostate cancer: CALGB 99813. *Proc Am Soc Clin Oncol* 21:195a, 2002.
86. Schellhammer P, **Small EJ**, Higano CS, Neumunaitis J, Strang G, Valone FH. Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for hormone refractory prostate cancer: A phase III randomized, double blind, placebo-controlled trial. *Proc Am Soc Clin Oncol* 21:183a, 2002.

87. **Small EJ.** Recent developments in the treatment of advanced bladder cancer: Non-cisplatin combinations. Proc EORTC State of the Art in the Management of Urologic Malignancies. Barcelona, Spain, 2002.
88. Kelly WK, Galsky MD, **Small EJ**, Rini B, Oh W, Kantoff P, et al. Multi-institutional trial of epothilone B analogue with or without estramustine phosphate in patients with progressive castrate-metastatic prostate cancer. Proc Am Soc Clin Oncol 22: 394, 2003.
89. Ando D, Simons J, Nelson W, Nemunaitis J, Howard C, **Small E.** A phase II trial of a GM-CSF gene-transduced prostate cancer cell line vaccine in hormone refractory prostate cancer. Proc Am Urol Soc 169: 396, 2003.
90. Trump DL, Wilding G, Miller K, **Small EJ**, et al. Pilot trials of ZD1839 (Iressa), an orally active selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisone or docetaxel/estramustine in patients with hormone refractory prostate cancer. Proc Am Urol Soc 169:244, 2003.
91. Halabi S, **Small E**, Kattan M, Kantoff P, Dawson N, Levine E, Oh W, Kaplan E, Vogelzang N. A model for predicting progression-free survival in men with hormone refractory prostate cancer: An analysis of CALGB studies. Proc Am Soc Clin Oncol 22: 397, 2003.
92. Tangen CM, Hussain M, Wilding G, **Small EJ**, Goldenberg L, Akdas A, Crawford ED. Determinants of prostate specific antigen normalization in prostate cancer patients treated with androgen deprivation on Southwest Oncology Group (SWOG) Study 9346. Proc Am Soc Clin Oncol 22: 396, 2003.
93. Smith M, Kaufman D, George D, Oh W, Slovin S, Rini B, **Small E**, Kazanis M, Manola J, Kantoff P. Rosiglitazone vs. placebo for men with prostate cancer and a rising PSA after radical prostatectomy and/or radiation therapy. Proc Am Soc Clin Oncol 22: 395, 2003.
94. Picus J, Halabi S, Rini B, Vogelzang N, Kelly W, **Small E.** The use of bevacizumab with docetaxel & estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006. Proc Am Soc Clin Oncol 22:392, 2003.
95. Stadler WM, Rosner G, Rini B, Hollis D, Ratain MJ, **Small EJ.** Successful implementation of the randomized discontinuation trial design with the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma: A Cancer and Leukemia Group B (CALGB) Study. Proc Am Soc Clin Oncol 22: 193, 2003.
96. Rini BI, Weinberg V, Bok RA, Nguyen S, **Small EJ.** A phase II study of prostatic acid phosphatase-pulsed dendritic cells (APC8015; Provenge) in combination with bevacizumab in patients with serologic progression of prostate cancer after local therapy. Proc Am Soc Clin Oncol 22:174, 2003.
97. Simons J, Higano C, Corman J, Hudes G, Centeno A, Dula E, Smith D, Steidle C, Sacks N, **Small E.** A phase I/II study of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone refractory prostate cancer. Proc Am Soc Clin Oncol 22: 166, 2003.
98. Shaw VA, Rini BI, Park JW, **Small EJ.** A phase II study of UCN-01 in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 22: 442, 2003.
99. **Small EJ**, Higano C, Redfern C, Valone F, Schellhammer PF. A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer. Proc Am Soc Clin Oncol 22: 382, 2003.
100. Picus J, Halabi S, **Small E**, Hussain A, Philips G, Kaplan E, Vogelzang N. Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782. Proc Am Soc Clin Oncol 23: abstr. 4559, 2004.
101. Humphrey P, Halabi S, Picus J, Vogelzang N, **Small E**, Kantoff P. Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480. Proc Am Soc Clin Oncol 23: abstr. 9613, 2004.

102. Kelly WK, Galsky MD, **Small EJ**, Oh W, Chen I, et al. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate in patients with progressive castrate-metastatic prostate cancer: Updated results. Proc Am Soc Clin Oncol 23: abstr. 4509, 2004.
103. Philips G, Halabi S, Sanford B, Bajorin D, **Small E**. Phase II trial of cisplatin, fixed-dose rate gemcitabine and gefitinib for advanced transitional cell carcinoma of the urothelial tract: Preliminary results of CALGB 90102. Proc Am Soc Clin Oncol 23: abstr. 4540, 2004.
104. Halabi S, **Small EJ**, Gilligan T, Barrier R, George S, Vogelzang NJ. The effect of race on progression-free survival in patients with metastatic hormone refractory prostate cancer: A pooled analysis of CALGB studies. Proc Am Soc Clin Oncol 23: abstr. 4573, 2004.
105. Rosenberg JE, Galsky MD, Weinberg V, Kelly WK, **Small EJ**. Response to second-line taxane-based therapy after first-line epothilone B analogue BMS-247550 therapy in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 23: abstr. 4564, 2004.
106. Ryan CJ, Halabi S, Kaplan E, Vogelzang N, Kantoff P, **Small EJ**. Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen-independent prostate cancer: Results from CALGB 9583. Proc Am Soc Clin Oncol 23: abstr. 4558, 2004.
107. Taplin ME, George DJ, Halabi S, Sellers WR, Sanford B, Hennessy KT, Mihos CG, **Small EJ**, Kantoff PW. Prognostic significance of plasma chromogranin A levels in hormone refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. Proc Am Soc Clin Oncol 23: abstr. 4557, 2004.
108. Stadler WM, Halabi S, Picus J, **Small EJ**. A phase II study of gemcitabine and capecitabine in patients with metastatic renal cell cancer: a report of CALGB 90008. Proc Am Soc Clin Oncol 23: abstr. 4515, 2004.
109. Wilding G, Carducci M, Yu DC, Burke J, Birekkuni F, Aimi J, Working P, Ando D, Kim D, **Small E**. A phase I/II trial of IV CG7870, a replication-selective, PSA targeted oncolytic adenovirus, for the treatment of hormone refractory, metastatic prostate cancer. Proc Am Soc Clin Oncol 23: 3036, 2004.
110. Fong L, Rini B, Kavanaugh B, **Small E**. CTLA-4 blockade-based immunotherapy for prostate cancer. Proc Am Soc Clin Oncol 23: abstr. 2590, 2004.
111. Petrylak DP, Tangen C, Hussain M, Lara PN, Jones J, Taplin ME, Burch P, Greene G, **Small E**, Crawford ED. SWOG 9916: Randomized phase III trial of docetaxel/estramustine versus mitoxantrone/prednisone in men with androgen-independent prostate cancer. Proc Am Soc Clin Oncol 23: abstr. 3, 2004.
112. D'Amico AV, Halabi S, Vogelzang NJ, **Small EJ**. A reduction in the rate of PSA rise following chemotherapy chein patients with metastatic hormone refractory prostate cancer predicts survival: Results of a pooled analysis of CALGB HRPC trials. Proc Am Soc Clin Oncol 23: abstr.4506, 2004.
113. Crawford ED, Pauler DK, Tangen CM, Hussain MA, **Small EJ**, et al. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone refractory prostate cancer: Data from Southwest Oncology Group Study S9916. Proc Am Soc Clin Oncol 23: abstr. 4505, 2004.
114. Randall M, Rini B, Ryan C, Rosenberg J, Garcia J, Bublely G, **Small EJ**. The addition of imatinib mesylate to estramustine/docetaxel for the treatment of hormone refractory prostate cancer patients: Results of a phase I trial. Proc Am Soc Clin Oncol 23: abstr. 4617, 2004.
115. Garcia JA, Weinberg V, Rini BI, Rosenberg JE, Ryan CJ, **Small EJ**. Prior estrogen therapy as a predictor of response to subsequent estramustine-based therapy in androgen-independent prostate cancer patients. Proc Am Soc Clin Oncol 23: abstr. 4595, 2004.

116. Rini B, Weinberg V, Cadman B, Elchinoff A, Yu N, Bok R, Small E. A phase II trial of interferon-alpha and celecoxib in metastatic renal cell carcinoma: Clinical and anti-angiogenic effects. Proc Am Soc Clin Oncol 23: abstr. 4604, 2004.
117. **Small E**, Higano C, Smith D, Corman J, Centeno A, et al. A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone refractory prostate cancer. Proc Am Soc Clin Oncol 23: abstr. 4565, 2004.
118. **Small EJ**, Schellhammer PF, Higano C, Valone F, Hershberg RM. Immunotherapy for androgen-independent prostate cancer: Final survival data from a phase III randomized trial. Proc Am Soc Clin Oncol 24, 2005.
119. **Small EJ**, Schellhammer PF, Higano CS, Neumanaitis J, Valone F, Hershberg R. Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 23: 378, 2005.
120. Ryan CJ, Elkin E, **Small E**, Duchane J, Carroll, P. Predictors of mortality in patients with bony metastasis at the time of initial prostate cancer diagnosis: data from CaPSURE. Proc Multidiscipl Prostate Cancer Symp, 2005.
121. Rini B, Weinberg V, Fong L, **Small E**. Clinical and immunologic characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with GM-CSF. Proc Multidiscipl Prostate Ca Symp, 2005.
122. Ryan CJ, Rosenberg J, Rini B, Nguyen T, Weinberg V, **Small E**. A phase II trial of ketoconazole plus granulocyte macrophage colony-stimulating factor in androgen independent prostate cancer. Proc Multidiscipl Prostate Ca Symp, 2005.
123. Dawson NA, Halabi S, Kelly WK, **Small E**. A phase II study of estramustine, docetaxel and exisulind in hormone refractory prostate cancer: toxicity results of CALGB 90004. Proc Multidiscipl Prostate Ca Symp, 2005.
124. Ross RW, Manola J, Hennessy K, Galsky M, Scher H, **Small E**, Kelly WK, Kantoff P. Reverse transcriptase polymerase chain reaction for prostate-specific antigen responses may predict time to progression in hormone refractory prostate cancer patients treated with chemotherapy. Proc Multidiscipl Prostate Ca Symp, 2005.
125. Smith M, Kabbinavar F, Saad F, Hussain A, Hei YJ, **Small E**, Cook R, Higano C. Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer. Proc Multidiscipl Prostate Ca Symp, 2005.
126. Rosenberg JE, Kelly WK, Michaelson D, Wilding G, Hussain M, Gross M, Weinberg V, **Small EJ**. A randomized phase II study of ixabepilone or mitoxantrone and prednisone in patients with taxane-refractory hormone refractory prostate cancer. Proc Multidiscipl Prostate Ca Symp, 2005.
127. Halabi S, **Small EJ**, Ou SS, Vogelzang NJ. The impact of age on clinical outcomes in men with hormone refractory prostate cancer. Proc Multidiscipl Prostate Ca Symp, 2005.
128. **Small EJ**, Higano C, Smith D, Corman J, Centeno A, Steidle C, Gittelman M, Hudes G, Sacks N, Simons JW. A phase II study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone refractory prostate cancer. Proc Multidiscipl Prostate Ca Symp, 2005.
129. Rosenberg JE, Galsky MD, Weinberg VK, Oh WK, Kelly WK, **Small EJ**. Response to second-line taxane-based therapy after first-line epothilone B analog ixabepilone therapy in hormone refractory prostate cancer. Proc Multidiscipl Prostate Ca Symp, 2005.
130. **Small EJ**, Schellhammer PF, Higano C, Neumanaitis J, Valone F, Hershberg RM. Immunotherapy (APC8015) for androgen-independent prostate cancer: final survival data from a phase III randomized placebo-controlled trial. Proc

Multidiscipl Prostate Ca Symp, 2005.

131. Lin AM, Fong K, Weinberg V, Rini BI, Ryan CJ, Rosenberg J, Fong L, Haqq C, **Small EJ**. A phase II trial of imatinib mesylate in prostate cancer patients with biochemical relapse after definitive local therapy. Proc Multidiscipl Prostate Ca Symp, 2005.
132. Ryan CJ, Stadler WM, Roth BJ, Dong RP, Pucalski TA, Koehler M, **Small EJ**. Safety and tolerability of AZD2171, a highly potent VEGFR inhibitor, in patients with advanced prostate adenocarcinoma. Proc Multidiscipl Prostate Ca Symp, 2005.
133. Elkin E, **Small EJ**, Duchane J, Carroll P. Reduced incidence of bony metastasis at the time of initial prostate cancer diagnosis: data from CaPSURE. Proc Multidiscipl Prostate Ca Symp, 2005.
134. Rini B, Weinberg V, Fong L, **Small E**. A phase II study of prostatic acid phosphatase-pulsed dendritic cells (APC8015) in combination with bevacizumab in patients with serologic progression of prostate cancer after local therapy. Proc Multidiscipl Prostate Ca Symp, 2005.
135. Sokoloff MH, Halabi S, Sanford B, Eastham J, Mohler J, Walther P, Steinberg G, Vogelzang N, **Small E**. Management of recurrent prostate cancer after radiotherapy: preliminary results of CALGB 9687, a contemporary salvage prostatectomy series. Proc Multidiscipl Prostate Ca Symp, 2005.
136. Rini BI, Beinart G, **Small EJ**. Immunotherapy for androgen-dependent, biochemically-relapsed prostate cancer. Proc Am Urol Soc 173:1018, 2005
137. Lin AM, Ryan CJ, Rosenberg J, Rini BI, Nguyen T, Weinberg VI, **Small EJ**. A phase II trial of ketoconazole plus granulocyte/macrophage-colony stimulating factor in androgen-independent prostate cancer patients. Proc Am Soc Clin Oncol 23: 406, 2005.
138. Ryan C, Stadler W, Roth B, Koehler M, **Small EJ**. Safety and tolerability of AZD2171, a highly potent VEGF-r-inhibitor, in patients with advanced prostate adenocarcinoma. Proc Am Soc Clin Oncol 23: 204, 2005.
139. Ross RW, Manola J, Hennessey J, Galsky M, Scher H, **Small E**, Kelly WK, Kantoff P. Reverse transcriptase polymerase chain reaction for prostate-specific antigen responses may predict time to progression in hormone refractory prostate cancer patients treated with chemotherapy. Proc Am Soc Clin Oncol 23: 381, 2005.
140. Smith M, Kabbinavar F, Saad F, Hussain A, Hei Y-J, **Small E**, Cook R, Higano C. Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer. Proc Am Soc Clin Oncol 23: 381, 2005.
141. Halabi S, **Small EJ**, Ou SS, Vogelzang NJ. The impact of age on clinical outcomes in men with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 23: 408, 2005.
142. Dawson NA, Halabi S, Biggs DD, Kelly WK, **Small EJ**. A phase II study of estramustine, docetaxel and exisulind in hormone refractory prostate cancer: Initial results of CALGB 90004. Proc Am Soc Clin Oncol 23: 415, 2005.
143. Rosenberg JE, Kelly WK, Miichaelson M, Wilding G, Hussain M, Gross M, Weinberg V, **Small EJ**. A randomized phase II study of ixabepilone or mitoxantrone and prednisone in patients with taxane-refractory hormone refractory prostate cancer. Proc Am Soc Clin Oncol 23: 394, 2005.
144. Simons JW, Higano C, Smith D, Corman J, Steidle C, Gittelman M, Huders G, Aimi J, Sacks N, **Small E**. Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone refractory prostate cancer. Proc Am Soc Clin Oncol 23:170, 2005.
145. **Small EJ**, Schelhammer PF, Higano CS, Neumanaitis J, Valone F, Hershberg R. Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 23: 378, 2005.

146. Kavanagh B, Rini B, Weinberg VK, Shaw V, **Small EJ**, Fong L. CTLA-4 blockade-based immunotherapy for hormone refractory prostate cancer. *Blood*, 112(4):1175-1183, 2008.
147. **Small EJ**, Higano CS, Smith D, Corman J, Steidle C, Gittelman M, Hudes G, Sacks N, Simons JW. Analysis of prognostic variables in phase II trials of GVAX vaccine for prostate cancer in metastatic hormone refractory prostate cancer. *Proc Multidiscipl Prostate Ca Symp*, 2006.
148. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson DM, Hussdain M, Wilding G, Gross ME, **Small EJ**. Randomized phase II study of ixabepilone or mitoxantrone and prednisone in patients with taxane-resistant hormone refractory prostate cancer. *Proc Multidiscipl Prostate Ca Symp*, 2006.
149. Lin AM, Ryan CJ, Rosenberg JE, Ruttner L, **Small EJ**. A phase II trial of ketoconazole and granulocyte macrophage colony-stimulating factor for androgen-independent prostate cancer. *Proc Multidiscipl Prostate Ca Symp*, 2006.
150. Ryan CJ, Stadler WM, Roth B, Puchalski T, Morris C, **Small EJ**. Phase I evaluation of AZD2171, a highly potent VEGFR tyrosine kinase inhibitor, in patients with hormone refractory prostate cancer. *Proc Multidiscipl Prostate Ca Symp*, 2006.
151. Halabi S, Ou S, Vogelzang NJ, **Small EJ**. The impact of prior prostatectomy in men with metastatic hormone refractory prostate cancer: a pooled analysis of CALGB trials. *Proc Multidiscipl Prostate Ca Symp*, 2006.
152. Ryan CJ, Youngren J, Haqq C, Zavodovskaya M, Maddux BM, Fong K, Goldfine ID, **Small EJ**. Nordihydroguareacetic acid (NDGA), a novel insulin like growth factor receptor (IGF-1R) inhibitor in prostate cancer. *Proc Multidiscipl Prostate Ca Symp*, 2006.
153. Philips G, Sanford B, Halabi S, Bajorin D, **Small EJ**. Phase II study of cisplatin, gemcitabine and gefitinib for advanced urothelial carcinoma: Analysis of the second cohort of CALGB 90102. *Proc Am Soc Clin Oncol* 24: 236s, 2006.
154. Picus J, Halabi S, **Small EJ**, Hussain A, Philips G, Kaplan E, Vogelzang N. Long-term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782. *Proc Am Soc Clin Oncol* 24: 234s, 2006.
155. Halabi S, Ou S, Vogelzang NJ, **Small EJ**. An elevated body mass index predicts for better clinical outcomes in men with metastatic hormone refractory prostate cancer. *Proc Am Soc Clin Oncol* 24: 230s, 2006.
156. Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Small EJ, et al. CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma. *Proc Am Soc Clin Oncol* 24: 237s, 2006.
157. Hussain M, Tangen CM, Schellhammer PF, Crawford ED, Higano CS, Small EJ, et al. Absolute PSA value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346. *Proc Am Soc Clin Oncol* 24: 221s, 2006.
158. Fong L, Kavanaugh B, Rini BI, Weinberg V, Small EJ. A phase I trial of combination immunotherapy with CTLA-4 blockade & GM-CSF in hormone refractory prostate cancer. *Proc Am Soc Clin Oncol* 24:102s, 2006.
159. Ryan CJ, Rosenberg J, Lin A, Ruttner L, Weinberg V, Small E. Outcome of patients with non-metastatic vs. metastatic hormone refractory prostate cancer treated with second-line hormonal therapy consisting of ketoconazole plus granulocyte macrophage colony stimulating factor. *Proc Am Soc Clin Oncol* 24:248s, 2006.
160. **Small EJ**, Higano C, Tchekmedyian N, Sartor O, Stein B, Young R, Vestal J, et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of

- docetaxel in patients with hormone refractory prostate cancer. *Proc Am Soc Clin Oncol* 24: 243s, 2006.
161. D'Amico A, Halabi S, Titelbaum D, Loffredo M, McMahon E, Sanford B, Archer L, **Small E**, Kantoff P. p53 protein expression status and recurrence in men managed using radiation therapy and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II CALGB study. *Proc ASTRO*, 2007.
 162. So-Rosillo R, **Small EJ**, Weinberg V. Intermittent androgen deprivation therapy for patients with non-metastatic prostate cancer: A retrospective review. *Proc Am Soc Clin Oncol* 25: 660s, 2007.
 163. Harzstark AL, Ryan C, Diamond M, Jones J, Zavodovskaya M, Maddux B, Claros C, Goldfine I, **Small EJ**. A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA. *Proc Am Soc Clin Oncol* 25: 650s, 2007.
 164. Halabi S, Ou S, Vogelzang NJ, Scher H, **Small EJ**. A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer. *Proc Am Soc Clin Oncol* 25: 263s, 2007.
 165. D'Amico A, Halabi S, Tempany C, Vollmer R, Loffredo M, Sanford B, **Small EJ**. Changes on endorectal MRI during neoadjuvant hormonal therapy for prostate cancer and biochemical outcome in men managed using radiation therapy: A prospective phase II Cancer and Leukemia Group B study. *Proc Am Soc Clin Oncol* 25: 252s, 2007.
 166. Ryan CJ, Rosenberg J, Lin A, Valiente J, Kim J, **Small EJ**. Phase I evaluation of abiraterone acetate (CB7630), 17 alpha hydroxylase C17, 20-Lyase inhibitor in androgen-independent prostate cancer. *Proc Am Soc Clin Oncol* 25: 250s, 2007.
 167. Fong L, Kavanaugh B, Hou Y, O'Brien S, Valiente J, Weinberg V, Rini BI, **Small EJ**. Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansion of activated effector and regulatory T cells. *Proc Am Soc Clin Oncol* 25: 118s, 2007.
 168. Lee G, La Rochelle J, Ryan C, Butch A, **Small EJ**, Grant R, Beldegrun A. Development of an ultrasensitive testosterone (UST) assay to redefine castration resistant prostate cancer (CRPC): An important tool for future research and clinical decisions. *Proc Genitourinary Ca Symp Mtg*, 2008.
 169. Halabi S, Ou N, Vogelzang J, **Small EJ**. Is progression-free survival a predictor of overall survival in men with castration-resistant prostate cancer (CRPC)? *Proc Genitourinary Ca Symp Mtg*, 2008.
 170. Ryan C, Rosenberg J, Lin A, Huey V, Kim J, Lee G, **Small EJ**. Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17 alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer. *Proc Genitourinary Ca Symp Mtg*, 2008.
 171. Harding T, Nguyen M, Koprivnikar K, Huan-Tu G, Sacks N, **Small EJ**. Identification of antibody responses induced in patients with metastatic hormone-refractory prostate cancer (mHRPC) treated with GVAX immunotherapy for prostate cancer. *Proc Genitourinary Ca Symp Mtg*, 2008.
 172. Harzstark AL, Weinberg VK, Sharib J, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Ryan CJ, **Small EJ**, Rosenberg JE. Second-line combination therapy: A phase I trial of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC) previously treated with chemotherapy. *Proc Genitourinary Ca Symp Mtg*, 2008.
 173. Kelly WK, Halabi S, Clark J, Richardson WP, Leung E, Kaplan E, Taylor J, **Small EJ**. Understanding clinical trial barriers in hormone refractory prostate cancer (HRPC): Insights into a randomized phase III trial. *Proc Genitourinary Ca Symp Mtg*, 2008.
 174. Aggarwal RR, Weinberg V, Oh W, **Small EJ**, Ryan C. Association of change in hormone levels and response to estrogen treatment in patients (pts) with castration resistant prostate cancer (CRPC). *Proc Genitourinary Ca Symp*

Mtg, 2008.

175. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena D, Ou S, Taylor J, Tanguay S, Dutcher J, **Small EJ**. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Proc Genitourinary Ca Symp Mtg, 2008.
176. Rosenberg JE, Weinberg VK, Claros C, Lin AM, Ryan CJ, Fong L, Brocks D, **Small EJ**. Phase I study of sorafenib and RAD001 for advanced clear cell renal cell carcinoma. Proc Genitourinary Ca Symp Mtg, 2008.
177. Fong L, Dao V, O'Brien S, Simko J, Weinberg VK, Ryan C, Rosenberg JE, Lin AM, Carroll P, **Small EJ**. Neoadjuvant immunotherapy for prostate cancer with GM-GSF and tumor infiltration by antigen presenting cells. Proc Am Soc Clin Oncol Mtg, 2008.
178. Ryan C, Smith MR, Rosenberg JE, Lin AM, Taplin M, Kantoff PW, Huey V, Kim J, **Small EJ**. Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol Mtg, 2008.
179. Rosenberg JE, Weinberg VK, Claros C, Ryan C, Lin AM, Fong L, Brocks D, **Small EJ**. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. Proc Am Soc Clin Oncol Mtg, 2008.
180. Fong, L, Kwek S, Kavanaugh B, O'Brien S, McNeel D, Weinberg B, Rini BI, **Small, EJ**. CTLA-4 blockade for hormone refractory prostate cancer: Dose-related induction of CD8+ T cell activation and clinical responses. Proc, AACR, 2008.
181. **Small E**, Demkow T, Gerritsen WR, Rolland F, Hoskin P, Smith DC, Parker C, Chondros D, Ma J, Hege K. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Proc Genitourinary Ca Symp Mtg, 2009.
182. Ryan CJ, Efstathiou E, Smith M, Taplin M, Bublely G, Logothetis CJ, Kheoh T, Haqq CM, Molina A, **Small EJ**. Abiraterone acetate plus prednisone in chemotherapy (chemo)-naïve castration-resistant prostate cancer (CRPC) patients not exposed to ketoconazole: Results of a multicenter phase II study. Proc Genitourinary Ca Symp Mtg, 2009.
183. Rosenberg JE, Weinberg VK, Sharib J, Smith DC, Mathew P, Beer TM, Liu G, **Small EJ**, for the DOD Prostate Cancer Clinical Trials Consortium. A phase II study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPC) refractory to docetaxel-based therapy. Proc Genitourinary Ca Symp Mtg, 2009.
184. Halabi S, Vogelzang N, Kornblith A, Arther L, Kantoff PW, Dawson NA, **Small EJ**. Pain interference scores at 6-weeks from baseline and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). Proc Genitourinary Ca Symp Mtg, 2009.
185. Reid AH, Attard G, Danila D, Ryan CJ, Thompson E, Kheoh T, Molina A, **Small EJ**, Scher H, De-Bono JS. A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). Proc Am Soc Clin Oncol Mtg, 2009.
186. **Small EJ**, Harzstark A, Weinberg VK, Smith DC, Mathew P, Beer T, Liu G, Sharib J, Rosenberg J. Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium. Proc Am Soc Clin Oncol Mtg, 2009.
187. Ryan C, Efstathiou E, Smith M, Taplin M, Bublely G, Logothetis C, Kheoh T, Haqq C, Molina A, **Small EJ**. Phase II multicenter study of chemotherapy (chemo)-naïve castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. Proc Am Soc Clin Oncol Mtg, 2009.

188. Harzstark AL, Rosenberg JE, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, **Small EJ**. A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. Proc Am Soc Clin Oncol Mtg, 2009.
189. Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher J, **Small EJ**. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. Proc Am Soc Clin Oncol Mtg, 2009.
190. Shah SK, Ryan CJ, Molina A, Kheoh TS, Haqq CM, **Small EJ**. Bone scan flare in patients receiving abiraterone acetate (AA) for metastatic androgen deprivation-resistant prostate cancer (mADRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Proc Genitourinary Ca Symp Mtg, 2010.
191. Kantoff P, Higano CS, Berger ER, Shore N, **Small EJ**, Penson DF, Sims RB, Xu Y, Frohlich MW. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC). Proc Genitourinary Ca Symp Mtg, 2010.
192. Hussain M, Tangen CM, Higano CS, Eisenberger MA, **Small EJ**, Wilding G, Donnelly BJ, McLeod DG, Crawford E, Thompson I. Improved overall survival (OS) of patients (pts) with new metastatic prostate cancer (PCA): Better efficacy or stage migration? Data from SWOG: S9346 and 8894.
193. **Small EJ**, Beer TM, Weinberg VK, Higano CS, Alumkal JJ, Yu EY, Nordquist LT, Rosenbeg JE, Sun J, Lin AM. Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the Department of Defense Prostate Cancer Clinical Trails Consortium. Proc Genitourinary Ca Symp Mtg, 2010.
194. Friedlander TW, Roy R, Kobayashi Y, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, **Small EJ**, Ryan CJ, Paris P. Identification of gene copy number changes associated with lethal metastatic castration-resistant prostate cancer (CRPC). Proc Genitourinary Ca Symp Mtg, 2010.
195. Friedlander TW, Weinberg VK, Sharib J, Harzstark AL, Lin AM, Fong L, **Small EJ**, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating IGF-1 and on PSA in patients with castration-resistant prostate cancer (CRPC): Results of a phase II study. Proc Genitourinary Ca Symp Mtg, 2010.
196. Ryan CJ, Jones J, Diamond M, Molina A, Haqq CM, **Small EJ**. Role of mineralocorticoid elevation in the antiandrogen activity of abiraterone acetate. Proc Genitourinary Ca Symp Mtg, 2010.
197. Kelly WK, Halabi S, Archer L, Bogart J, Zelefsky M, **Small EJ**. Five-year follow-up of a multicenter phase II study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin (TEC) plus androgen-deprivation therapy (ADT) prior to radiation therapy in patients with unfavorable-risk localized prostate cancer: CALGB 99811. Proc Genitourinary Ca Symp Mtg, 2010.
198. Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase SJ, **Small EJ**, CALGB. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: Long-term results of CALGB 99809. Proc Genitourinary Ca Symp Mtg, 2010.
199. Harzstark AL, Halabi S, Stadler WM, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher JP, Rini BI, **Small EJ**. Hypertension is associated with clinical outcome for patients (pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206. Proc Genitourinary Ca Symp Mtg, 2010.
200. Halabi S, Rini BI, Stadler WM, Archer L, **Small EJ**. Evaluation of progression-free survival (PFS) as a predictor of overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Proc Genitourinary Ca Symp Mtg, 2010.
201. Fong L, Kwek S, Dao V, Roy R, Hou Y, Simko J, **Small EJ**. Identification of novel prostate cancer-associated

- antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade. *J Clin Oncol.*, 28:233s, 2010.
202. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk JP, **Small EJ**. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. *J Clin Oncol.*, 28:951s, 2010.
203. Halabi S, Rini BI, Stadler WM, **Small EJ**. Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). *Proc Am Soc Clin Oncol Mtg*, 2010. *J Clin Oncol.*, 28:348s, 2010.
204. Shah SK, Ryan CJ, Kilian C, bbell A, Kheo TS, Haqq CM, Molina A, **Small EJ**. Bone scan “flare” in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. *J Clin Oncol.*, 28:353s, 2010.
205. Higano CS, **Small EJ**, Schellhammer PF, Kantoff P, Redfern CH, Nemunaitis JJ, Nabhan C, Xu Y, Whitmore JB, Frohlich MW. Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. *J Clin Oncol.*, 28:354s, 2010.
206. Friedlander TF, Weinberg VK Formaker C, Mi J, Lin AM, Harzstark AL, Fong L, **Small EJ**, Ryan CJ. The effect of inhibition of the insulin-like growth factor receptor with nordihydroguaiaretic acid on PSA progression: Results of a phase II study. *J Clin Oncol.*, 28:384s, 2010.
207. Ryan CJ, Smith MR, Logothetis C, Koepfgen K, Taplin M, Harzstark AL, Kantoff P, Kheoh TS, Mollina A, **Small EJ**. Median time to progression in chemotherapy (chemo)-naïve patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred). *J Clin Oncol.*, 28:384s, 2010.
208. **Small EJ**, Beer TM, Weinberg VK, Higano CS, Nordquist LT, Rosenberg JE, Alumkal JJ, Yu EY, Sun J, Lin AM. Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. *J Clin Oncol.*, 28:387s, 2010.
209. Harzstark AL, Fong L, Weinberg K, Ryan CJ, Lin AM, Sun J, **Small EJ**. Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC). *J Clin Oncol.*, 28:388s, 2010.
210. Hall SJ, Schellhammer PF, Higano CS, Corman JM, Beer TM, **Small EJ**. Integrated Safety Results from 4 Randomized, Double-blind, Placebo-controlled Studies of Sipuleucel-T. *Proc Am Urol Assoc Mtg*, 2010.
211. Friedlander TW, Roy R, Tomlins A, Kobayashi Y, Rubin MA, Pienta KJ, Chinnaiyan A, **Small EJ**, Ryan CJ, Paris P. Identification of gene copy number and whole-genome methylation changes associated with lethal metastatic castration-resistant prostate cancer (CRPC). *Proc Genitourinary Ca Symp Mtg*, 2011.
212. Smith DC, Smith MR, **Small EJ**, Sweeney c, Kurzrock R, Gordon MS, Vogelzang NJ, Scheffold C, Ballinger MD, Hussain M. Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. *Proc Genitourinary Ca Symp Mtg*, 2011.
213. Harzstark AL, Beer TM, Weinberg VK, Higano CS, Nordquist LT, Rosenberg JE, Alumkal JJ, Yu EY, Mi J, **Small EJ**. Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Resulta of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. *Proc Genitourinary Ca Symp Mtg*, 2011.

214. Halabi S, Kelly WK, George DJ, Morris MJ, Kaplan EB, **Small EJ**. Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC). Proc Genitourinary Ca Symp Mtg, 2011.
215. Ryan CJ, Harzstark A, Lin M, Fong K, Grycz R, Szmulewitz Z, Weinberg VK, Molina A, **Small EJ**. Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium Study. Proc Am Soc Clin Oncol Mtg, 2011.
216. Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Haas NB, Harzstark AL, Kurzock R, Lara P, Lin C, Sella A, **Small EJ**, Spira AI, Vaishampayan UN, Vogelzang NJ, Scheffold C, Ballinger MD, Schimmoller F, Smith DC. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. Proc Am Soc Clin Oncol Mtg, 2011.
217. **Small EJ**, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. Proc Am Soc Clin Oncol Mtg, 2011.
218. Aparicio A, Harzstark AL, Lin E, Corn PG, Aruajo JC, Tu S, Pagliar LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ, Tannir NM, Lin AM, **Small EJ**, Mathew P, Jones DM, Troncoso P, Thall PF, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cispatin (EP). Proc Am Soc Clin Oncol Mtg, 2011.
219. **Small EJ**, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Time to disease-related pain after Sipuleucel-T in Asymptomatic Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC): Results from 3 Randomized Phase III Trials. Proc European Multidisciplinary Cancer Congress, 2011.
220. **Small EJ**, Weinberg VK, Ryan CH, Higano CS, Lin AM, Y, Alumkal JJ, Yu EY, Rosenberg JE, Beer TM. A prospective randomized phase II trial evaluating maintenance GM-CSF in an intermittent chemotherapy (chemo) regimen for metastatic castration-resistant prostate cancer (mCRPC): A DoD prostate cancer clinical trials consortium. Proc Genitourinary Ca Symp Mtg, 2012.
221. Sheikh NA, **Small EJ**, Quinn DI, Higano CS, Lin DW, Wesley JD, Haynes H, Stewart FP, Poehlein CH, Trager JB. Sipuleucel-T product characterization across different disease states of prostate cancer. Proc Genitourinary Ca Symp Mtg, 2012.
222. Harzstark AL, Halabi S, Kelly WK, Morris MJ, Febbo PG, **Small EJ**. Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy. Proc Genitourinary Ca Symp Mtg, 2012.
223. Fong L, Weinberg VK, Corman JM, Amling CL, Stephenson RA, Formaker C, Chan SE, Simko J, Sims RB, Carroll P, **Small EJ**. Immune responses in prostate tumor tissue following neoadjuvant sipuleucel-T in patients with localized prostate cancer. Proc Genitourinary Ca Symp Mtg, 2012.
224. Aggarwal RR, Formaker C, **Small EJ**, Molina A, Ryan CJ. Response to ketoconazole (keto) or docetaxel (D) following clinical progression on abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC). Proc Genitourinary Ca Symp Mtg, 2012.
225. Halabi S, Kelly WK, Kaplan EB, **Small EJ**. Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Proc Genitourinary Ca Symp Mtg, 2012.
226. Brondfield SC, Weinberg VK, Koepfgen KM, Molina A, Ryan CJ, **Small EJ**, Harzstark AL. Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC). Proc Genitourinary Ca Symp Mtg, 2012.
227. Friedlander TW, Weinberg VK, Yeung A, Burke J, Lamm DL, McKiernan MJ, Nemunaitis JJ, Stephenson, J, **Small**

- EJ**, Fong L, Meng MV. Updated results of a phase I/II trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure. Proc Genitourinary Ca Symp Mtg, 2012.
228. Fong L, Weinberg VK, Chan SE, Corman JM, Amling CL, Stephenson RA, Formaker C, Simko J, Sims RB, Peter Carroll P, **Small EJ**. Neoadjuvant sipuleucel-T in localized prostate cancer: Effects on immune cells within the prostate tumor microenvironment. Proc Am Soc Clin Oncol Mtg, 2012.
229. Small EJ, Halabi S, Carducci MA, Ryan CJ, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff P, Monk JP, Kelly WK. The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401). Proc Am Soc Clin Oncol Mtg, 2012.
230. Hussain M, Tangen CM, Higano, CS Crawford ED, Liu G, Wilding G, Prescott S, Akdas A, **Small EJ**, Dawson NA, Donnelly BJ, Venner P, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Vogelzang NJ, Thompson IM. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. Proc Am Soc Clin Oncol Mtg, 2012.
231. Smith MR, Sweeney C, Rathkopf DE, Scher HI, Logothetis C, George DJ, S. Higano CS, Yu EY, Harzstark AL, **Small EJ**, A. Sartor AO, Gordon MS, Vogelzang NJ, Smith DC, Hussain M, De Bono JS, Haas MB, Scheffold C, Lee Y, Corn PG. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). Proc Am Soc Clin Oncol Mtg, 2012.
232. Halabi S, Armstrong AJ, A. Sartor AO, De Bono JS, Kaplan EB, **Small EJ**; Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy. Proc Am Soc Clin Oncol Mtg, 2012.
233. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk JP, **Small EJ**. Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). Proc Am Soc Clin Oncol Mtg, 2012.
234. Harzstark AL, Weinberg VK, Grycz K, Hurd RE, Ardenkjaer-Larsen JH, Murray J, Chen A, Ferrone M, Park I, Reed G, Munster PN, **Small EJ**, Carvajal LE, VanCrieking ME, PeLarson PE, Chang J, Bok RA, Nelson SJ, Vigneron DB, Kurhanewicz JV. A first-in-human phase I imaging study using hyperpolarized 1c-13 pyruvate (h-Py) in patients (pts) with localized prostate cancer (l-PCa). Proc Am Soc Clin Oncol Mtg, 2012.
235. Apolo AB, Philips G, Ostrovnaya I, Rosenberg JE, Milowsky MI, **Small EJ**, Bajorin DF, Halabi S. External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. Proc Am Soc Clin Oncol Mtg, 2012.
236. Friedlander TW, Weinberg VK, Yeung A, Burke J, Lamm DL, McKiernan JM, Nemunaitis JJ, Stephenson J, Small EJ, Fong L, Meng MV. Activity of intravesical CG0070 in Rb-inactive superficial bladder cancer after BCG failure: Updated results of a phase I/II trial. Proc Am Soc Clin Oncol Mtg, 2012.
237. Ryan CJ, Smith MR, De Bono JS, Molina A, Logothetis C, De Souza PL, Fizazi K, Mainwaring PN, Rodriguez JMP, Ng S, Carles J, Mulders P, Kheoh TS, Griffin TW, **Small EJ**, Scher HI, Rathkopf DE. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2012.
238. Van Poppel HV, Rathkopf D, Smith MR, deBono J, Logothetis C, Shore ND, deSouza P, Fizazi K, Mulders P,

- Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin T, Park YC, Kheoh T, **Small EJ**, Scher HI, Molina A, Ryan CJ, on behalf of COU-AA-302 investigators. Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy. 28th Annual EAU Congress, 2013.
239. Aggarwal RR, Weinberg VK, Sosa EV, Lin AM, Harzstark AL, **Small EJ**, Fong L, Hsieh AC, Formaker C, Koepfgen KM, Friedlander TW, Ryan CJ. Evaluating the hypothalamic-pituitary-adrenal axis (HPAA) in men receiving ketoconazole for castrate-resistant prostate cancer (CRPC). Proc Genitourinary Ca Symp Mtg, 2013.
240. **Small EJ**, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. Proc Genitourinary Ca Symp Mtg, 2013.
241. **Small EJ**, Lance R, Gardner TA, Karsh LI, Stubbs A, McCoy C, DeVries T, Redfern CH, Shore ND. A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). Proc Genitourinary Ca Symp Mtg, 2013.
242. Ryan CJ, Molina A, Li J, Kheoh TS, **Small EJ**, Haqq CM, Grant RP, De Bono JS, Scher HI. Prognostic value of serum androgens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data. Proc Genitourinary Ca Symp Mtg, 2013.
243. Halabi S, Lin C-Y, **Small EJ**, Armstrong AJ, Kaplan EB, Petrylak DP, Sternberg CN, Shen L, Oudard S, De Bono JS, Sartor AO. A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed. Proc Genitourinary Ca Symp Mtg, 2013.
244. Smith MR, Halabi S, Ryan CJ, Stadler WM, Hussain A, Vogelzang NJ, Hauke RJ, Sanford BL, **Small EJ**. Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). Proc Genitourinary Ca Symp Mtg, 2013.
245. Rathkopf DE, Smith MR, De Bono JS, Logothetis C, Shore ND, De Souza PD, Fizazi K, Mulders P, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Fradet Y, Griffin TW, Park YC, Kheoh TS, **Small EJ**, Scher HI, Molina A, Ryan CJ. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. Proc Genitourinary Ca Symp Mtg, 2013.
246. Aggarwal RA, Weinberg VK, Sosa EV, Lin AM, Harzstark AL, **Small EJ**, Fong L, Hsieh AC, Formaker C, Koepfgen KM, Hang E, Friedlander TW, Ryan CJ. Evaluating the hypothalamic-pituitary-adrenal axis (HPAA) in men receiving keto conazole for castrate resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol Mtg, 2013.
247. Febbo PG, Goldstein TC, Baertsch R, Youngren J, Newton Y, Bivol A, **Small EJ**, Stuart J. Identification of polo-like kinase 1 (PLK1) in aggressive prostate cancer by paradigm analysis. Proc Am Soc Clin Oncol Mtg, 2013.
248. Nixon AB, Halabi S, Shterev I, Starr M, Brady JC, Dutcher JP, Hopkins JO, Hurwitz H, **Small EJ**, Rini BI, Febbo PH, George DJ, for the Alliance for Clinical Trials in Oncology. Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 990206 (Alliance). Proc Am Soc Clin Oncol Mtg, 2013.
249. Halabi S, Lin C-Y, **Small EJ**, Armstrong AJ, Kaplan EB, Petrylak DP, Sternberg CN, Shen L, Oudard S, DeBono JS, Sartor AO. A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy. Proc Am Soc Clin Oncol Mtg, 2013.

250. **Small EJ**, Lance RS, Redfern CH, Millard FE, Gardner TA, Karsh LI, Dawson NA, McCoy C, Stubbs A, DeVries T, dela Rosa CP, Sheikh NA, Shore ND. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2013.
251. Scher HI, Smith MR, Sweeney C, Corn PG, Logothetis C, Vogelzang NJ, Smith DC, Hussain M, George DJ, DeBono S, Higano S, **Small EJ**, Goldin J, Brown MS, Atfab DT, Noursalehi M, Weitzman A, Basch EM. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor clel (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of phase II nonrandomized expansion (NRE) cohort. Proc Am Soc Clin Oncol Mtg, 2013.
252. Ryan CJ, Londhe A, Molina A, Smith MR, DeBono JS, Mulders P, Rathkopf DE, Saad F, Logothetis C, Fizazi K, Scher HI, **Small EJ**, Matheny S, Kheoh TS, Griffin TW. Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Results of COU-AA-302.
253. Rathkopf DE, Smith Mr, DeBono JS, Logothetis C, Shore N, DeSouza PL, Fizazi K, Mulders P, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Fradet Y, Griffin TW, Park YC, Kheoh TS, **Small EJ**, Scher HI, Molina A, Ryan CJ. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). Proc Am Soc Clin Oncol Mtg, 2013.
254. Hertz DL, Owzar K, Halabi S, Kelly WK, Zembutsu H, Jiang C, Patel JN, Watson D, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, **Small EJ**, Febbo PG, Nakamura Y, Kubo M, Ratain MJ, McLeod HL. A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance). Proc Am Soc Clin Oncol Mtg, 2013.
255. **Small EJ**, Youngren J, Beer TM, Ryan CJ, Thomas G, Pourmand N, Reiter RE, Alumkal JJ, Stuart JM, Evans CP, Gleave ME, Chi KN, Toshci A, Foye A, Lara P, Witte O. The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Proc Genitourinary Ca Symp Mtg, 2014.
256. Aggarwal RR, Weinberg VK, Ryan CJ, Harzstark A, Bryce AH, Derleth CL, Lowe K, **Small EJ**. A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). Proc Genitourinary Ca Symp Mtg, 2014.
257. Kim W, Wilton J, Zhang L, Lin AM, Fong L, Friedlander TW, Hsieh AC, Aggarwal RR, Rodvelt TJ, Morse A, Bozeman J, Weinberg VK, Molina A, Mohler J, Fetterly GJ, Szmulewitz RZ, **Small EJ**, Ran CR. Activity of abiraterone acetate in metastatic patients with castration-resistant prostate cancer (mCRPC) previously treated with ketoconazole: A prospective phase II study from the prostate cancer clinical trials consortium. Proc Genitourinary Ca Symp Mtg, 2014.
258. Drake CG, Fran L-Q, GuhaThakurta G, Stewart F, Kantoff PW, **Small EJ**, Gardner TA, Sheikh NA, Trager JB, Higano CS. Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer. Proc Genitourinary Ca Symp Mtg, 2014.
259. Smith MR, Matheny S, Saad F, Rathkopf DE, Mulders PFA, DeBono JS, **Small EJ**, Shore ND, Fizazi K, Kheoh TS, Li J, Todd MB, Griffin TW, Yu MK, Ryan CJ. Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302. Proc Genitourinary Ca Symp Mtg, 2014.
260. Yu EY, Saad F, Londhe A, Shore ND, Van Poppel H, Rathkopf DE, Smith MR, Logothetis C, DeSouza PL, Fizazi

- K, Mulders PFA, Mainwaring PN, Hainsworth JD, Beer TM, North SA, **Small EJ**, Scher HI, Griffin TW, Yu MK, Ryan CJ. Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. Proc Genitourinary Ca Symp Mtg, 2014.
261. Oudard S, Kheoh TS, Yu MK, Smith MR, **Small EJ**, Mulders PFA, Fizazi K, Rathkoopf DE, Saad F, Scher HI, Bellmund J, Taplin M-E, Davis ID, Schrijvers DL, Protheroe A, Molina A, Griffin TW, DeBono JS, Ryan CJ. Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. Proc Genitourinary Ca Symp Mtg, 2014.
262. Smith MR, Liu G, Shreeve SM, Matheny S, Sosa A, Kheoh T, Yu MK, **Small EJ**. A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy versus ADT alone in nonmetastatic castration-resistant prostate cancer: The SPARTAN trial. Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting, 2014.
263. Patel JN, Jiang C, Hertz DL, Mulkey FA, Friedman PN, Halabi S, Ratain MJ, Morris MJ, **Small EJ**, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance). Proc American Association for Cancer Research Annual Meeting, 2014.
264. **Small EJ**, Youngren J, Alumkal J, Evans C, Ryan CJ, Lara P, Beer T, Witte O, aertsch R, Stuart J. Neuroendocrine Prostate Cancer (NEPC) in Patients (pts) with metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant to Abiraterone (Abi) or Enzalutamide (Enz): Preliminary Results from the SUC/PCF/AACR Rest Coast Prostate Dream Team (WCDT). Proc European Society for Medical Oncology, Annual Meeting, 2014.
265. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternber CN, Miller K, Logothetis CJ, Shore ND, **Small EJ**, Carles J, Flaig TW, Taplin M-E, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Interpretation of the O'Brien-Fleming Rule for P Value Allocation on Interpretation of Overall Survival in the COU-AA-302 Study. Prostate Cancer Foundation Annual Meeting, 2014.
266. Smith MR, Liu G, Trudel GC, Sosa A, Kheoh TS, Yu MK, Rooney B, **Small EJ**. SPARTAN - a randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy vs ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC). Prostate Cancer Foundation Annual Meeting, 2014.
267. Tombal B, Jassem J, Shreeve SM, Trudel GC, Sosa A, Kheoh T, Yu MK, Smith M, **Small EJ**, Oudard S. SPARTAN - a randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy vs ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC) Proceedings of the European Society for Medical Oncology (ESMO) Annual Congress, 2014
268. Aggarwal RR, Rodvelt TJ, Rabow MW, Macaire G, Fedric R, Cortese-Jimenez G, **Small EJ**; A multidisciplinary clinic to mitigate the impact of androgen deprivation therapy in prostate cancer: A pilot study. Proc Genitourinary Ca Symp Mtg, 2015.
269. Aggarwal RR, Bryce AH, Weinberg VK, Ryan CJ, Derleth CL, Harzstark A, Lee M, **Small EJ**; A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). Proc Genitourinary Ca Symp Mtg, 2015.
270. Friedlander TW, Graff JN, Zhang L, Paz R, Premasekharan G, Dilip A, Hsieh AC, Aggarwal RR, Kim W, Lin AM, Fong L, **Small EJ**, Paris P, Ryan CJ; Initial results from a phase II study of increased-dose abiraterone acetate in patients with castration resistant prostate cancer (CRPC). Proc Genitourinary Ca Symp Mtg, 2015.
271. De Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, **Small EJ**, Shore ND, Fizazi K, De Porre P, Kheoh

- TS, Li J, Todd MB, Griffin TW, Ryan CJ; Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302. Proc Genitourinary Ca Symp Mtg, 2015.
272. Ryan CJ, Smith MR, Fizazi K, Saad F, Sternberg CN, Logothetis C, **Small EJ**, Carles J, Flaig TW, Taplin M-E, Higano CS, De Souza PL, De Bono JS, Griffin TW, De Porre P, Park YC, Li J, Kheoh TS, Molina A, Rathkopf DE; Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis. Proc Genitourinary Ca Symp Mtg, 2015.
273. Hadaschik B, Tombal B, Jassem J, Shreeve S, Trudel G, Sosa A, Kheoh T, Yu M, Smith M, **Small EJ**, Oudard S. SPARTAN - a randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy vs androgen deprivation therapy alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC). Proceedings of the Global Congress on Prostate Cancer, 2015.
274. Mainwaring P, Liu G, Lee JY, Semenov A, Tejwani S, Lara Jr P, Trudel GC, Sosa A, Kheoh T, Yu MK, Rooney B, Espina B, Smith MR, **Small EJ**. SPARTAN - a randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy vs androgen deprivation therapy alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC) Proceedings of the Urologic Society of Australia and New Zealand (USANZ) Annual Meeting, 2015.
275. Flaig TW, Smith MR, Saad F, Rathkopf DE, Mulders PFA, **Small EJ**, Shore ND, Fizazi K, De Porre P, Kheoh Thian, Jinhui Li M, Todd B, Griffin TW, Ryan CJ, De Bono JS. Treatment Patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302. Proc Genitourinary Ca Symp Mtg, 2016.
276. Kim W, Ryan CJ, Zhang L, Youngren J, Wilton J, Alumkal JJ, Beer TM, Baertsch R, Stuart J, Chi KN, Gleave M, Rettig M, Reiter RE, Lara P, Evans CP, **Small EJ**. Dehydroepiandrosterone in metastatic castration-resistant prostate cancer: Preliminary results from the SU2C-PCF West Coast Dream Team (WCDDT). Proc Genitourinary Ca Symp Mtg, 2016.
277. Dhawan MS, Lee M, Bryce AH, Weinberg VK, Ryan CJ, Derleth CL, Harzark AL, **Small EJ**, Aggarwal RR. A multicenter phase 1 study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Proc Genitourinary Ca Symp Mtg, 2016.
278. Aggarwal RR, Youngren J, Sokolov A, Huang J, Thomas G, Foye A, Alumkal JJ, Ryan CJ, Beer TM, Evans CP, Gleave M, Rettig M, **Small EJ**. Persistence and androgen receptor (AR) expression in patients (pts) with small cell prostate cancer (SCPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDDT). Proc Genitourinary Ca Symp Mtg, 2016.
279. **Small EJ**, Aggarwal RR, Huang J, Sokolov A, Zhang L, Alumkal JJ, Youngren J, Ryan CJ, Foye A, Reiter RE, Evans CP, Gleave M, Witte O, Stuart J, Goldstein TC, Thomas GV, True LD, Beltran H, Rubin MA, Beer Tm, West Coast Prostate Cancer Dream Team. Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team. Proc Am Soc Clin Oncol Mtg, 2016.
280. **Small EJ**, Fong L, Quinn DI, Drake CG, Campogan D, Vu T, Sheikh NA, Chang NN, Petrylak DP. Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2016.
281. Aggarwal RR, Youngren J, Sokolov A, Huang J, Thomas GV, True LD, Foye A, Alumkal JJ, Rhyann CJ, Beer TM, Evans CP, Gleave M, Rettig M, Stuart JM, Lara P, Goldstein TC, Zhang L, Reiter RE, Chi KN, **Small EJ**. Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical

- carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Proc Am Soc Clin Oncol Mtg, 2016.
282. Peng SL, Saunders L, Bheddah S, Williams S, Aggarwal RR, Shea JE, Lee EY, Huang J, Zemek AJ, Longacre TA, Ball DW, Scaife CL, Nelkin B, Anthony BL, Kunz PL, **Small EJ**, Dylia S. Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC). Proc Am Soc Clin Oncol Mtg, 2016.
283. Kim W, Ryan CJ, Zhang L, Youngren J, Wilton J, Alumkal JJ, Beer TM, Baertsch R, Stuart J, Chi KN, Gleave M, Rettig M, Reiter RE, Lara P, Evans CP, **Small EJ**. Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDT). Proc Am Soc Clin Oncol Mtg, 2016.
284. Fong L, Small EJ, Petrylak DP, Quinn DI, Antonarakis ES, Kibel AS, Chang NN, Kandadi H, Sheikh NA, Drake CG. Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC). Proc Genitourinary Ca Symp Mtg, 2017.
285. Small EJ, Lance RS, Redfern CH, Millard FE, Gardner TA, Dawson NA, Fong L, Karsh LI, Corman JM, Nordquist LT, Murdock MI, Curti BD, Chang NN, Shor ND. Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts). Proc Genitourinary Ca Symp Mtg, 2017.
286. Ryan CJ, Dutta S, Kelly WM, Middleberg R, Russell C, **Small EJ**, Morris MJ, Taplin M-E, Halabi S. Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance). Proc Am Soc Clin Oncol Mtg, 2017.
287. Aggarwal RR, Cooperberg MR, Nguyen HG, **Small EJ**, Ryan CJ, Feng FY, Chang A, Greene KL, Carroll P, Hope T. Incidence of intrathoracic (IT) metastases detected by ⁶⁸Ga-PSMA-11 PET in early stage prostate cancer (PC). Proc Am Soc Clin Oncol Mtg, 2017.
288. Hope T, Aggarwal RR, Greene KL, Chee B, Tao D, Felix Feng FY, Chang A, Cooperberg MR, Ryan CJ, **Small EJ**, Carroll P. Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. Proc Am Soc Clin Oncol Mtg, 2017.
289. George DJ, Halabi S, Starr MD, Hurwitz H, Brady JC, Barak I, Morris MJ, Rini BI, **Small EJ**, Kim W, Taplin M-E, Nixon AB. Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance). Proc Am Soc Clin Oncol Mtg, 2017.
290. Charles G. Drake CG, Antonarakis ES, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Campogan D, Haynes H, Vu T, Sheikh NA, **Small EJ**. Characterisation and treatment of patients with castration-resistant metastatic prostate cancer (mCRPC) developing neuroendocrine clonal divergence (NCD): A case series. Proc Am Soc Clin Oncol Mtg, 2017.
291. Mainwaring PN, **Small EJ**, Saad F, Chowdhury S, Hadaschik BA, Graff JN, Olmos D, Uemura Hiroji, Lopez-Gitlitz A, Trudel GC, Espina B, Shu Y, Park YC, Rackoff WR, Yu MK, Smith MR, on behalf of the SPARTAN Investigators. SPARTAN, a phase 3 double-blind, randomized study of apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Proceedings of the Urological Society of New Zealand and Australia (USANZ) Conference, 2018.
292. **Small EJ**, Saad F, Chowdhury S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Smith MR on behalf of the SPARTAN investigators. SPARTAN, a phase 3 double-blind randomized study of apalutamide (APA) vs. placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). Proc Genitourinary Ca Symp Mtg, 2018. J Clin Oncol. 2018, 36(suppl 6S); abstr 161.

293. **Small, EJ**, Lee JY, Lopez-Gitlitz A, Saad F, Rooney B, Hadaschik BA, Uemura H, Shu Y, Yu M, Smith MR. Prostate-specific antigen (PSA) outcomes in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA): Results from phase 3 SPARTAN study. Proceedings from the American Urological Association Annual Meeting, 2018.
294. Saad F, Mehra M, **Small EJ**, Lawson J, Dasgupta A, Hadaschik BA, Uemura H, Smith MR. A population-based study of the association of prostate-specific antigen doubling time (PSADT) with metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients (pts). Proceedings from the American Urological Association Annual Meeting, 2018.
295. **Small, EJ**, Saad F, Hadaschik S, Graff JN, Mainwaring PN, McQuarrie K, Li S, Lawson J, Lopez-Gitlitz, Smith MR. Patient (Pt)-reported outcomes (PROs) in SPARTAN, a phase 3, double-blind, randomized study of apalutamide (APA) plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Proceedings from the American Urological Association Annual Meeting, 2018.
296. Aggarwal RR, Zhang L, Beer TM, Youngren J, Stromlund A, Bell A, Foye A, Playdle D, Alumkal JJ, Reiter RE, Gleave M, Evans CP, Thomas GV, Huang J, True LD, Rettig M, Lara P, Chi KN, **Small EJ**. Serum neuroendocrine (NE) markers and clinical characteristics of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in men with metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team. Proc Genitourinary Ca Symp Mtg, 2018.
297. Borno H, McGuire JP, Griffin AC, Ryan CJ, Kaplan C, **Small EJ**. Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center. Proc Genitourinary Ca Symp Mtg, 2018.
298. Lee M, Hong H, Kim W, Friedlander TW, Fong L, Lin AM, **Small EJ**. A phase II study of itraconazole in biochemically recurrent prostate cancer. Proc Genitourinary Ca Symp Mtg, 2018.
299. Kim W, **Small EJ**, Aggarwal RR, Den RB, Lehrer J, Zhang L, Youngren J, Goldstein TC, Alumkal JJ, Gleave M, Rettig M, Evans CP, Beer TM, Reiter RE, Huang J, Thomas GV, Davicioni E, Ryan CJ, Spratt DE, Feng FY. Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications. Proc Genitourinary Ca Symp Mtg, 2018.
300. Saad F, **Small EJ**, Hadaschik S, Graff JN, Mainwaring PN, McQuarrie K, Li S, Lawson J, Lopez-Gitlitz, Smith MR. Patient (Pt)-reported outcomes (PROs) in SPARTAN, a phase 3, double-blind, randomized study of apalutamide (APA) plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Proceedings of the European Association of Urology Annual Meeting, 2018.
301. Smith MR, Thomas S, Chowdhury S, Olmos D, Li J, Mainwaring PN, Oudard S, Feng FY, Gormley M, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu MK, **Small EJ**. Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study. Proceedings of the American Association for Cancer Research Annual Meeting 2018.
302. Drake CG, Antonarakis ES, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Campogan D, Haynes H, Vu T, Sheikh NA, **Small EJ**. Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2018.
303. Smith MR, Mehra M, Nair S, Lawson J, **Small EJ**. Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC). Proc Am Soc Clin Oncol Mtg, 2018.
304. Smith MR, Saad F, Rathkopf DE, Hadaschik BA, Chowdhury S, Yu MK, Lopez-Gitlitz A, Rooney OB, Darif M, **Small EJ**. Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic

- castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial. Proc Am Soc Clin Oncol Mtg, 2018.
305. **Small EJ**, Saad F, Rathkopf DE, Hadaschik A, Chowdhury S, Yu MK, Lopez-Gitlitz A, Rooney OB, Shu Y, Darif M, Smith MR. Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial. Proc Am Soc Clin Oncol Mtg, 2018.
 306. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Fandi A, Araujo JC, Eisenberger MA, Logothetis C, Quinn DI, Fizazi K, Higano CS, George DJ, Morris MJ, **Small EJ**, Tannock I, Kelly WM. Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2018.
 307. **Small EJ**, Saad F, Zheng Y, Pan F, Mehra M, Lawson J, Hadaschik BA, Uemura H, Lee JY, Mainwaring PN, Smith MR. Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden. Proc Am Soc Clin Oncol Mtg, 2018.
 308. Feng FY, Thomas S, Gormley M, Lopez-Gitlitz A, Yu MK, Cheng S, Ricci DS, Rooney OB, Mainwaring PN, Olmos D, Saad F, Chowdhury S, Hadaschik BA, Fishbane N, Davicioni E, Liu Y, **Small EJ**, Smith MR. Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. Proc Genitourinary Ca Symp Mtg, 2019.
 309. **Small EJ**, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Espina BM, Shu Y, Rackoff WR, Rooney OB, Londhe A, Cheng S, Smith MR. Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). Proc Genitourinary Ca Symp Mtg, 2019.
 310. Chen WS, Aggarwal RR, Zhang L, Zhao S, Beer TM, Qigley DA, Foye A, Playdle D, Lloyd P, Rettig M, Gleave M, Evans CP, Lara P, Kothari V, Chi KN, Reiter RE, Maher C, Feng FY, **Small EJ**, Alumakal JJ. Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer. Proc Genitourinary Ca Symp Mtg, 2019.
 311. Halabi S, Dutta S, Chi KN, Tangen CM, Petrylak DP, Araujo JC, Fizazi K, Quinn DI, Higano CS, Tannock I, **Small EJ**, Kelly WM. Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration resistant prostate cancer (mCRPC). Proc Genitourinary Ca Symp Mtg, 2019.
 312. Pollock YG, Zhang L, Rodvelt TJ, Ma B, Macaire G, Weinberg R, Kentfield S, Chan JM, Topp K, Van Blarigan E, Friedlander TW, Lin AM, Fong L, Kim W, Hough J, Lee M, Ryan CJ, **Small EJ**, Aggarwal RR. A multidisciplinary team-based approach to mitigate the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Proc Genitourinary Ca Symp Mtg, 2019.
 313. Morris MJ, Heller G, Bryce AH, Armstrong AJ, Beltran H, Hahn OM, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Hillman DW, Taplin M-E, Ryan CJ, Halabi S, **Small EJ**. Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2019.
 314. Romero GR, Weinstein A, Friedl V, Foye A, Playdle D, Sabol A, Li P, Huang J, Feng FY, Sturart JM, **Small EJ**. Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2019.
 315. **Small EJ**, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee Y, Uemura H, Lopez-Gitlitz A, Londhe A, Bhaumik A, Cheng S, Rooney OB, Smith MR. Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM). Proc Am Soc Clin Oncol Mtg, 2019.

316. Halabi S, Dutta S, Chi KN, Tangen CM, Xuan M, Petrylak DP, Araujo JC, Fizazi K, Quinn DI, Morris MJ, Higano CS, Tannock I, **Small EJ**, Kelly WM. PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2019.
317. Fraf JN, Smith MR, Saad F, Hadaschik Ba, Uemura H, Lee JY, Mainwaring PN, Olmos D, Oudard S, Londhe A, Bhaumik A, Rooney OB, Lopez-Gitlitz A, **Small EJ**. Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN. Proc Am Soc Clin Oncol Mtg, 2019.
318. Halabi S, Dutta S, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, DeBono JS, Petrylak DP, Fizazi K, Higano CS, **Small EJ**, Kelly WM. External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2019.
319. Szmulewitz Z, Coleman J, Gleave M, Evans CP, Hillman DW, Beltran H, Taplin M-E, Hahn OM, Parsons K, **Small EJ**, Mohler J, Morris MJ. CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC). Proc Am Soc Clin Oncol Mtg, 2019.
320. Pollock YG, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Olmos D, Mainwaring PN, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney OB, Lopez-Gitlitz A, Mudle S, Cheng S, **Small EJ**. Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (mCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). Proc Am Soc Clin Oncol Mtg, 2019.
321. Reimers MA, Abida W, Chou J, George DJ, Heath EI, McKay RR, Pachynski RK, Zhang J, Choi JE, Feng FY, Neshwat G, Cieslik M, Daignault-Newton S, **Small EJ**, Chinnaiyan A, Alva AS. IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations. Proc Am Soc Clin Oncol Mtg, 2019.
322. Sartor AO, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, **Small EJ**, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Freedland SJ, Higano CS. Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis. Proc Am Soc Clin Oncol Mtg, 2019.
323. **Small EJ**, Aggarwal RR, Friedl V, Weinstein A, Thomas GV, True LD, Foye A, Beer TM, Rettig R, Gleave M, Evans CP, Alumkal JJ, Reiter RE, Lara P, Chi KN, Feng FY, Bailey A, Stuart J, Huang J. Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Proc Genitourinary Ca Symp Mtg, 2020.
324. Kwon D, Li Zhang L, Foye A, Chen WS, Feng FY, Bailey B, Huang J, Quigley DA, Stuart J, Friedl V, Weinstein A, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara P, Li P, Lui A, **Small EJ**, Aggarwal RR. ADRB2 expression in progressive metastatic castration-resistant prostate cancer. Proc Genitourinary Ca Symp Mtg, 2020.
325. Aggarwal RR, Costin D, O'Neill VJ, Burg CR, Healey DI, De Bono JS, Zhang J, **Small EJ**. Safety of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (pembro, anti-PD-1) monoclonal antibody, in men with metastatic castration-resistant prostate cancer (mCRPC). Proc Genitourinary Ca Symp Mtg, 2020.
326. Philip EJ, Wright F, Kim DM, Kwon D, Ho H, Ho S, Cheung E, Chan E, Porten SP, Wong AC, Borno H, Desai A, Chou J, Oh DY, Aggarwal RR, Fong L, **Small EJ**, Terence W, Friedlander TS, Vadim S, Koshkin TS. Efficacy of

- immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer. Proc Genitourinary Ca Symp Mtg, 2020.
327. Kwon D, Wright F, Zhang L, Chou J, Borno H, Desai A, Oh DY, Pollock YG, Bose R, Huang FW, Hope T, Friedlander TW, Fong L, Feng FY, **Small EJ**, Aggarwal RR, Koshkin KS. Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations. Proc Genitourinary Ca Symp Mtg, 2020.
328. Aggarwal RR, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, **Small EJ**. A randomized phase II study of apalutamide (APA), androgen deprivation therapy (ADT), or APA + ADT in patients (pts) with biochemically relapsed (BCR) prostate cancer (PC). Proc Genitourinary Ca Symp Mtg, 2020.
329. Fendler W, Ferdinandus J, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RR, Rettig M, Gartmann J, Smith R, **Small EJ**, Slavik R, Carroll P, Herrmann K, Czernin J, Hope T. Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. Proc Genitourinary Ca Symp Mtg, 2020.
330. Chu C, Alshalalfa M, Sjöström M, Zhao S, Herlemann A, Chou J, Baskin AJ, Mahal BAV, Spratt DE, Cooperberg MR, **Small EJ**, Aggarwal RR, Wong AC, Porten SP, Hope T, Nguyen PL, Schaeffer EM, Carroll P, Feng FY. Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer. Proc Genitourinary Ca Symp Mtg, 2020.
331. Chu C, Alshalalfa M, Sjöström M, Zhao S, Herlemann A, Chou J, Brandon Mahal BAV, Kishan AU, Spratt DE, Karnes J, **Small EJ**, Wong AC, Porten SP, Hope T, Davicioni E, Nguyen PL, Carroll P, Schaeffer EM, Feng FY, Cooperberg MR. Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer. Proc Genitourinary Ca Symp Mtg, 2020.
332. Chi KN, Rathkopf DE, Attard G, Smith MR, Efsthathiou E, Olmos D, **Small EJ**, Lee JY, Sieber PR, Dunshee C, Ricci DS, Simon JS, Zhao X, Kothari N, Cheng S, Sandhu SK. A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641). Proc Genitourinary Ca Symp Mtg, 2020.
333. **Small EJ**, Zhao S, Chen WS, Li H, Foye A, Sjöström M, Hua JJ, Aggarwal RR, Alumkal JJ, Beer TM, Gleave M, Rettig M, Witte O, Lara P, Chinnaiyan A, Maher C, Quigley DA, Feng FY. The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT). Proc Am Soc Clin Oncol Mtg, 2020.
334. **Small EJ**, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith A, Brookman-May SD, Li S, Zhang K, Rooney OB, Lopez-Gitlitz A, Smith MR. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). Proc Am Soc Clin Oncol Mtg, 2020.
335. Tong B, Borno G, **Small EJ**, Alagala F, Blanco A, Dhawan MS. Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Proc Am Soc Clin Oncol Mtg, 2020.
336. Chi KN, Saad F, Chowdhury S, Graff NJ, Agarwal N, Oudard S, Li G, Lopez-Gitlitz A, Larsen JS, McCarthy SA, Mundle S, Smith MR, **Small EJ**. Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies. Proc Am Soc Clin Oncol Mtg, 2020.
337. Chi KN, Rathkopf DE, Attard G, Smith MR, Efsthathiou E, Olmos D, **Small EJ**, Lee JY, Deborah S, Ricci DS, Simon JS, Zhao X, Kothari N, Cheng S, Sandhu SK. A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE). Proc Am Soc Clin Oncol Mtg, 2020.

338. Saad F, Graff JN, Hadaschik BA, Oudard SO, Mainwaring PN, Bhaumik A, Gormley M, Londhe A, Thomas S, Lopez-Gitlitz A, Mundle S, Davicioni E, **Small EJ**, Smith MR, Feng FY. Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN. Proc Am Soc Clin Oncol Mtg, 2020.
339. Aggarwal RR, Costin D, O'Neill VJ, Corsi-Travali S, Adurthi S, Adedoyin A, Healey DI, De Bono JS, Monk P, Zhang J, **Small EJ**. Phase 1b study of BXCL701, a novel small molecule inhibitor of dipeptidyl peptidases (DPP), combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2020.
340. Divya Natesan D, Henry Martell H, Patrick Devine P, Bradley A, Stohr BA, James P, Grenert JP, Jessica Van Ziffle J, Nancy M, Joseph NM, Bastian BC, Umetsu SE, Onodera C, Chan E, Desai A, Wong AC, Porten SP, Chou J, Friedlander TW, **Small EJ**, Fong L, Eric Sweet-Cordero A, Koshkin VK. Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer. Proc Am Soc Clin Oncol Mtg, 2020.
341. Feng FY, Aguilar-Bonavides C, Lucas J, Thomas S, Gormley M, Sharon McCarthy SA, Brookman-May SD, STriantos S, Mundle S, Matthew Smith MR, **Small EJ**. Molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC). Proc Genitourinary Ca Symp Mtg, 2021.
342. Kwon D, Vashisht R, Borno H, Aggarwal RR, **Small EJ**, Butte A, Huang FW. Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study. Proc Genitourinary Ca Symp Mtg, 2021.
343. Borno H, Li P, Zhang S, Idossa D, Desai A, Rodvelt TJ, Bose R, Koshkin VS, Chou J, Friedlander TW, Huang FW, **Small EJ**, Aggarwal RR; Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center. Proc Genitourinary Ca Symp Mtg, 2021.
344. de Kouchkovsky I, Behr S, Zhang L, Foye A, Vanbrocklin H, **Small EJ**, Feng FY, Friedlander TW, Li P, Frey N, Chung A, Lui A, Subramanian A, Rodvelt TJ, Barlesi B, Evans M, Aggarwal RR. Feasibility study of gallium-68 citrate PET as a bone-tropic imaging biomarker in mCRPC. Proc Genitourinary Ca Symp Mtg, 2021.
345. Kwon D, Vashisht R, Borno H, Aggarwal RR, **Small EJ**, Butte A, Huang FW. Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study. Proc Genitourinary Ca Symp Mtg, 2021.
346. Glover M, Wu J, Kwon DH, Zhang S, Henry S, Wood D, Rubin D, Borno H, **Small EJ**, Schapira L, Koshkin VS, Shah S. Patterns in cancer management changes for patients with COVID-19 in northern California. Proc Am Soc Clin Oncol Mtg, 2021.
347. Zhang L, Sinha M, Subudhi SK, Chen B, Marquez J, Liu E, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal RR, Spitzer M, Allison JP, **Small EJ**, Sharma P, Fong L. The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2021.
348. de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, **Small EJ**, Friedlander TW, Fong L, Paris P, Ryan CJ, Szmulewitz RZ, Aggarwal RR. A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2021.
349. Kwon DH, Paciorek A, Zhang L, Borno H, Desai A, Bose R, Chou J, Fong L, Friedlander TW, Huang FW, Koshkin VS, **Small EJ**, Aggarwal RR. Rate of skeletal-related events (SREs) for abiraterone acetate (AA) versus

- enzalutamide (ENZ) in prostate cancer: A population-based study using the SEER-Medicare database. Proc Am Soc Clin Oncol Mtg, 2021.
350. **Small EJ**, Chi KN, Chowdhury C, Bevans KB, Bhaumik A, Saad F, Chung B, Karsh LI, Oudard S, De Porre P, Brookman-May SD, McCarthy SA, Mundle S, Uemura H, Smith MR, Agarwal N. Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies. Proc Genitourinary Ca Symp Mtg, 2022.
351. Shui D, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Huang FW, Koshkin VS, de Kouchkovsky I, Hong JC, Mohamad O, Feng FY, Aggarwal RR, Hope TA, **Small EJ**, Kwon DH, Borno H. Serial stereotactic body radiation therapy for oligometastatic prostate cancer (PCa) detected by positron emission tomography (PET) imaging. Proc Genitourinary Ca Symp Mtg, 2022.
352. de Kouchkovsky I, Zhang L, Huang J, Trepka K, Chou J, Foye A, Shui D, Wong C, Friedl V, Weinstein A, Hope TA, Quigley DA, Stuart J, Beer TM, Reiter RE, Gleave ME, Evans Cp, Feng FY, **Small EJ**, Aggarwal RR. Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Proc Genitourinary Ca Symp Mtg, 2022.
353. Tamukong P, Kuhlmann P, You S, Su S, Wang Y, **Small EJ**, Rini BI, Halabi S, Janes J, Freeland SJ, Kim JL. HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC). Proc Genitourinary Ca Symp Mtg, 2021.
354. Chi KN, Rathkopf DE, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, **Small EJ**, Gomes AJ, Rouband G, Saad M, Zurawski B, Sakalo V, Mason G, de Corral A, Wang GC, Wu D, Diorio B, Lipez-Gitlitz AM, Sandhu SK. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Proc Genitourinary Ca Symp Mtg, 2022.
355. Jindal T, Zhang L, Chou J, Shui D, Porten SM, Wong AC, Chan E, Stohr BA, de Kouchkovsky I, Borno H, Bose R, Kwon DH, Desai A, Huang FW, Aggarwal RR, **Small EJ**, Fong L, Friedlander TW, Koshkin VS. Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC). Proc Genitourinary Ca Symp Mtg, 2022.
356. Westbrook T, Guan X, Udager AM, Haffner U, Beer TM, Aggarwal RR, Ryan CJ, Gleave M, Huang J, Evans CP, Reiter RE, Witte O, Rettig M, Stuart J, Thomas GV, Feng FY, **Small EJ**, Yates J, Xia Z, Alumkal JJ. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2022.
357. Aggarwal RR, Vuky J, VanderWeele DJ, Rettig M, Heath EI, Beer TM, Huang J, Pawlowska N, Sinit R, Abbey J, Liu B, Nasoff M, Dorr A, **Small EJ**. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol Mtg, 2022.
358. Sandhu S, Attard G, Olmos D, Efstathiou E, Castro E, Rathkopf DE, Smith MR, Roubaud G, **Small EJ**, Gomes AJ, Saad M, Tural D, Thomas S, Urtishak K, Gormlley M, Mason G, Diorio B, Wang GC, Lopez-Gitlitz L, Chi KN. Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Proc Am Soc Clin Oncol Mtg, 2022.
359. Skafel A, Aggarwal RA, **Small EJ**. Maximizing efficiency in managing the trial activation pipeline: activating high-priority trials in a timely manner. Proc Association of American Cancer Institutes (AACI), Clinical Research Innovation (CRI) 15th Annual Mtg, 2023.